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Abstract 
Background 
Cigarette smoking is responsible for increased morbidity and mortality, but 
smoking rates remain high. There is a medical and political imperative to 
find new ways to reduce smoking rates. Previous prevalence studies have 
revealed a large number of smokers who have lung damage. Lung function 
gradually declines with age but smoking can effect the lungs as if they are 
are aging more quickly. The concept of lung age has been known for many 
years but has never been investigated as a potential motivator for behaviour 
change. 
 
The literature review covers the impact of smoking on chronic respiratory 
health, the measurement of lung function (including lung age), background 
information about current NHS smoking cessation therapies and available 
evidence  for  promoting  behaviour  change  in  the  context  of  a  range  of 
psychological theories.  
 
The research study 
This thesis presents the results of a randomised controlled trial (RCT) of 
confronting smokers with their lung age as a complex intervention aimed at 
motivating  people  to  quit.  The  RCT  was  conducted  in  the  primary  care 
setting. Over 500 smokers aged over 35 years were randomised to control 
and intervention groups. All had spirometry and those in the intervention 
groups received their results as lung age.  
   4 
 
Results 
At twelve months after the intervention, the smokers in the lung age group 
were twice as likely as the control group to have quit smoking, irrespective 
of  the  severity  of  their  lung  aging.  Quit  rate  in  intervention  and  control 
groups, respectively,
 were 13.6% and 6.4% (difference 7.2%, P=0.005, 95% 
confidence
 interval 2.2% to 12.1%; number needed to treat 14).  
 
Conclusion  
Telling smokers their lung age significantly improves
 the likelihood of them 
quitting smoking, but the mechanism by
 which this intervention achieves its 
effect  is  unclear.
  The  discussion  and  reflective  section  consider  the 
potential and actual impact of the research findings for policy, practice and 
future primary care research.  
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1  Scope of this thesis 
The core of this thesis is the planning, conduct and results of a randomised 
controlled  trial  (RCT)  to  investigate  the  effect  of  a  complex  intervention 
conducted in the real world of primary health care, for the benefit of smokers. 
 
The  scope  of  this  thesis  is  to  place  this  RCT  in  the broad  context  of  the 
national and worldwide consequences of smoking cigarettes and in particular 
the impact on the respiratory health of individuals. Furthermore, the complex 
intervention presented in this thesis is placed against a background of current 
knowledge  about  what  works  in  smoking  cessation  strategies.  As  the 
research is conducted in primary care in England some detailed background 
is given regarding Government policy and action over the past ten years to 
demonstrate ‘where we are now’. I discuss the ways that the results of this 
research may be used to improve smoking cessation rates by changes to 
strategy, policy and clinical practice. 
 
The intervention tested in this thesis was an existing technology which GPs 
were being encouraged to use, and hence the design was pragmatic rather 
than theory driven. However, in my literature review I have reviewed a limited 
number of popular behaviour theories with the purpose of giving a ‘theory 
context’ for smoking behaviour research. I have attempted to demonstrate 
some of the benefits, barriers and shortcomings of these theories in relation 
to smoking behaviour and cessation. 
   13 
All research should lead to further questions and this thesis is no exception. 
Therefore, I also present ideas for further research and how this study could 
have been done differently. 
 
This research was conducted in the busy, untidy world of general practice in 
suburban England and therefore I include some personal reflections on the 
process and practical aspects of conducting this research.   14 
 
2  The policy context 
2.1  Worldwide problem 
According  to  estimates  by  the  World  Health  Organisation,  tobacco  is  the 
substance causing the most damage to health worldwide.
1 One third of the 
world population over the age of 15 years smoke tobacco, which equates to 
over 1000 million people.
1  
 
Smoking seriously reduces life expectancy. In Europe smoking is the second 
most common cause of premature mortality (the commonest cause is high 
blood pressure and the third is alcohol). In the year 2000 smoking accounted 
for 12.3% of total years of life lost due to premature mortality.
2 
  
Smoking  is  the  main  cause  of  respiratory  cancers  including  trachea, 
bronchus and lung. Standardised death rates from respiratory cancers are 
still climbing in women.
2 As well as being the prime cause of cancer and 
heart  disease,  it  also  causes  many  other  fatal  conditions  and  chronic 
illnesses among adults (see Table 1, p. 15).
3 
 
Reducing  smoking-related  morbidity  and  mortality  is  among  the  most 
important tasks of clinicians.
4 Approximately one in four smokers will develop 
some degree of (non-malignant) lung damage.
5 Those who are susceptible 
will have progressive damage through-out their life, which will only slow down 
if  they  stop  smoking.
6  Even  if  they  do  not  develop  chronic  obstructive   15 
pulmonary  disease  (COPD)  they  may  develop  other  ill-effects  of  smoking 
such  as  coronary  heart  disease,  peripheral  vascular  disease,  stroke  or 
cancer.
7 
 
 
Cancer 
 
Lung, Upper respiratory, Oesophagus, Bladder, 
Kidney, Stomach, Pancreas, Myeloid leukaemia. 
 
Respiratory 
Chronic obstructive pulmonary disease, 
Pneumonia 
Circulatory  Ischaemic heart disease, Cerebro-vascular 
disease, Aortic aneurysm, Myocardial 
degeneration 
Digestive  Ulcer of stomach and duodenum 
 
Table 1 Smoking related diseases 
 
The harm caused by cigarettes goes beyond that of the individual smoker. 
Exposure to smoking home or at work can have serious consequences. In 
the UK it is estimated that several hundred people per year die from lung 
cancer  caused  by  passive  smoking.
8  Passive  smoking  almost  certainly 
contributes to deaths from heart disease which itself causes more deaths 
than lung cancer.
9-11  
 
Even in low levels passive smoking can cause illness. Asthma sufferers are 
more prone to attacks in smoky atmospheres. Children are more vulnerable 
than  adults  and  are  exposed  to  smoke  from  adult  behaviour.  Children  of 
smokers get more asthma and respiratory complications of viral infections 
and smoking pregnant women will reduce average birth weight, increase pre-  16 
term birth rate and increase peri-natal mortality.
12;13 
 
In summary it is clear that tobacco is a major worldwide threat to the health of 
smokers, families of smokers and other close contacts.    17 
 
2.2  Smoking- British Government policy and personal 
behaviour  
2.2.1 Smoking statistics (Great Britain)  
The harmful effects of smoking have been recognised for many years. There 
is an inevitable tension between personal, public and political interests. Since 
1998 there has been an increased political will to reduce smoking in Great 
Britain.  This  important  milestone  was  marked  by  the  Government  White 
Paper entitled ‘Smoking kills’  which summarised the economic and health 
costs to the Nation and introduced a number of plans to achieve new  targets 
for smoking reduction.
14  
 
  
At  that  time  (1998),  according  to  the  Government  White  Paper,  in  Great 
Britain alone:  
•  over 120,000 people died per year because they smoked  
  
•  half of all who continued to smoke for most of their lives died of the 
habit.
15
 
  
•  those who smoked regularly and died of a smoking-related disease 
lost on average 16 years from their life expectancy compared to non-
smokers.
16  
 
•  smoking caused 84% of deaths from lung cancer, and 83% of deaths   18 
from chronic obstructive pulmonary disease.
3  
  
•  smoking caused 46,500 deaths from cancer a year , which was a third 
of all cancer deaths.
3  
  
•  treating illness and disease caused by smoking was estimated to cost 
the  NHS  up  to  £1.7  billion  per  year  for  medical  consultations, 
prescriptions, treatment and operations.
17  
2.2.2 Smoking inequalities and cost 
Smoking is a major identifiable factor contributing to the gap in health and life 
expectancy between socio-economic groups. Even though average smoking 
rates have fallen over the past few decades, the rates have fallen less in the 
poor. For example, in 1996, one in ten men in professional jobs smoked, 
compared  with  over  a  third  of  men  in  unskilled  manual  jobs.
14  The  most 
recent  figures  available  from  government  census  (the  General  Household 
Survey)  data  show  that  there  has  been  some  improvement  in  social 
inequalities since the start of the 1998 plan. However in 2006, the prevalence 
of cigarette smoking continued to be higher for people in unskilled jobs (29%) 
compared to average (22%).
18 Moreover the children in poorer families are 
more likely to suffer the health and financial burden of smoking. In the United 
Kingdom, children in the lower socio-economic groups are nearly three times 
as  likely  to  be  exposed  to  tobacco  smoke  in  the  home  compared  to 
households with parents who are professionals.
2 
 
Such differences are reflected in the impact of smoking on health. A higher   19 
rate of smoking among people in manual jobs is matched by much higher 
rates of disease such as cancer and heart disease. Between 1991 and 1993, 
those  in  unskilled  manual  work  were  five times  more  likely  of  die  of  lung 
cancer than men in professional work.
19 For the same period and age group, 
three times as many unskilled manual workers died of coronary heart disease 
than professional workers.
a 
 
In  1989,  it  was  estimated  that  smoking  cost  the  NHS  approximately  £1.7 
billion per year.
17 The cost was high in both ill health and loss of productivity. 
It was estimated that the country lost 50 million working days per year (about 
1% of the total).  
 
Increasing taxation on cigarettes can produce a reduction in smoking. A 10% 
increase  in  taxes  leads  to  an  estimated  4%  cut  in  smokers  or  smoking. 
However  the  impact  on  poor  households  is  magnified  due  to  the 
disproportionate  numbers  of  smokers  on  benefits  or  low  income.  Mothers 
with dependent children who receive income support are more than twice as 
likely  to  be  smokers  than  average.
2  Remarkably,  poor  households  may 
spend as much as 15% of their disposable income on smoking. Smoking 
prevalence can be regarded as a marker of deprivation.
20  
2.2.3 Smoking- Government plans and targets 
In  1997  the  British  Government  expressed  its  determination  to  tackle  the 
problem of smoking. At that time, well over a quarter of the people of Britain 
                                            
a 81 per 100,000 professional workers died from coronary heart disease compared with 235 
per 100,000 in unskilled manual jobs (1991-1993).   20 
smoked. Whilst maintaining the right of individuals to make decisions they 
declared that: 
‘Smokers have a responsibility to themselves - to their own health, and 
to ensure that in making the choice to smoke, their choice is based on 
a real understanding of the risks involved. With their right to smoke, 
too, comes the responsibility to others who choose not to smoke. Just 
as the Government is determined not to infringe upon people's rights 
to make free and informed choices, it is also determined to ensure that 
the responsibilities of smokers to people who choose not to smoke are 
carried out. That means a balance of rights and responsibilities -for 
those who smoke and for those who do not. Striking that balance is a 
clear and tough challenge - for the Government, for business, for local 
authorities, for voluntary groups and especially for individuals.’
14  
 
Through  a  series  of  proposals  for  legislation  and  improved  NHS  smoking 
cessation programme provision they created targets: 
‘To reduce adult smoking in all social classes so that the overall rate 
falls from 28% to 24% or less by the year 2010
b; with a fall to 26% by 
the year 2005. In terms of today's population, this would mean 1.5 
million fewer smokers in England’.
c 
                                            
b This target was for improvements measured against a baseline of 28 per cent smoking 
prevalence among men and women aged 16 and over in 1996. 
c The objective is not only to see smoking in all socio-economic groups reduce to a new 
average figure of 24% by 2010, but also to reduce the difference in smoking rates between 
manual and non-manual groups.   21 
2.2.4 Smokers –Government action 
A large part of the Government action concentrated on legislation, advertising 
bans and presentation of unpleasant words and images on cigarette packets.  
The intention of anti-smoking legislation is to reduce tobacco consumption 
and to create less exposure and a more supportive environment for those 
smokers who would like to quit.  
 
Bans on workplace smoking have been effective in reducing prevalence of 
smoking.
21 Remarkably, following bans on smoking in public places the new 
rules have widespread public support and smoking has become socially less 
acceptable in some countries including Ireland and the UK.
18 Four out of five 
people  agree  with  the  ban  of  smoking  in  public  places  according  to  the 
General  Household  Survey.
18  This  top-down  approach  with  government 
legislation  about  public  places  and  restrictions  on  advertising  and  health 
warnings are ways of trying to force behaviour change.
22;23 However, early 
evidence is supportive of the ban of smoking in public places and has led to a 
5.5% fall in the numbers smoking in the 9 months after the ban (compared to 
a fall of 1.6% in the 9 months before the ban) and positive support of over 
60% of the population.
24 It is too early to determine the sustainability of this 
fall. 
 
More resources have been put into helping those who have decided to quit 
smoking and NHS clinics to support potential quitters and increased use of 
medication to reduce the unpleasant physiological and psychological barriers 
to change. In 2007 the net ingredient cost of pharmacotherapies used to help   22 
people stop smoking was over £60 million and a similar amount was spent on 
NHS Stop Smoking Services.
18 This represented a sevenfold increase in the 
expenditure  on  smoking  therapy  over  5  years.
18  While  costs  of  helping 
people  stop  smoking  have  increased  the  estimated  expenditure  on  NHS 
treatment of smoking related disease has dropped to £1.4 billion from £1.7 
billion in 1989 (see p. 18).
18 The implication is that the policy is working even 
if progres is rather slow. 
2.2.5 The ‘right to smoke’ lobby 
Some controversy and opposition has arisen to the increasing trend to regard 
smoking as antisocial and as a reaction to anti-smoking legislation. Some 
writers regard smoking as a ‘public good’. Here is one point of view: 
‘Tax is levied on tobacco in three ways: excise duty at a specific 
rate per 1,000 cigarettes, an additional rate based on 20% of 
the  total  retail  price,  plus  VAT  at  17.5%  of  the  final  price  - 
including  the  other  taxes.  The  end  result  is  that  tobacco 
taxation, the amount levied in various ways by the government 
on  every  packet  of  cigarettes,  cigars  or  smoking  tobacco, 
comes to £12 billion per year, six times more than any NHS 
bills run up by nicotine addicts. In fact, between 80% and 90% 
of the cost of a packet of fags is tax’.
25 
 
It is likely that those who continue to smoke will be increasingly ostracised to 
the  point  that  there  will  be  polarisation  of  opinion  among  the  public  with 
smoking seen as antisocial by the majority and illegal in many places, but 
with a hard core of dedicated smokers opposed to legislation and bans.    23 
2.2.6 Future developments 
Although  prevention  should  be  the  ultimate  aim  (i.e.  discouraging  young 
people from starting to smoke) there remains a large cohort of smokers who 
have not committed themselves to quitting or who have considered quitting 
but not been able to succeed. Nearly 80% of smokers in the UK have an 
intention to quit,
18;20 but wanting to quit is not the same as quitting.
26   In 
studies investigating predictors of quitting the most frequently cited reasons 
for  quitting  were  concern  for  current  and  future  health  (92%)  and  cost 
(59%).
27 Any new strategies that can move people towards a decision to quit 
and then to successfully abstain from smoking will be of potential benefit.   24 
 
2.3  Health service standards 
2.3.1 The  National  Institute  for  Health  and  Clinical  Excellence 
(NICE) 
Guidelines  for  the  diagnosis  and  management  of  chronic  obstructive 
pulmonary disease (COPD) were produced in March 2004 by the National 
Institute  for  Health  and  Clinical  Excellence  (NICE)  and  published  as  a 
supplement to Thorax, the journal of the British Thoracic Society.
28 NICE has 
also produced guidance on brief interventions for smoking cessation.
29 
 
The  National  Institute  for  Health  and  Clinical  Excellence  (NICE)  is  the 
independent  organisation  established  by  the  British  Government  by  the 
merger  of  the  Health  Development  Agency  and  the  National  Institute  of 
Clinical Excellence in April 2005. Their stated aim is to be responsible for 
providing  national  guidance  on  the  promotion  of  good  health  and  the 
prevention  and  treatment  of  ill  health.  NICE  guidance  is  developed  by  a 
number  of  independent  advisory  groups  made  up  of  health  professionals, 
those working in the NHS, patients, their carers and the public.  
 
In  general  there  are  three  main  areas  of  guidance  that  are  produced  by 
NICE:  public  health,  health  technologies  and  clinical  practice.  The 
development of all clinical practice guidance follows a common pathway. The 
selection of topics can be based on recommendations by any interested party   25 
but have to comply with various criteria including the following: 
•  burden of disease (population affected, morbidity, mortality)  
•  resource impact (i.e. the cost impact on the NHS or the public sector)  
•  policy  importance  (i.e.  whether  the  topic  falls  within  a  government 
priority area)  
First the Department of Health (DoH) refers the topic to NICE. Once the topic 
has  been  selected,  stakeholders  register  their  interest  and  the  National 
Collaborating  Centre  (NCC)  is  commissioned  to  prepare  the  scope  of  the 
guideline.  Within  the  scope  of  the  guideline  a  group  made  up  of  health 
professionals,  representatives  of  patient  and  carer  groups  and  technical 
experts start to collect evidence and develop recommendations. There is at 
least one public consultation period for registered stakeholders to comment 
on the draft guideline. An independent guideline review panel reviews the 
guideline to check that stakeholder comments have been taken into account. 
 
The  scope  of  the  guidelines  for  chronic  obstructive  pulmonary  disease 
(COPD)  includes  diagnosis,  drug  therapy  and  other  management  and  it 
grades the recommendations by the levels of evidence available. Evidence is 
classified according to the types and quality of research studies that have 
been published.
30 NICE then grades their recommendations based on this 
hierarchy (see Table 2, p. 26).   26 
 
  Hierarchy of evidence
d    Grading of recommendation
30 
1a  Evidence from systematic 
reviews or meta analysis of 
randomised controlled trials 
1b  Evidence from at least one 
randomised controlled trial 
A  Based on hierarchy 1 evidence 
Ila  Evidence from at least one 
controlled study without 
randomisation 
Ilb  Evidence from at least one 
other type of quasi 
experimental study 
B  Based on hierarchy II evidence 
or extrapolated from hierarchy 
I evidence 
III  Evidence from non 
experimental descriptive 
studies, such as comparative 
studies, correlation studies 
and case control studies 
C  Based on hierarchy III 
evidence or extrapolated from 
hierarchy 1 or II evidence 
IV  Evidence from expert 
committee reports or opinions 
and /or clinical experience of 
respected authorities 
D  Directly based on hierarchy IV 
evidence or extrapolated from 
1,II or III evidence 
DS  Evidence from diagnostic 
studies 
  Evidence from diagnostic 
studies 
NICE  Evidence from NICE 
guidelines or Health 
Technology Appraisal   
programme 
  Evidence from NICE 
guidelines or Health 
Technology Appraisal   
programme 
Table 2 Hierarchy of evidence and NICE  
 
The following extracts are taken from the 2004 NICE guidance for COPD and 
have some relevance to the background for this randomised controlled trial.  
                                            
d This was based on the structure of the Scottish Intercollegiate Guidelines Network 
current in 2004 and reproduced in the NICE guidance for COPD 2004. The SIGN hierarchy 
of evidence was last changed in June 2008.
31    27 
 
1.  ‘All  COPD  patients  still  smoking,  regardless  of  age,  should  be 
encouraged to stop, and offered help to do so, at every opportunity’ 
(Grade A evidence).
28  
2.  ‘COPD  can  be  present  in  the  absence  of  symptoms’  (Level  III 
evidence).
32  
3.  ‘A study of opportunistic case finding, found that 27% of patients who 
were  aged  over  35  years,  were  current  or  ex-smokers  and  had  a 
chronic cough had reduced FEV1’ (Level III evidence).
5 
4.  ‘Spirometry should be performed in patients who are over 35, current 
or  ex-smokers,  with  a  chronic  cough’  (Grade  D  evidence. 
Recommendation number 20). 
5.  ‘Spirometry  is  fundamental  to  making  a  diagnosis  of  COPD  and  a 
confident diagnosis of COPD can only be made with spirometry’ (Level 
IV evidence). 
6.  ‘Opportunistic case finding should be based on the presence of risk 
factors (age and smoking) and symptoms. The diagnosis should be 
confirmed using spirometry’ (Level IV evidence). 
7.  ‘COPD can be detected by opportunistic case finding in primary care’ 
(Level III evidence).
32 
33;34  
8.  ‘Knowledge  of  abnormal  lung  function  as  part  of  a  motivational 
package,  significantly  affects  the  success  of  smoking  cessation 
therapy’ (Level Ib evidence).
35;36 
It is noteworthy that the levels of evidence for most of these statements and 
recommendations are at a level D or lV. This is compatible with lower levels   28 
of evidence based on opinions and expert committees (see Table 2, p. 26). 
 
Part  of  the  problem  with  the  NICE  guidance  on  COPD  is  that  it  had  an 
extremely broad remit with a limited amount of time. In a rapidly changing 
research environment guidelines may be out of date by the time they are 
produced. In contrast, guidelines based on low-level evidence highlight the 
fact that much of the evidence required either does not exist or are of too low 
quality to give robust evidence based advice (see points 4, 5, 6 and 7 above). 
 
Next,  politics  cannot be  altogether  excluded  from  production of guidelines 
that  have  resource  implications.  NICE  has  a  remit  to  include  cost  benefit 
economic analyses whereas the Scottish Intercollegiate Guidelines Network 
do not.
31 NICE guidance is therefore tempered by the cost and the benefit of 
widespread implementation. Although it is desirable and right to encourage 
stakeholders  to  have  significant  input  to  guidance,  vested  interests  from 
pharmaceutical  companies,  specialist  charities  and  others  may  have 
significant effect on the flavour and affordability of the guidance due to their 
individual agendas. 
 
One worrying point in the NICE guidance for COPD is the quality of analysis 
of the available evidence. For example the NICE document claims that the 
evidence that ‘Knowledge of abnormal lung function as part of a motivational 
package, significantly affects the success of smoking cessation therapy’- is 
level  1b  in  the  hierarchy,  which  equates  to  ‘evidence  from  at  least  one 
randomised controlled trial’. Their claims are not substantiated by the limited   29 
evidence cited and are not consistent with a Cochrane review published a 
year  later.  This  will  be  discussed  in  detail  in  Section  3.4.2  (see  p.78). 
Moreover whilst Cochrane reviews are usually focussed on evidence relating 
to a specific research question, NICE guidance is very broad in scope and 
perhaps this is responsible for the detriment to quality. 
 
The NICE guidance on brief interventions for smoking cessation considers 
whether brief smoking cessation interventions are effective at encouraging 
individuals  to  quit  smoking.
29  The  impact  of  wider  policy  and  practice  on 
smoking cessation will be the subject of a future document by NICE. By their 
definition: 
‘Brief interventions are health promotion by a range of primary and 
community  care  professionals.  For  smoking  cessation,  brief 
interventions typically take between 5 and 10 minutes. The particular 
package  that  is  provided  will  depend  on  a  number  of  factors, 
including the individual’s willingness to quit and how acceptable they 
find the intervention’.
29 
Brief interventions include one or more of the following: 
• simple opportunistic advice to stop 
• an assessment of the patient’s commitment to quit 
• an offer of medication or behavioural support, provision of self-help 
material and referral to more intensive support such as the NHS Stop 
Smoking Services.
29 
They assert that help that is offered should depend on a number of factors, 
which include the smoker’s willingness to quit, acceptability of the different   30 
interventions available and the previous methods used.  
 
In  conclusion  within  the  whole  thrust  of  the  guidance  from  NICE  is  the 
underlying principle that the only reliable way of preventing deterioration of 
chronic progressive lung damage from smoking, is smoking cessation.
37 This 
concludes the main recommendations so far from NICE guidance for COPD 
relevant to this thesis. This and other evidence about smoking cessation will 
be discussed in more detail in the first literature review (see Section 3, p.36). 
2.3.2 National service framework (NSF) for COPD 
National service frameworks (NSFs) are a rolling programme launched by the 
British Government in April 1998, which cover many different clinical areas. 
NSFs set long-term strategies for improving specific areas of care. They 
set measurable goals within set time frames.
38 
In particular NSFs: 
•  set  national  standards  and  identify  key  interventions  for  a  defined 
service or care group  
•  put in place strategies to support implementation  
•  establish ways to ensure progress within an agreed time scale  
•  are  one  of  a  range  of  measures  to  raise  quality  and  decrease 
variations in service, introduced in the document: ‘The New NHS and 
A  First  Class  Service’.  The  NHS  Plan  re-emphasised  the  role  of 
NSFs as drivers in delivering the Modernisation Agenda.  
On the 28 June 2006, the Secretary of State announced that a National 
Service  Framework  (NSF)  should  be  developed  for  Chronic  Obstructive   31 
Pulmonary  Disease  (COPD)  following  recommendations  published  in  the 
Chief Medical Officer's Annual Report of 2004. 
To ensure that the NSF meets the needs of COPD patients and their carers 
an External Reference Group was established to produce final advice by the 
winter of 2007. The NSF for COPD will be published at the end of 2008 and 
implementation is planned for the beginning of 2009.
38 The contribution of 
this research thesis to potential changes to policy will be discussed further in 
Section 8.7 under the heading of ‘Government policy’. 
2.3.3 Quality and outcomes framework (QOF)  
The  new  General  Medical  Services  (nGMS)  contract  is  the  title  of  the 
agreement between the British Government and general practitioners which 
was implemented in 2004. The new contract moved away from the old item-
of-service  method  of  calculating  pay  and  proposed  to  pay  doctors  for 
reaching quality targets.  
 
The  following  principles  are  among  those  agreed  by  the  negotiators  for 
inclusion of indicators in the QOF.
39 
•  Indicators  should,  where  possible  be  based  on  best  available 
evidence. 
•  The number of indicators in each clinical condition should be kept to 
the  minimum  number  compatible  with  an  accurate  assessment  of 
patient care. 
•  Only data which are useful in patient care should be collected. The 
basis of the consultation should not be distorted by an over-emphasis   32 
on data collection.  
 
With respect to chronic obstructive pulmonary disease the nGMS contract 
included  some  incentives  to  promote  the  wider  use  of  reliable  diagnostic 
measurements, follow up of patients and clinical recording of smoking habits. 
In  particular  the  supporting  documents  for  the  new  GMS  contract  2003 
contained eight indicators for COPD. They outlined the rationale for inclusion 
of  COPD  and the  choice  of  quality  indicators.  Each  of the  indicators  was 
given similar value and, if target levels were reached overall, accounted for a 
maximum of 45 points out of a total of 1000 points in the whole system.  The 
eight indicators were as follows: 
•  1. The practice can produce a register of patients with COPD. 
•  2. The percentage of patients in whom diagnosis has been confirmed 
by  spirometry  including  reversibility  testing  for  newly  diagnosed 
patients with effect for 1
st April 2003 (target 90%). 
•  3. The percentage of all patients with COPD in whom diagnosis has 
been  confirmed  by  spirometry  including  reversibility  testing  (target 
90%). 
•  4. The percentage of patients with COPD in whom there is a record of 
smoking status in the previous 15 months (target 90%). 
•  5. The percentage of patients with COPD who smoke, whose notes 
contain  a  record  that  smoking  cessation  advice  or  referral  to  a 
specialist service, if available, has been offered in the past 15 months 
(target 90%). 
•  6. The percentage of patients with COPD with a record of FEV1 in the   33 
previous 27 months (target 70%). 
•  7. The percentage of patients with COPD receiving inhaled treatment 
in whom there is a record that inhaler technique has been checked in 
the preceding 2 years (target 90%).  
•  8.  The  percentage  of  patients  with  COPD  who  have  had  influenza 
immunisation in the preceding 1
st September to 31
st March. 
The criteria set for the spirometric diagnosis of COPD were different from 
both the British Thoracic Society and GOLD guidelines.  Both of these well-
established guides indicate that FEV1 should be below 80% of the predicted 
value for diagnosis of COPD to be made among other criteria (see Table 3, 
p.  41).  However,  the  QOF  required  the  FEV1  to  be  less  than  70%  for 
inclusion  in  the  register.  The  rationale  given  for  this  diversion  from  well 
established practice was:  
‘a significant number of patients with a FEV1 less than 80% predicted  
may have minimal symptoms. The use of 70% enables clinicians to      
concentrate on symptomatic COPD.’ 
The implications of this policy and the relevance of the results of this study 
are discussed in the section on Government policy (see Section 8.7, p. 225). 
 
Smoking indicators were not included as a distinct category in the QOF of 
2003. In particular there was no requirement for an overall smoking register 
or indicators of promotion of smoking cessation. Instead the QOF included 
targets  for  recording  of  smoking  status  (in  the  previous  15  months)  and 
smoking cessation advice or specialist referral (being offered in the previous 
15months) for people who had specific diagnosed disease categories caused   34 
by or made worse by smoking. These two indicators were listed under the 
disease categories of coronary heart disease (total 11 points), stroke and 
transient ischaemic attack (total 5 points), and hypertension (total 20 points), 
diabetes mellitus (total 8 points), asthma (total 12 points) and COPD (total 12 
points). Therefore a sum total of 68 (out of the 1000) points were offered as a 
financial  incentive  for  reaching  90%  targets  of  recording  smoking  in  each 
disease category and either 70 or 90% target of giving smoking cessation 
advice or referral. 
 
Since  the  initial  development  of  the  QOF  indicators  a  number  of  minor 
changes have been made but the total number of points available (68 points) 
under the categories of COPD and smoking remain the same. Quality criteria 
2 and 3 have been combined into a single criterion of the percentage of those 
with  a  diagnosis  of  COPD  in  whom  diagnosis  has  been  confirmed  by 
spirometry. There has been an important change to the diagnostic criteria. 
Reversibility  is  no  longer  included  as  an  indicator  which  had  been  a 
controversial  inclusion  since  2004  as  it  was  out  of  line  with  NICE 
recommendations and  with  other  international  standards.
32  The  criteria  for 
diagnosis  were  changed  in  the  revision  of  the  contract  for  2008/09  to 
‘confirmation  by  post-bronchodilator  spirometry’,  which  is  consistent  with 
American  Thoracic  Society  and  European  Respiratory  Society  (ATS/ERS) 
recommendations (see Table 3, p. 41). Moreover the FEV1 level (to below 
80%  of  predicted)  for  diagnosis  is  now  compatible  with  British  Thoracic 
Society Guidelines but not with the ATS/ERS guidance. 
   35 
Despite  the  fact  that  the  true  prevalence  of  COPD  has  been  difficult  to 
establish  and  estimates  have  been  wide,
40  the  Government  has  also 
factored-in  a  financial  reward  for  those  practices  who  have  identified 
sufficient patients with COPD in line with national and regional prevalence 
rates.  Most estimates of COPD prevalence from research data indicate that 
there are a large proportion of those with COPD are as yet undiagnosed.
5 
Therefore, I believe this to be a useful development for the QOF to improve 
the quality of the disease registers and to increase case identification. 
 
In line with the negotiated principles, it is important that the structure and 
payment incentives of QOF reflect the current levels of evidence for smoking 
cessation strategies and prevention and treatment of COPD. The background 
principles that should be used for the QOF indicate that any changes should 
be directed by clinical evidence and therefore any new clinical data needs to 
be considered during reviews and in contract negotiations. It will be important 
to disseminate any new information and evidence from this study and others 
to gain maximum beneficial impact for smokers and for the best use of finite 
resources of the health service.  
   36 
 
3  Literature review 1: General background on 
smoking cessation 
3.1  Chronic obstructive airways disease and smoking 
 
Smoking  is  the  most  common  cause  of  chronic  obstructive  pulmonary 
disease  (COPD).
41  The  burden  of  disease  from  COPD  is  enormous. 
Population  studies  in  the  United  Kingdom  indicate  a  prevalence  of  14% 
among adults.
42 According to official statistics 26,000 people died of COPD in 
England and Wales in 1999.
43 The British Thoracic Society (BTS) estimates 
that  there  are  as  many  as  200  patients  with  COPD  on  each  General 
Practitioner’s list. Consultation and admission rates are high among those 
200  patients  on  each  GP  list,  and  several  of  them  will  die  each  year. 
Worldwide it is difficult to estimate the prevalence of COPD. Information from 
collated  data  gives  an  estimated  prevalence  of  between  three  and  ten 
percent and it is the fourth most common cause of death worldwide.
40 
44 
 
It is now acknowledged that the most reliable way of diagnosing COPD is 
using the results of spirometry (see Appendix 1. Glossary, p.286) although 
there  is  still  some  debate  about  the  diagnostic  criteria.
45;46  The  British 
Thoracic Society has been calling for the widespread use of spirometry for 
many years but uptake has been slow until recently.
47 The technology for 
diagnosis is now increasingly available in primary care in the UK and many   37 
other developed countries. Undoubtedly the changes to the General Medical 
Services contract have encouraged wider use of spirometry in the UK, as 
there are now financial incentives for confirming diagnosis and for regular 
monitoring  of  disease  progression  using  spirometry  (see  Section  2.3.3,  p. 
31). 
 
In the early stages of COPD there may be few if any symptoms and therefore 
symptom scoring strategies have been found to be unreliable for very early 
detection. However spirometry can detect changes in the lungs even before 
typical symptoms of breathlessness, cough or wheeze become apparent. In 
cross sectional surveys of smokers over 40 as many as a quarter may have 
previously undetected lung damage even in the absence of symptoms.
48  
 
Many years of research have established that drugs and other techniques 
have little impact on disease progression if people continue to smoke. The 
most important factor in slowing down deterioration of the lung damage is to 
stop smoking.
4;49 Even the most recent results of combination inhaled drug 
therapy (TORCH study) have been disappointing.
50;51   
 
The TORCH study (TOwards a Revolution in Chronic obstructive pulmonary 
disease) recorded smoking related deaths in those with moderate COPD. 
50  
They defined moderate COPD as a forced expiratory volume less than 60% 
of  predicted  value  and  FEV1/FVC  ratio  of  less  than  0.70  and  selected 
smokers with at least ten pack-year history. This was a randomised double 
blind trial of over 6000 patients comparing different inhalers against placebo.   38 
The  main  aim  of  the  study  was  to  compare  mortality  for  different 
combinations of inhalers. The revolution that they hoped for  proved to be a 
misnomer as combination treatment of COPD with fluticasone and salmeterol 
did not reduce mortality in those with COPD compared to placebo. One in 
eight of those with COPD died in the three year study and nearly half of the 
deaths were judged to be attributable to smoking.
50 Therefore, this not only 
illustrates the high mortality in this group but also that drug therapy does not 
yet hold the key to improving mortality in those with COPD. 
 
It is widely acknowledged that COPD is unrecognised in large numbers of 
smokers and ex smokers.
52;53 Many authorities believe that obstruction can 
be detected a long time before the patient becomes aware of their limitations 
or  develops  typical  symptoms  such  as  cough,  shortness  of  breath  or 
wheeze.
46;49 Late diagnosis and misdiagnosis of COPD is common in the UK. 
Surveys  of  asthma  registers  in  United  Kingdom  general  practice  have 
revealed that many people are misdiagnosed on asthma registers.
54 Up to 
three quarters of people with COPD remain undiagnosed and it is common 
for diagnosis of damage to lung to be delayed for up to 20 years from the 
time  of  detectable  changes.
5;37;55  Lung  changes  can  be  detected  after  20 
pack years of smoking. The majority of people start smoking when they are in 
their teens and therefore likely to show changes as early as the age of 35 
years. Some studies have even detected changes in college students aged 
under 25 years, after only a few years of smoking although these findings 
have not been replicated elswhere.
56  
   39 
People do not necessarily seek medical help even if they have symptoms 
suggestive  of  COPD.  In  one  study  a  random  sample  of  the  public  were 
screened. Of the people with newly detected COPD only a third of them had 
ever consulted a doctor about their symptoms.
44;57 Moreover, the average 
age of diagnosis of COPD in the United Kingdom is 55 years.
37 This 20-year 
delay in diagnosis offers a potential large window of opportunity for earlier 
detection and possible intervention to reduce morbidity.  
 
Many authors have proposed screening of smokers in the pre-symptom or 
early symptomatic stage so that intervention can be concentrated on those 
likely to benefit most.
58;59;60 However, other authorities maintain that there is 
insufficient evidence of benefit with early detection and resources should be 
concentrated on those with established symptomatic disease.
61 These issues 
will be discussed further in a later section on the pros and cons of screening 
(see Section 8.7.2, p.227). 
3.1.1 Lung damage and its measurement  
As explained in the previous section, although COPD is the diagnostic label 
of a group of conditions typically characterised by respiratory symptoms of 
shortness of breath, cough and sputum production in combination with airflow 
limitation  (obstruction)  and  chronic  inflammation  of  the  lung,  in  the  early 
stages  there  be  minimal  or  no  symptoms.
32  Therefore  it  is  vital  to  have 
objective diagnostic testing of those suspected of having lung damage from 
smoking. Spirometry is now regarded as a vital tool in the assessment of 
severity of obstruction in lung disease (COPD and asthma) as well as being 
useful  in  distinguishing  these  diseases  from  other  causes  of  respiratory   40 
symptoms.
47 
 
The British Thoracic Society (BTS), Global Initiative for Chronic Obstructive 
Lung  Disease  (GOLD)  and  the  American  Thoracic  Society/  European 
Thoracic Society (ATS/ERS) have each produced criteria for the diagnosis of 
COPD  using  spirometry  at  the  centre  of  diagnostic  testing.
47;62  The  main 
measures of lung function are FEV1 (forced expiratory volume in 1 second) 
and FVC (forced vital capacity) (see Appendix 1. Glossary, p. 286).  
The current diagnostic spirometry criteria for COPD (Table 3, p.41) of these 
three influential organisations are listed and compared as follows: 
 
•  BTS British Thoracic Society.
32 
•  GOLD Global Initiative for Chronic Obstructive Lung Disease.
63 
•  ATS American Thoracic Society/ European Thoracic Society.
62     41 
 
Table 3 Diagnostic criteria for COPD  
   
BTS 
 
GOLD 
 
 
ATS and ERS 
(Post broncho- 
-dilator FEV1) 
 
   
FEV1 % 
predicted 
 
FEV1/FVC 
 
FEV1 % 
predicted 
 
FEV1/FVC 
 
FEV1 % 
predicted 
 
FEV1/FVC 
 
Mild COPD 
 
50 to 
80% 
 
<0.7 
 
≥80% 
 
<0.7 
 
≥80% 
 
≤0.7 
 
Moderate  
 
30 to 
49% 
 
<0.7 
 
≥50<80% 
 
<0.7 
 
50 to 
80% 
 
≤0.7 
 
Severe 
 
<30% 
 
<0.7 
 
≥30<50% 
 
<0.7 
 
30 to 
50% 
 
≤0.7 
 
Very severe 
 
   
<30% 
 
<0.7 
 
<30% 
 
≤0.7 
 
Very severe 
   
<50% + 
respiratory 
failure 
 
<0.7 
 
 
Reference values 
used 
 
 
ECCS64 
 
ECCS64 
 
NHANES 365 
 
 
There is considerable dispute about the value and technique of ‘reversibility 
testing’.
66;67 By definition, those with COPD have obstruction of the airways 
which  is  mostly  irreversible  and  have  very  little  day-to-day  variation  in 
symptoms or FEV1/PEFR measurements on spirometry. Asthma should be 
distinguishable  from  COPD  by  the  tendency  for  variable  wheeze  and 
breathlessness  and  a  significant  change  (15%  and  400ml)
e  in  FEV1  after 
                                            
e If the FEV1 improves by 15% but < 400ml the subject is said to have COPD with reversibility not asthma.   42 
using drugs to maximise broncho-dilation.  Other researchers have thrown 
doubt  on  the  value  and  use  of  reversibility  testing.
68  However,  between 
countries and even within the United Kingdom the techniques of reversibility 
testing  are  very  varied.  A  survey  of  hospital  lung  function  laboratories 
revealed  the  use  of  a  wide  variety  of  different  drugs,  doses  and  delivery 
systems (for the drug) used as well as wide variations in repeat spirometric 
testing  for  reversibility.
69  The  BTS  has  attempted  to  standardise  the 
technique but there has been little consistent use.
47  
 
There is a move away from routine use of ‘reversibility’ as part of spirometry 
testing.  Doubts  have  been  thrown on  the  usefulness  of  ‘reversibility’  as  a 
theoretical or practical tool. There are various reasons for this change. First 
there is the lack of evidence that a 15% change of FEV1 after administration 
of  bronchodilators  is  predictive  of  a  subsequent  response  to  treatment  of 
COPD  with  steroids  or  beta  agonist  and  therefore  it  is  argued  that  the 
distinction is irrelevant. Secondly, the diagnosis of asthma can be made by 
clinical  features  with  assessment  of  variability  of  airways  obstruction  with 
serial peak flow measurements. Finally, in the United Kingdom the General 
Practitioners’  contract  was  revised  in  2008/9
70  in  a  move  towards  the 
ATS/ERS
62  method  of  assessment,  which  uses  post-bronchodilator 
measurements as the standard measurement of FEV1.
62 However they still 
use  different  reference  tables  and  definitions  (by  percentage  of  predicted 
value) for the different levels of severity of disease. 
 
   43 
It is important for any intervention to be conducted by the most appropriately 
trained personnel in the most economic way consistent with good standards 
of care. Training of primary care assistants and the early detection of new 
cases  of  COPD  by  screening  in  primary  care  is  possible,  quick  and 
inexpensive.
5;71 
 
A  single  measurement  of  FEV1  cannot  completely  represent  the  complex 
clinical  consequences  of  COPD  because many  patients  have  few  or  very 
subtle symptoms and persistent cough and sputum production may precede 
the  development  of  airflow  limitation  and  the  first  symptom  may  be  the 
development of shortness of breath with previously tolerated activities.  
 
The  Medical  Research  Council  dyspnoea  scale  can  be  used  to  assess 
functional dyspnoea as follows in Box 1: 
 
 
0. Not troubled with breathlessness except with strenuous exercise  
1. Troubled by shortness of breath when hurrying or walking up a slight hill. 
2. Walks slower than people of the same age due to breathlessness or has to 
stop for breath when walking at own pace on the level. 
3. Stops for breath after walking about 100 metres or after a few minutes on 
the level. 
4.  Too  breathless  to  leave  the  house  or  breathless  when  dressing  or 
undressing. 
 
Box 1 MRC dyspnoea scale 
 
Classification of COPD using all the different components of the disease (e.g.   44 
weight  loss,  breathlessness,  impact  on  life)  is  not  yet  available.  Other 
symptom and impact scoring systems will be discussed later (see Section 
5.6, p. 176). 
Lung age  
Normal  lung  function  gradually  reduces  throughout  adult  life.  This  was 
documented  graphically  by  Fletcher  and  Peto  in  their  prospective 
epidemiological study of lung function in men, 30 years ago.
6 They showed 
that forced expiratory volume in one second falls over time (red line in Figure 
1)  but  in  non-smokers  and  in  many  smokers  (who  are  apparently  not 
 
Figure 1 Lung function with time and smoking  
(Adapted from Fletcher and Peto)
6
 
 
susceptible),  significant  airflow  obstruction  never  develops.  However,  in 
susceptible  individuals  irreversible  obstruction  develops  (blue  line).   45 
Furthermore, when a susceptible smoker stops smoking lung function does 
not significantly improve but the rate of FEV1 loss returns to normal (green 
and brown line).  
 
The concept of ‘lung age’ and the use of a formula for the calculation was 
first developed over 20 years ago.
72 Morris and Temple developed a formula
Equation 1) based on reference linear regression equations permitting lung 
age  estimation  in  terms  of  ventilatory  function.  This  age  can  then  be 
compared with the individual's chronological lung age.  
Equation 1   Lung age calculation formula developed by Morris and Temple 
Men 
Lung
 age=2.87 x height (in inches)–(31.25 x observed FEV1 (litres)–39.375  
Women 
Lung
 age=3.56 x height (in inches)–(40 x observed FEV1 (litres)–77.28 
 
Normal and abnormal groups determined by a respiratory health questionnaire 
and pulmonary function testing were used to compare the value of single and 
combination  spirometric  tests.  The  forced  expiratory  volume  at  one  second 
(FEV1)  proved  superior  to  any  other  single  test  or  combination  for  best 
separation of the two groups and had the lowest standard error for estimated 
lung  age.  They  speculated  that  both  spirometry  and  estimated  lung  age 
calculation might be useful for motivating cessation of cigarette smoking.  
 
Lung age is a way of conceptualizing this deterioration of function and a way of 
expressing  lung  damage  rather  than  using  mathematical  concepts  of 
percentage of expected value of FEV1 for height, age and gender. For example   46 
a 52-year-old man with 70% of normal function may have little or no symptoms 
and the individual may not appreciate the damage being done but if he is told 
that his lung age is 80 he may be more impressed. However, since that time no 
research  has  been  published  exploring  the  psychological  impact  of  giving 
information to smokers in terms of lung age. Moreover, no research has tested 
the  thesis  that  measurement  of  lung  age  could  be  effective  in  smoking 
cessation.  The  practical  use  of  this  concept  is  described  using  a  graphic 
demonstration in Section 6.4 (p.189) on instruments and tests.  
3.1.2 Does quitting reverse or arrest harm from smoking? 
There is some evidence of improved lung function (FEV1) in the twelve months 
following cessation (by as much as 2%) but by far the most important benefit is 
the subsequent reduced rate of decline of lung function, calculated to be half 
the rate of decline compared to that in continuing smokers. Therefore it is well 
established that smokers who quit can benefit despite previous heavy smoking, 
advanced age, poor baseline function or airway hyper-responsiveness.
73 
 
Much has been written about other benefits of smoking cessation. There are 
improvements to other systems of the body (in addition to the lungs) and also 
social and economic benefits for individuals and those who live with smokers.
74 
Cardiovascular risk declines rapidly and significantly with smoking cessation.
75 
Reduced  mortality  rates  from  cardiovascular  disease  in  the  US  are  partly 
attributable  to  reductions  in  smoking.
76  Within  five  years  of  quitting,  women 
reduced  their  risk  of  coronary  death  and  have  a  20%  reduction  in  smoking 
related lung cancer.
77 Further analysis and discussion of the social, economic 
and effects of passive smoking on families are beyond the remit of this thesis.   47 
 
3.2  Why do people smoke and why is quitting so difficult? 
Individual smokers may offer a multitude of reasons that they started, continue, 
or  cannot  stop  smoking  (or  have  relapsed).  Quantitative  research  may  give 
some information about the relative importance of some of these factors but 
qualitative research also has an important role to play in helping us understand 
the perspective of individuals. Reasons given by smokers for their behaviour 
may overemphasise their own perceptions of the cause and may depend on the 
circumstances in which they are questioned. Therefore, in this section I include 
evidence from a spectrum of research to give an overview of ideas about the 
causes of smoking and the difficulties in quitting. 
3.2.1 Why do people start or stop smoking? 
Most  commonly  people  start  smoking  in  their  teens.  The  usual  reason  for 
starting  is  experimentation,  which  is  motivated  by  psychosocial  factors.  In 
simple terms children start smoking to assert their perception of adulthood or as 
an aspect of rebellion. Smoking in children is most common if a teenager or 
child has close contact with smokers (parents, siblings or peers), has low self 
esteem, poor achievement in education, lives in socio-economic deprivation or 
attends a school where smoking is common.
78 Once the initial adverse effects 
of smoking have been overcome, the addiction to nicotine and habit set in to 
promote continued smoking. By the age of 20 years most smokers (80%) regret 
starting and will make repeated attempts to quit.
78 
 
Every year approximately a third of adult smokers attempt to quit smoking but   48 
typically relapse within days or weeks.
79 There are at least three distinct aspects 
to  smoking  cessation:  the  decision  to  quit,  the  attempt  to  stop  and  the 
maintenance of abstinence. Predictors of these different aspects are different.  
 
A  large  prospective  cohort  study  of  smokers  in  four  developed  countries 
(Canada, Australia, USA and UK) including nearly 2000 people from the UK 
was  published  in  2006.
80  They  used  questions  to  measure  intention  to  quit 
smoking and belief in their ability to succeed (see Appendix 3, p. 290). The 
questions of intention are almost identical to those used in the trans-theoretical 
model used to classify participants into stage of change into pre-contemplative, 
contemplative  and  action  stages,  but  without  any  overt  reference  to  that 
behaviour  change  model  (see  Section  4.4,  p.116).  Motivation  to  quit  was 
assessed using questions about opinions of the health benefits of quitting and 
concerns  over  health  and  the  impact  on  quality  of  life  in  the  future  from 
continued smoking. 
 
Other questions were used to assess the scale of positive attitude over the time 
of  the  study  and  outcomes  of  quit  attempts  and  successful  cessation.  They 
found that factors predictive of making a quit attempt included intention to quit, 
making a quit attempt in the previous year, longer duration of past quit attempts, 
less nicotine dependence, more negative attitudes about smoking and younger 
age. Lower levels of nicotine dependence were the main factor that predicted 
future cessation among those that made a quit attempt. 
 
Their conclusion was that ‘Intention to quit and other cognitive variables were   49 
associated with quit attempts, but not cessation. Behavioural variables related 
to  task  difficulty,  including  measures  of  dependence,  predicted  both  making 
attempts and their success’.
80 This aspect is highly relevant to the potential use 
of  confronting  individual  smokers  with  the  health  consequences  of  their 
smoking, because an intervention may seem to motivate individuals towards 
change  but  in  reality  only  change  intentions  without  successfully  changing 
behaviour. This problem is discussed further under the section on behaviour 
change models. It highlights that it is vital not to use ‘intention’ as a research 
outcome  measure  as  it  is  not  an  accurate  predictor  or  measure  of  actual 
behaviour change. 
 
Reasons  for  quitting  may  be  broadly  divided  into  extrinsic  and  intrinsic  (see 
Figure  2,  p.  93).
81  A  prospective  cross-sectional  study  of  over  2500  North 
American smokers concluded that success was more likely if there were health 
concerns, higher levels of education and social pressures to quit.
82  Concern 
about health is the most common reason patients give for quitting, and addiction 
is  the  most  important  barrier  to  quitting.
82  Better  education,  social  pressure, 
health provider advice, and formal cessation programs (but not over-the-counter 
devices), appear to increase the chances that smokers will quit.  
 
Established disease attributable to smoking is also likely to lead to cessation.
83 
However, many studies of smokers, demonstrate that a substantial proportion of 
smokers  have  co-morbidities  caused  by  smoking,  but  nevertheless  they  are 
often resistant to changing behaviour and frequently have no immediate plans 
to stop smoking.
84 Extrinsic motivational reinforcement for reducing smoking in   50 
COPD  patients  have been  tried  (e.g.  lottery  tickets  for  reductions  in  expired 
CO)
85 but with limited and temporary success.  
 
The  health  benefits  of  quitting  smoking  have  been  well  documented.
86-88 
Despite the evidence many individuals will resist change by expressing their 
enjoyment, denial of harm from smoking or simply on the basis of their rights of 
personal  freedom.  Personal  rights  come  under  pressure  due  to  the  wider 
implications  of  damage  to  others  through  passive  smoking,  harm  to  unborn 
children or harm within a household either directly or on the economic well-
being of the family. Individual freedom has to be put in the context of another 
person’s right to be free from harm. This is one of the reasons given for the 
recent ban in smoking in public places introduced in a number of countries. 
Moreover  positive  attitudes  to  smoking  restrictions  in  public  places  are  an 
independent predictor of the occurrence of smoke free homes.
89 
3.2.2 Addiction 
Addictions (as well as obsessions, and compulsions) relate to loss of voluntary 
control  and  getting  trapped  in  a  repeated  cycle  of  self-destructive,  harmful 
behaviour. Traditionally, scientists have confined the use of the term addiction 
to substance addiction. However, this has changed with the appreciation that 
the  brain  perceives  various  stimuli  as  a  ‘reward’  that  may  be  chemical  or 
experiential.
90  Therefore,  the  term  addiction  cannot  only  apply  to  chemical 
substances but also to some activities (e.g. gambling).  
 
Research has identified changes in neural circuits, which promote and continue 
the behaviour even in the absence of external chemical input. The changes are   51 
mediated through the amounts of dopamine released whether the stimulus is 
behavioural or chemical.
91 For example, as many as half of addicted gamblers 
demonstrate  withdrawal  symptoms  similar  to  drug  withdrawal  and,  like  drug 
addicts, they are at risk of sudden relapse many years later. Therefore some 
chemicals  (including  nicotine)  and  some  activities  (gambling)  appear  to 
stimulate the brain’s reward system. In addition, nicotine has been shown to 
alter the balance of neuron input, which increases the duration, and intensity of 
the pleasure from smoking.  
 
‘Situated  in  a  region  of  the  brain  called  the  ventral  tegmental  area 
(VTA),  these  reward-system  neurons,  called  dopaminergic  neurons, 
trigger release of the neurotransmitter dopamine (DA) in a nearby brain 
region called the nucleus accumbens (NAc). When nicotine attaches to 
these  neurons  they  increase  their  activity,  flooding  the  NAc  with 
dopamine,  which  produces  pleasure  and  a  disposition  to  repeat  the 
behaviours that led to it. That pleasure and disposition drive the process 
of addiction’.
91
 
 
A detailed analysis of the neurochemistry and physiology of addiction is beyond 
the scope of this thesis, but it is important to determine where smoking lies in 
the spectrum of addictions and the characteristics that may be shared with other 
types of  addiction  and  which  may determine  how  people  have difficulty  with 
smoking cessation or relapse. On the spectrum of substance addiction nicotine 
is probably more addictive than cannabis or alcohol but is still in the modest 
range.
92   52 
 
There  are  various  schools  of  thought  about  the  nature  of  dependence  or 
addiction. It is a apparent that not all addictive behaviours are pleasurable and 
not  all  pleasurable  activities  are  addictive.  There  may  be  some  delay  from 
exposure to dependence and the progress of dependence can be extremely 
variable.  Relapse  is  more  likely  during  periods  of  boredom  or  crisis  and  in 
circumstances and situations which remind the person of their previous habit.
92 
 
Approximately  80%  of  cigarette  smokers  can  be  classified  as  dependent 
according  to  measures  of  dependence  defined  by  established  tools  (see 
Section 5.2, p. 149).
93 Compared to the treatment of other substance addiction, 
nicotine dependence has been investigated in a relatively large number of well-
conducted randomised controlled trials. Most studies achieve a twelve-month 
abstinence rate of between 10 and 15% with a combination of pharmacological 
and psychological intervention (see Section 3.3.1, p. 62).  
 
In the discussion about the psychology of behaviour change I include a number 
of theories from the social-cognition model. By definition these cognition models 
assume  that  a  large  part  of  behaviour  and  behaviour  change  is  based  on 
making conscious choices. Addiction can be seen, at least initially, as part of a 
rational informed choice. With the exception of malicious, criminal attempts at 
enforcing addiction to some drugs for illegal motives or profit it is reasonable to 
view the initial taking of drugs as a choice. Once on the path of taking drug, 
apparently many would see their consumption as a continuing decision process 
of weighing up the pros and cons of stopping or continuing. Therefore, some   53 
observers  deny  the  existence  of  addiction  in  the  usual  sense  of  an 
uncontrollable compulsion fuelled by psychological and physiological factors.
92 
Making reference to the attribution theory, they argue that drug takers continue 
to  make  choices,  which  confer  benefits  in  the  context  of  their  life  and 
circumstances.  When  confronted  by  authority  (e.g.  police  or  the  medical 
establishment), drug takers may be content to assume the role of the addict 
who cannot control behaviour. According to this idea the addict’s apparent lack 
of control needs to be excused or forgiven because they are not responsible for 
their  behaviour.  This  translates  into  the  addict’s  appeal  of  helplessness,  the 
needs of the family in understanding why someone might harm themselves or 
their loved ones and those in positions of authority in helping to make sense of 
behaviour that is difficult to understand. 
 
Assuming  that  addicts  are  making  real  choices  some  researchers  have 
observed that addicts’ so-called choices may change over time and be unstable 
even  during  a  brief  period  (from  one  drink  to  the  next).  In  choice  theory, 
depending on personal preferences, desires, interests and their assessment of 
environmental  constraints  and  opportunities  they  will  weigh-up  various 
alternatives, choose the best according to those preferences and beliefs, and 
then behave accordingly. However, it is important to note that the preferences 
may not be stable over time, and they do not have to be in line with social 
conventions and norms. They are dynamically inconsistent planners and they 
do not adhere to their original plans, but tend to give in to temptation.
94 
 
Although I have presented the two extreme perspectives (addiction v. choice)   54 
the  choice  theory  rather  ignores  the  compelling  evidence  for  physiological 
craving  and  symptoms,  which  some  consumers  of  tobacco  experience.  The 
theories of dynamic unstable choice and control does open a useful area of 
thought which permits us to view the choices of addicts, including many smoker, 
as  real  choice  (and  not  simply  driven  by  chemical  forces)  and  therefore 
amenable to intervention or behavioural therapy. 
3.2.3 Review of qualitative research  
The  value  of  qualitative  research  in  the  context  of  behavioural  change  is  to 
establish the subjective reasons that people give about their continued smoking 
and difficulties with stopping or relapse after cessation. These studies have the 
potential value of supplying important information to help researchers develop 
understanding  about  smoking  behaviour  and  difficulties  and  barriers  with 
cessation and therefore the potential to help develop new and innovative ways 
to intervene. 
 
Smokers  express  varying  attitudes  to  advice  from  health  professionals. 
Although many smokers expect advice when attending a health professional 
they do not believe that it will make a difference and either become annoyed or 
ignore it.
95 They may resent the interference when lifestyle advice is given.
96 
The stages of change model of behaviour change shows that action oriented 
advice for those who are not ready to change is at best unhelpful, and could 
even  entrench  unhealthy  behaviour.  To  make  the  most  of  opportunities  for 
smoking intervention that arise in normal health care, it may be important to 
understand patients’ perceptions of the acceptability of interventions they have 
received. Acknowledging the onset of actual harm may be a trigger to changed   55 
behaviour and help quitting in those who are receptive.
97  
 
Smokers often blame themselves for their smoking behaviour and believe that 
quitting is the responsibility of the individual and although they expect advice 
from professionals they do not have high expectations of benefit. Contact with 
professionals may simply enhance the feelings of guilt and alter health seeking 
behaviour.
95 Women from deprived economic circumstances experience guilt. 
Their guilt is related to worries over their own health and that of their children.
98 
This  concern  may  be  justified  as  over  a  third  of  British  children  live  in  a 
household where at least one person smokes, and nearly 20,000 children under 
the age of five are admitted to hospital every year with illnesses resulting from 
passive smoking.
98  
 
Smoking for many, especially the more disadvantaged, is a social and culturally 
ingrained behaviour.
98 Despite high levels of motivation to quit many of these 
women  have  lapsed  into  a  hopeless  frame  of  mind  from  repeated  failure.
98 
Descriptions of the power of smoking include words like ‘craving’, ‘habit’ and 
‘addiction’ to describe their relationship with smoking.
99 Addiction is particularly 
used in the context of the first cigarette of the morning. For others in particular 
in socio-economic deprivation smoking may be a major pleasure in dismal life 
circumstances.
99 In contrast, whatever the social circumstances smoking after 
meals or with a drink are described as ‘wanted’ or ‘pleasurable’ or ‘satisfying’.
99 
Feelings of dependence on smoking not only cause hopelessness about the 
idea of quitting but also run in tandem with scepticism about the effectiveness of 
nicotine replacement therapy as this does not tackle the life circumstances that   56 
they believe perpetuate their smoking.
100 
 
The scientist’s view of anxiety and smoking is that the symptoms of withdrawal 
are frequently interpreted as feelings of anxiety and a cigarette will relieve those 
symptoms,  which  therefore  lead  to  the  impression  that  smoking  relieves 
anxiety.
98 Despite the fact that many people firmly believe smoking relieves their 
anxiety the data from international research contradicts that belief. Rather than 
helping  smokers  to  relax,  smoking  probably  increases  anxiety  disorders.
101 
Those  with  established  COPD  also  continue  to  use  cigarettes  because  they 
believe  it  will  stop  them  getting  bad  tempered.
97  Stressful  events  or 
bereavement can be a trigger that causes relapse.
97 
 
Beliefs and attitudes of certain groups of smokers may not be apparent to those 
outside certain cultural or religious groups. For example among some cultural 
groups in the UK smoking may be very common in middle-aged men (50% in 
middle aged Bangladeshi and Pakistani men in Newcastle) but it is rare and 
actually shameful among women.
102 Among older men smoking is associated 
with maleness and socializing activity but is less acceptable and more hidden 
among young people.
102 
 
While  some  cultures  or  religious  groups  accept  or  expect  groups  to  smoke 
(middle aged men) or condemn certain groups (women and youth) the older 
smoker has seen a large shift in public opinion over their lifetime. Those with 
smoking related illness gained the habit in their youth when it was perfectly 
acceptable and a means of socializing, and now find themselves isolated and   57 
smoking  alone.
103  It  is  not  known  what  factors  promote  smoking  in  later  life 
especially  when  smoking  related  illness  has  already  become  established.  In 
contrast, especially prior to the smoking ban in public places, smoking may be 
regarded as a sociable activity and perceived as demonstrating hospitality by 
not  rejecting  the  smoker.
104  Sometimes  social  norms  will  support  continued 
smoking  rather  than  discourage  it  especially  among  young  women  in  poor 
areas.
105 
 
Self-perceptions  may  vary  among  different  smokers.  Some  smokers  are 
concerned about revealing their habit to others. Other smokers are not bothered 
and do not worry about the opinions of other people but will respect restrictions 
and  avoid  smoking  near  non-smokers.
106  A  third  typology  of  smoker  –  the 
adamant smoker – does not support restrictions and is less accommodating to 
other people. 
 
Surveys in Britain demonstrate that the public appreciate that smoking is much 
more  dangerous  than  other  risks  of  death  (e.g.  from  murder  or  road 
accidents).
107 All age groups underestimate the risk of death before the age of 
70 years. The actual risk of death from smoking is about 250 deaths per 1000 
smokers. However the median estimate (of death in smokers) given by those 
over 25 years of age was less than half the actual rate. There is little difference 
in  perceptions  of  risk  between  groups  of  smokers,  ex-smokers  and  never-
smokers. There is no evidence that smokers deny the health risks of smoking or 
are less knowledgeable.
107 The notion of risk to self and to others has become 
very strong and has been discussed above when related to guilt and anxiety.   58 
 
Many smokers from varying socio-economic backgrounds will try to restrict their 
smoking in circumstances where they might expose children to smoke. Most 
appreciate  and  accept  the  dangers  of  passive  smoking.
104  Children  are 
perceived as vulnerable and various self-imposed restrictions are reported by 
smokers to reduce exposure such as by opening windows, not smoking in cars. 
This is conceptualized as a moral identity of a caring parent or grandparent.
104 
 
Qualitative studies in deprived areas of the UK have highlighted a number of 
barriers to use of smoking cessation services. Poor awareness of services and 
availability and effectiveness of interventions is a major barrier. Perceived cost 
of medication prevented many accessing services. Many fear the judgment of 
professionals and fear failure,
108 whilst other simply perceive a lack of support 
to help them stop smoking especially in deprived areas where smoking remains 
most common.
109 
 
Across  cultural  groups  in  the  UK,  smokers  experience  failure  with  repeated 
attempts at cessation and believe that stress and fear of withdrawal symptoms 
prevent successful cessation. Often those wanting to quit find it difficult to resist 
the temptation to continue by on-going contact with those who smoke.
110 
 
Most  smokers  want  to  quit  but  feel  unable  to  because  of  the  importance  of 
smoking in their daily routine and their addiction to nicotine. Even those with an 
established COPD diagnosis may attribute their symptoms to other factors (e.g. 
environment, work, pollution, age, fitness), often do not perceive any benefit in   59 
trying to stop and attribute the death or deterioration of friends on their stopping 
smoking.
97 Social and family contacts of those with COPD may not be helpful. 
Some smokers even with established disease find that friends and family create 
barriers by offering cigarettes.
97   
 
Many  of  these  observational  studies  create  a  rich  backdrop  to  smoking 
behaviour in different cultural and socio-economic groups. Even though no firm 
conclusions  can  be  drawn  and  ideas  cannot  be  generalised,  the  research 
provides  a  deeper  understanding  of  some  of  the  issues  involved  and  may 
generate ideas for further research into effective interventions. In the context of 
this  research  project  I  am  aware  that  the  research  population  is  not 
homogenous and that the individual response to the invitation to participate and 
the reaction to the intervention may be very varied. 
 
3.3  Intervention trials in smoking cessation 
The background quit rate without intervention is estimated to be between three 
and eight percent.
111 When assessing the rate of cessation it is important to 
consider  the  meaning  of  quitting,  the  population  being  studied  and  how  the 
study group are recruited.
112 
 
In  some  studies,  point  prevalence  at  six  or  twelve  months  is  measured.  In 
addition the period of abstinence may be recorded and therefore cessation may 
not only be defined in terms of cessation at the time of data collection but also 
the length of time at that point prevalence that cessation has been successful 
(e.g.  four  weeks  continuous  abstinence).  Therefore,  there  is  a  spectrum  of   60 
cessation, which does not simply equate with a simple dichotomy of being a 
smoker or non-smoker.  
 
The relapse rate for those who have given up smoking is high. The National 
Health Service (U.K.) smoking cessation campaign measures quit rates at four 
weeks. Many research studies clearly state that any meaningful follow up of 
cessation should be done at twelve months to establish true quit rates for any 
given technique.  For some people smoking or stopping is simply a matter of 
making a decision. For others it is a massive struggle with chemical addiction, 
habit, circumstances and environment. Some people who have quit smoking 
may remain dependent on nicotine replacement for a considerable length of 
time.
107;107  
 
The factors that determine the transition from established smoker to established 
non-smoker are complex. The state of any individual should be seen as a place 
on a spectrum of behaviour. This change in behaviour will be discussed in more 
detail in the section about behaviour and change. A number of theories will be 
explored for different states of change and motivation. 
 
Much of the vast literature on smoking cessation concentrate their attention on 
the various behavioural and pharmacological tools that have been used to aid 
people who have expressed a desire to quit smoking. The Cochrane database 
has multiple references to smoking. There are nearly 40 systematic reviews or 
meta-analyses. These include reviews of: 
1.  Acupuncture and related interventions for smoking cessation
113   61 
2.  Antidepressants for smoking cessation
114 
3.  Biomedical risk assessment as an aid for smoking cessation
115 
4.  Community interventions for reducing smoking among adults
116 
5.  Community pharmacy personnel interventions for smoking cessation
117 
6.  Enhancing partner support to improve smoking cessation
118 
7.  Exercise interventions for smoking cessation
119 
8.  Group behaviour therapy programmes for smoking cessation
120 
9.  Individual behavioural counselling for smoking cessation
121 
10. Interventions for promoting smoking cessation during pregnancy
13 
11. Nicotine replacement therapy for smoking cessation
122 
12. Nursing interventions for smoking cessation
123 
13. Physician advice for smoking cessation
124 
14. Relapse prevention interventions for smoking cessation
125 
15. Self-help interventions for smoking cessation
126 
16. Smoking cessation for chronic obstructive pulmonary disease
57 
17. Hypnotherapy for smoking cessation
127 
 
A detailed analysis and comparison of the different aspects of smoking research 
is beyond the scope of this thesis. However it is useful to have an overview of 
the breadth of interventions that have been tried in primary care in order to put 
this research thesis into perspective.  
 
As  the  main  emphasis  of  smoking  cessation  intervention  in  the  NHS  are 
psychological support (counselling) and nicotine replacement therapy these are 
included in the literature review. This research project did not set out to directly   62 
compare the efficacy of NRT or counselling with the lung age intervention but 
participants were free to access local smoking cessation facilities (although only 
a small minority of participants in this research project reported using NRT in 
their quit attempt after our intervention). It is also highly likely that the participant 
populations are very different due to recruitment methods, the information given 
and inclusion and exclusion criteria. Therefore, it is important to consider how 
the  different  types  of  intervention  being  investigated  might  attract  different 
participants, which could influence the relative success of the interventions. 
 
Despite those reservations, it is worth putting our research into the context of 
some of those other well-established and widely researched interventions and 
to  consider  the  relative  usefulness  of  the  interventions  using  nicotine 
replacement  therapy  or  counselling  services  in  research  and  in  this  thesis. 
Therefore I will briefly outline some of the key studies that have shaped opinion 
and practice within the United Kingdom so that some of these comparisons can 
be made and will I discuss the other aspects in a later section (see Section 8.2, 
p. 207). 
3.3.1 Smoking cessation trials 
Nicotine replacement therapy (NRT)  
Nicotine  replacement  therapy  (NRT)  has  been  a  key  area  of  research  in 
smoking cessation for more than 30 years. There is general agreement in most 
research  into  NRT  that  it  works  for  a  proportion  of  smokers  and  in  many 
different developed countries and contexts but that relapse rates are high.  
   63 
Early  trials  of  the  efficacy  of  NRT  were  not  promising.  One  of  the  earliest 
published trials (1980) of NRT in the United Kingdom tested the effect of NRT 
chewing  gum  against  placebo  gum  in  200  volunteers  who  wanted  to  stop 
smoking, mainly recruited from newspaper and workplace advertising.
128 After 
the treatment, initially about a third of both the intervention and placebo groups 
had quit but by six months most of them had relapsed and the differences with 
control  were  not  significant.  The  numbers  were  too  small  for  statistical 
assessment. No psychological measure of motivation or nicotine dependence 
was reported but all volunteers had enrolled ‘wanting to stop’. Despite voluntary 
participation  with  the stated  aim of quitting  these  results  were  disappointing. 
This early study would have cast doubt on the efficacy of this therapy but larger 
studies were needed to establish the role of nicotine replacement therapy 
 
It might be assumed that highly motivated smokers given the opportunity for 
support  and  help  with  symptoms  of  nicotine  withdrawal  would  do  well.  A 
moderate sized study conducted in primary care in Nebraska, USA, used NRT 
patches in well motivated smokers consuming at least 20 cigarettes per day.
129 
Nearly 400 smokers with high levels of motivation to stop were randomised into 
a double blind placebo controlled trial in 20 primary care clinics. Motivation was 
assessed  using  an  eleven-point  scale  and  confirmed  to  be  high  and  evenly 
distributed between the groups. They were all given brief counselling on two 
occasions during the study. The twelve-month abstinence rates for the active 
and placebo patch groups were 14.7% and 8.7%. The over 45 year olds and 
those  with  higher  nicotine  dependence  and  those  who  spontaneously 
volunteered did better with NRT compared to the equivalent subgroup using   64 
placebo, although the study was not powered to detect significant differences in 
those  subgroups.
129  Considering  that  these  smokers  were  supposedly  highly 
motivated  to  quit  the  quit  rates  are  not  impressive  but  nevertheless  are  in 
keeping with other studies of NRT improving rates by about 50%. Duration of 
counselling, older age and higher levels of dependence were in favour of better 
quit rates compared to placebo. 
 
In a primary care study in Oxfordshire, written invitations were sent to those 
aged  15  to  65  on  19  practice  lists.  Others  smokers  were  recruited  through 
contact with recipients of the letters. An average of 32% of the 15-65 year olds 
in  these  practices  were  invited.  In  those  days  (1994)  computer  registers  of 
smokers would have been less available or accurate and the authors did not 
report  what  proportion  of  smokers  responded  to  the  invitation.  Nevertheless, 
this  randomised  double  blind  trial  of  nearly  1700  smokers  with  confirmed 
cessation, using carbon monoxide and saliva cotinine testing, resulted in rates 
of cessation of 10.8% in the NRT patch group and 7.7 % in the placebo group 
continuously from 3 months to 12 months.
130 
 
Other  studies  in  the  UK  have  produced  similar  results  over  a  twelve-month 
period. A multi-centre randomised double blind placebo controlled primary care 
study  recruited  1200  smokers  between  20  and  60  years  of  age  who  were 
motivated to quit. Approximately 70% of participants wanted ‘very strongly’ to 
stop smoking altogether.
131;132 At one year the nicotine patch group achieved 
9.3%  continuous  abstinence  compared  to  5%  in  the  placebo  group.  An 
important deficiency of the generalisability of this study to primary care was the   65 
deliberate exclusion of those who would have most to gain from quitting notably 
those with heart disease, hypertension or diabetes. They also failed to include 
clear  methodological  details  of  their  scales  for  measuring  motivation  and 
dependence. 
 
Attempts have been made to compare the relative success of using different 
strengths of NRT for smokers with different levels of nicotine dependence as 
scored by the modified Fagerstrom score and the heaviness of smoking index 
(HSI).
133 Garvey et al. recruited just over 600 volunteers through newspaper 
advertising in the Boston area and randomised them to receive placebo or one 
of  two  different  strengths  of  NRT  gum.
133  Brief  counselling  was  on  offer  for 
about ten minutes at each contact. After twelve months the abstinence rates 
were  6.4%  in  the  placebo,  and  up  to  13.4%  in  those  using  NRT.  Low 
dependence smokers did better with placebo than high dependence smokers as 
one would expect but gum strength did not make a significant difference to the 
success of high compared with lower dependent smokers. Therefore gum users 
doubled  their  quit  rate  over-all  compared  to  placebo.  Again  levels  of  initial 
motivation were measured as high on the same scale as the Nebraska study by 
Daughton et al.
129 (described above) and recruitment method attracted those 
with a prior desire and confidence of quitting  success (average confidence of 
success >7 on a scale up to 10). 
 
None  of  the  studies  above  included  data  about  co-morbidity  and  their 
recruitment  methods  tended  to  exclude  those  at  most  risk  from  continued 
smoking  (e.g.  cardiac  disease).  One  can  therefore  conclude  that  healthy   66 
volunteers who are well motivated are a group who can (at most) double their 
chances of quitting compared to their respective controls treated with placebo. It 
is important to know how well those with serious co-morbidity would respond to 
intervention  to  stop  smoking.  Smoking  may  cause  serious  disease  or  cause 
acceleration of complications of other diseases (like diabetes) 
 
A Welsh study specifically recruited those who have smoking related disease. 
This group already are at special risk of exacerbating their primary disease or of 
secondary  events  and  therefore  likely  to  be  well  versed  in  the  dangers  of 
smoking. Therefore they are likely to represent a group who struggle with their 
habit  and  are  resistant  to  change.
134  In  a  twelve-month  period  the  clinicians 
referred  over  400  high-risk  patients  to  see  the  smoking  counselor.  All  had 
recently  been  admitted  with  smoking  related  diseases  included  those  with 
chronic  obstructive  pulmonary  disease,  coronary  heart  disease  and  vascular 
disease.
134 Of these nearly half either did not attend or refused to be included in 
the trial. They were randomised by month of entry to a control group, which 
received  monthly  counseling  support  or  an  intervention,  which  involved 
counseling and NRT. At the end of twelve months quit rates in both groups was 
the  same  at  around  14%.  This  outcome  in  this  special  group  of  high-risk 
individuals can be interpreted in a variety of ways. It could be viewed a success 
that  the  extra  support  enabled  14%  to  quit  for  12  months  or  that  nicotine 
replacement is not the key for these smokers or that even if health is overtly 
being harmed the majority of smokers are unable to quit. It is unfortunate that 
this  study  did  not  include  any  psychological  measure  of  motivation  or  self-
efficacy. This prospect that pre-existing smoking related disease does not seem   67 
to  be  a  major  stimulus  to  change  has  major  (negative)  implications  for  the 
intervention presented in this thesis and for other research that concentrates on 
the impact of confronting smokers with the real consequences of their habit. 
 
Two  very  important  findings  have  emerged  from  more  recent  reviews  of  the 
data. Firstly long-term quit rates are most important but few studies continue 
beyond one year. Those that have done long term follow up have demonstrated 
continued  attrition  of  the  benefits.
135  Secondly,  randomised  controlled  trials 
often  exclude  the  most  vulnerable  patients.  They  select  patients  with  lower 
levels  of  co-morbidity  or  have  exclusions  that  render  the  results  non-
generalisable. Therefore those participating are not representative of patients in 
normal general practice. Trial participants are generally healthier and are likely 
to be more motivated to quit smoking.
136 
 
The implications for practice of the research on NRT are neatly summarised in 
NICE Guidance.
137 Therefore they will not be reproduced in this thesis except 
for the following excerpt: 
‘All of the commercially available forms of nicotine replacement therapy 
(NRT),  i.e.  gum,  transdermal  patch,  nasal  spray,  inhaler,  lozenge  and 
sublingual tablet, are effective as part of a strategy to promote smoking 
cessation. They increase the rate of long-term quitting by approximately 
50% to 70% regardless of setting. These conclusions apply to smokers 
who  are  motivated  to  quit  and  who  have  high  levels  of  nicotine 
dependence. There is little evidence about the role of NRT for individuals 
smoking less than 10 to 15 cigarettes a day’.   68 
 
 
Smoking cessation, COPD and NRT 
As  outlined  in  the  previous  section,  only  a  minority  of  studies  of  NRT  have 
deliberately  targeted  high-risk  groups  and  those  with  smoking  related  co-
morbidity.  With  respect  to  this  research  thesis  on  the  impact  of  lung  age 
estimation, the group of people who already know they have pre-existing lung 
damage are of particular interest.  
 
One systematic review (2004) attempted to identify studies that targeted those 
with chronic obstructive pulmonary disease.
138 The five studies that remained 
after  their  initial  search  were  a  heterogeneous  group  with  a  variety  of 
interventions. Three of the studies recruited less than 60 participants each and 
two of them did not isolate the effect of NRT. One study used the concept of 
‘smoker’s lung’ without any other form of intervention or pharmacotherapy to 
promote  behaviour  change  but  was  small,  suffered  contamination  between 
groups and it could not produce meaningful statistical differences.
139  
 
Finally they included a large randomised clinical trial (ten centre and over 5000 
patients) in the US and Canada but it was not primarily designed to study the 
use  of  smoking  cessation  interventions.
140  Their  main  objective  was  to 
determine whether a program incorporating smoking intervention and use of an 
inhaled bronchodilator can slow the rate of decline in forced expiratory volume 
in 1 second (FEV1) in smokers aged 35 to 60 years who have mild obstructive 
pulmonary disease. However they did randomize their sample to three groups; 
a smoking intervention plus bronchodilator, smoking intervention plus placebo,   69 
or no intervention. They concluded that the success of smoking interventions in 
this group of respiratory patients is low despite the high risk of progression to 
more severe COPD.
140 They stated that this is consistent with the commonly 
held view that that continued smoking in the presence of established COPD is 
an  indication  that  these  patients  are  particularly  addicted  and  would  have 
already quit if they were likely to. This rather defeatist view is a real barrier to 
progress when it comes to research and treatment of those with COPD at any 
stage. There is almost a hopeless resignation by authors to the inevitability of 
negative  attitudes  and  lack  of  changed  behaviour.  Generally  the  paucity  of 
studies of smoking cessation and COPD and the poor methodological quality 
and size of studies that have been done are a further reflection of negative 
attitudes about those with COPD. 
 
Finally,  a  recent  update  of  a  Cochrane  review  (2008)  analysed  111  studies 
which tested the efficacy of one or more types of NRT.
141 All the studies in the 
analysis  compared  the  effect  of  NRT  to  placebo  or  no  NRT.  Definitions  of 
abstinence in those studies varied widely with three quarters of them reporting 
sustained abstinence or repeated point prevalence. Some were self- reported 
but most had some type of biochemical verification. The most common form of 
validation was measurement of carbon monoxide in expired air. Validation of 
cessation by cotinine (in blood saliva or urine) was included in 27 trials. They 
produced evidence from trials, which included data from a total of over 40,000 
participants. They concluded that offering NRT to dependent smokers who are 
prepared  to  try  to  quit  increases  the  chance  of  success  irrespective  of  the 
method of delivery of NRT. The absolute effect of NRT depends on a number of   70 
different factors evident in different studies. Without any pharmacotherapy or 
support quit rates over twelve months are about 3-5%. Using NRT can increase 
successful quit rates by 2-3% (NNT 33-50) but where study populations are 
primed to better baseline quit rates (by better predictors of success or intense 
behavioural support) the rates may be improved from 15% in controls by 8% 
(NNT  12).  In  other  word  there  is  a  50%  improvement  from  the  baseline 
wherever that happens to be. 
 
In conclusion, although nicotine replacement therapy (NRT) is not an integral 
part of the intervention in this research project, it is likely that quit rates and cost 
comparisons will be made. It is fair to say that NRT works well for those who 
use  them  as  part  of  a  supervised  smoking  cessation  programme.  This 
presupposes  that  people  are  motivated  to  attend  these  programmes  and 
comply with taking medication in the prescribed manner. However, they should 
not be used or offered to those who have little intention to give up smoking. 
Motivational interviewing 
Intensive  counselling  and  even  brief  verbal  intervention  in  primary  care  by 
clinicians  will  increase  the  likelihood  that  someone  will  give  up  smoking. 
Attempting to quit smoking involves two major components. The two distinct 
parts of the quitting process are the initiation of an attempt and then maintaining 
cessation.
27 Although the majority of smokers would like to quit there are some 
who need motivating to change. In a large survey in four developed countries, it 
was found that the majority of smokers would like to quit.
80 It is important to 
motivate smokers to act upon these desires and to encourage patients to stop 
as quickly and as early as possible.   71 
 
Motivational  interviewing  (MI)  attempts  to  ‘overcome  the  ambivalence  that 
keeps many people from making desired changes in their lives’.
142 Proponents 
of  the  technique  conceptualize  MI  as  occurring  in  two  phases  with  two 
overlapping  goals.  The  first  phase  involves  building  intrinsic  motivation.  In 
practice this is usually the actions of a health professional by highlighting the 
problem at every opportunity in a way that is not going to jeopardize the client-
professional relationship and that is appropriate to the stage of motivation. With 
reference to stage it is important to note that motivational interviewing draws 
heavily on the assumption that the trans-theoretical model of change is a well-
established, accepted and sound theory. Phase one of MI is regarded as non-
confrontational and uses open questioning with reflective listening techniques 
similar to many forms of counselling.  
 
The second phase of MI involves strengthening the commitment to change and 
developing a plan to accomplish the transition.
142 The second phase of MI uses 
confidence-building techniques. This avoids the idea that the professional can 
‘sort the problem out’ and draws the client away from negative thoughts about 
their own ability to make plans to change and to build problem solving skills. For 
example asking: 
‘What problems do you foresee, and how might you deal with them?’  
 
The technique and type of questioning could be conceptualized in a number of 
cognitive  and  social  cognitive  theories.  This  is  evident  by  the  use  of  open 
questions about confidence to change that might be called self-efficacy, and   72 
personal strengths as well as social support and previous experience of the 
smoker. 
 
Most of the evidence for the utility of MI in changing behaviour comes from the 
realms of problems with alcohol, gambling or physical activity.
142 Part of the 
difficulty assessing the content and quality of trials is the use of an ill-defined 
intervention, which may or may not be reproducible by different therapists. For 
example in assessing the results of various studies which purport to use MI it is 
necessary to understand what the researchers actually did, for how long and 
with what training. Essential components often include feedback to a person on 
their  individual  results  derived  from  standard  assessments.  In  fact  most 
research studies purporting to be testing the efficacy of MI use adaptations of 
motivational  interviewing  (called  AMI)  which  contain  an  element  of  feedback 
carried out by non specialists.
143 
 
There have been only two controlled clinical trials of motivational interviewing in 
smokers.  Only  one  of  these  investigated  smoking  in  adults  and  was  large 
enough and had sufficiently long follow up to be worth considering here.
26 The 
main outcomes were behavioural measures and readiness for change at six 
months. Overall the results were disappointing and there were no significant 
differences in abstinence, reduction in cigarettes smoked or overall quit rates. 
However there was a movement towards a more advanced stage of change.
26 
As  discussed  before,  a  change  in  stage  is  not  a  reliable  or  useful  primary 
outcome for trials, as it does not equate to behaviour change. 
   73 
So far the research on motivational interviewing has been inconclusive due to 
low power, inadequate follow-up and problems with consistent delivery of the 
intervention. 
 
3.4  Biomedical markers  
A  possible  strategy  for  improving  smoking  cessation  rates  could  be  giving 
feedback on  the  biomedical  or  potential  future  effects  of  smoking  in  a  more 
personalised  way  in  comparison  to  the  broad  generalised  public  health 
message  of  ‘smoking  is  harmful’.  The  simple  facts  are  that  a  minority  of 
smokers will get cardiovascular disease (15%)
144 and the majority of smokers 
will not get chronic obstructive lung disease (75%).
5 
 
Although ‘smoking kills’ is written on many packets of cigarettes only a quarter 
of smokers will die of diseases attributable to their habit.
16;107 Although smoking 
is  the  major  cause  of  lung  cancer  and  smoking  cessation  is  recommended, 
large trials indicate that the lag time for a beneficial effect of smoking cessation 
on lung cancer may be as long as 20 years.
145 
 
A Cochrane review has shown that community based health messages about 
smoking have been ineffective.
116 However, the concept of using personalised 
risk as a method of encouraging behaviour change has some merit and has 
been investigated in a number of different contexts. Biomarkers can be broadly 
classified into three types as indicators of: 
1. Exposure to harmful substances e.g. the presence of cotinine in   74 
smokers’ urine indicating exposure to harmful chemicals 
2. Damage caused by exposure to harmful substances e.g. abnormal 
angiograms in smokers 
3.  Susceptibility  to  disease  as  a  result  of  the  marker  e.g.  the 
presence  of  genetic  markers  indicating  an  increased  risk  of  lung 
cancer. 
The factors that trigger and sustain changes in health behaviour are difficult to 
evaluate. A number of different models of behaviour change have been used to 
try  to  predict  or  explain  the  actions  of  individuals.  Some  of  them  combine 
several aspects that individuals consider when making decisions. For example 
their perception of personal disease susceptibility, the severity of that disease 
according to their understanding and experience and an analysis of the benefits 
or risks of changing behaviour may influence an individual (see Section 4, p. 
89). Motivational interviewing incorporates elements of these three factors to 
treat alcohol, opiate and cigarette use.
146   
3.4.1 Non-systematic review of biomarkers 
McClure  has  published  a  non-systematic  overview  of  twelve  studies  using 
feedback  on  individual’s  biomarkers.
147  Some  studies  used  multiple  markers 
ranging from genetic markers for lung cancer risk, through to urinary, blood or 
breathed air markers of smoking. Their conclusion was that the successful use 
of  biomarkers  to  alter  attitudes  of  those  with  unhealthy  behaviour  probably 
depend on several interrelated factors- 
•  How the information is conveyed.  
•  If the information is understood and accepted.   75 
•  Understanding of the purpose of the marker and what is actually 
being tested and how it relates to their behaviour and health.  
•  Comprehension can be enhanced by use of written handouts and 
graphic displays of the biomarker values. 
•  Repeated measurement and reinforcement of the message. 
•  How  the  message  is  conveyed  in  terms  of  harm  or  benefit. 
According  to  prospect  theory  people  respond  better  to  the 
prospect of potential gain rather than the messages about costs 
and disadvantages. 
Weaknesses of review 
Unfortunately the evidence used for the above conclusions have some major 
flaws. Apart from the fact that that there was no clear search strategy, a number 
of  the  research  papers  that  they  used  in  their  review  had  serious 
methodological shortcomings.  
 
The  review  claimed  that  ‘biomarker  feedback  may  enhance  the  likelihood  of 
cessation  because  a  trend  for  increased  abstinence  was  found  in  three 
randomised trials’.
36;148 However, one of the three papers quoted and reputed to 
be by Hoffman 1998 was never published (claimed to be in Behavioral Medicine 
Journal).  The  other  two  trials  had  serious  methodological  shortcomings.  For 
example: 
 
1. Risser and Belcher studied 90 smokers in a general screening clinic.
36 They 
were randomised to receive education alone or education plus an additional   76 
motivational intervention that contained immediate feedback about the smoker's 
exhaled  carbon  monoxide  (CO)  values,  spirometry  results,  and  pulmonary 
symptoms.    Including  all  patients  not  successfully  contacted  at  follow  and 
assuming they were continuing to smoke, the self reported quit rates were 20% 
vs. 7% (p = 0.06) in intervention and control groups respectively, and therefore 
not  significant.  The  major  methodological  problems  with  this  study  were  the 
absence  of  a  power  calculation,  small  numbers  in  the  study,  no  clear 
randomisation  procedure,  and  the  lack  of  generalisability  as  the  study  was 
predominantly in U.S. male veterans (96%). 
 
2. Walker and Franzini recruited 64 smokers, by media advertising and financial 
incentive, into this randomised controlled trial study comparing two therapies.
148 
The  intervention  group  had  exhaled  carbon  monoxide  measurement  and 
spirometry  feedback.  Half  of  them  also  had  taste  satiation  (TS)  or  focused 
smoking (FS) (in 50%) and voluntary booster sessions. The control group did 
not  have  spirometry  or  carbon  monoxide  measurements  but  otherwise  were 
treated the same. The setting was a stop-smoking clinic in the United States. 
The method of randomisation was not explained. Only 64 agreed to take part 
and the 2 x 2 groups therefore contained very small numbers. Follow up at six 
months measured quit attempts and biochemical validation of non-smoking. The 
main  problems  with  this  study  were  the  lack  of  a  power  calculation,  small 
numbers of participants divided into very small groups for the complex 2 x 2 
study  which  resulted  in  a  lack  of  data  for  analysis  which  prevents  any 
meaningful results or conclusions. Not surprisingly no statistical analysis was 
given.   77 
 
Four  other  studies  included  in  the  review  were  trying  to  simultaneously  test 
many  different  components  so  that  the  effect  of  the  biomarker  could  not  be 
identified or isolated. In addition they were not randomised controlled trials. 
 
 A study by Li et al. tested the hypothesis (one of three hypotheses) that male 
asbestos-exposed workers who had abnormal pulmonary function tests would 
be more likely to respond to counselling by a physician to stop smoking than 
those  with  normal  results.
149  From  1231  men  recruited  only  579  were 
successfully  followed  up  at  11  months.  The  participants  were  not  properly 
randomised. Those with abnormal pulmonary function test result (PFT) were 
randomised to get minimal counselling or detailed prolonged counselling on the 
basis of their results. Only 47 had abnormal pulmonary function and contrary to 
the protocol one of the research physicians did not comply with the counselling 
protocol and the groups had to be re-constituted.  
 
Despite the deficiencies of the study the researchers were surprised to find that 
prolonged  cessation  rates  of abnormal  PFT  subjects  were  not  different  from 
those of subjects with normal PFTs. In fact they found that those with normal 
results  were  much  more  likely  to  give  up  4.3%  v  9.5%.  Neither  a  power 
calculation nor confidence intervals were given.  Questionnaire data showed 
that  nearly  all  subjects  perceived  a  link  between  smoking  and  lung  disease 
(90%) and had previously tried to quit (77%). Although the study was fatally 
flawed by methodological problems it does raise the interesting fact that one   78 
cannot assume that bad results of lung function and lots of counseling will yield 
better  quit  results  than  good  results  and  similar  or  less  counselling  and 
information. 
 
Overall, I conclude that the review by McClure is useful in highlighting some of 
the published studies but disappointing in that the quality of studies means that 
no real conclusions can be drawn. However on the positive side some ideas 
have been generated about what might influence smokers and is a source of 
lessons for future research and interventions. 
3.4.2 Critical appraisal of Cochrane systematic review (2005) 
A detailed and comprehensive review by Bize et al was published in October 
2005, twelve months after the start of the Step2quit RCT and more than two 
years after the initial development of the research proposal.
115 As this is such 
an important and relevant review for this thesis I present a critical appraisal of 
this review below.  
 
In the context of my research proposal, the studies of particular interest are 
those in which markers of lung damage have been used to promote smoking 
cessation.  It  is  important  to  note  that  none  of  the  studies  selected  by  the 
Cochrane review used lung age as tool for measuring or explaining the effects 
of  smoking  on  the  lungs.  A  summary  of  some  key  aspects  of  the  different 
studies outlined in the Cochrane review are contained in the Appendix 2 (p. 
287) along with the key flaws in methodology. 
   79 
The systematic review by Bize et al will be critically appraised according to the 
following headings.
150 
1. Has the review addressed an important clinical question? 
2. Have the reviewers made a thorough search and explored other 
sources? 
3. Was methodological quality assessed and trials weighted? 
4. How sensitive are the results to the way the review was done? 
5. Have the numerical results been interpreted with common sense 
and due regard to broader aspects? 
 
Has the review addressed an important clinical question? 
Antismoking  campaigns  and  public  health  bodies  have  used  blunt  and 
occasional  graphic  messages  to  inform,  alert  and  scare  smokers  for  many 
years.  Very  little  evidence  is  available  that  these  are  effective  in  reducing 
smoking but the display of general aversive information has effectively taken 
responsibility  about  harm  away  from  the  producers  of  cigarettes  and 
governments and firmly places the responsibility onto the individual.
116 
 
Whilst  the  public  health  messages  and  other  strategies  to  improve  health 
education  and  reduce  smoking  should  continue  it  is  important  to  review  the 
messages  given  to  individuals  and  the  most  effect  way  of  giving  that 
information.  The  Cochrane  collaboration  correctly  concluded  that  this  is  an 
important area of study with the following central focused question: 
‘Does  feedback  on  personal  characteristics  indicating  effects  of 
smoking, or susceptibility to smoking-related illness, increases rates   80 
of smoking cessation?’ 
And the following objectives:  
•  To  determine  the  efficacy  of  biomedical  risk  assessment  provided  in 
addition to various levels of counselling, as a contributing aid to smoking 
cessation. 
•  Are  multiple  types  of  measurement  (e.g.  spirometry  and  exhaled  CO 
measurement used together) more effective for smoking cessation than 
single forms of measurement? 
 
Have the reviewers made a thorough search and other sources explored? 
They  searched  the  Cochrane  Collaboration  Tobacco  Addiction  Group 
Specialized  Register,  Cochrane  Central  Register  of  Controlled  Trials 
(CENTRAL),  MEDLINE  (1966  to  2004),  and  EMBASE  (1980  to  2004).  They 
combined  methodological  terms  with  terms  related  to  smoking  cessation 
counselling  and  biomedical  measurements  in  a  thorough,  explicit  and 
systematic way. They were very strict and rigid in their choice of trials for further 
analysis. The pros and cons of this will be discussed below. They included only 
RCTs of smoking cessation trials with interventions based on a biological test 
aimed  to  improve  motivation.  They  excluded  trials  in  which  the  effect  of 
biomedical  test  was  confounded  by  the  use  of  other  components  in  the 
intervention group. From 4049 retrieved references, they selected 170 for full 
text assessment. The researchers give a very clear indication of their intention 
to  include  only  randomised  controlled  studies,  which  display  rigorous 
quantitative  methodology.  For  this  reason  out  of  the  original  170  selected 
abstracts only eight trials met the inclusion criteria. In conclusion, the review   81 
conducted a thorough search for sources in keeping with Cochrane principles. 
 
Was methodological quality assessed and trials weighted? 
The trials were assessed according to rigorous criteria. Studies were excluded if 
they were not randomised trials or if they did not have feedback on biological 
measurements  of  some  aspect  of  the  smoker’s  health.  If  the  intervention 
strategy was not clear-cut or the period of follow up was deemed inadequate 
(six  months)  they  were  excluded.    Furthermore  the quality  of  each  trial  was 
assessed using transparent pre-determined criteria. Despite their strict criteria, 
among the eight studies that were included in their final list for detailed analysis, 
there were plenty of flaws in the methodology. For example only one of the 
eight trials reported an adequate randomisation procedure.
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How sensitive are the results to the way the review was done? 
If  anything  the  methodology  of  this  systematic  review  is  so  rigorous  and 
exclusive that no other conclusion could be reached. It is feasible that a more 
inclusive  approach  may  have  found  some  merit  in  the  use  of  biomedical 
markers but would have carried less weight. The authors state that they used 
other studies (non-RCTs) for background information but not for any objective 
analysis  of  effectiveness.  This  approach  is  in  keeping  with  the  Cochrane 
principles  and  the  SIGN  hierarchy  of  evidence.  However  if  cross  sectional 
studies and those which concentrate on qualitative analysis is ignored important 
information and insights from other studies may be overlooked. However, these 
issues will be discussed more under the section 3.4.3 below about trials that 
have  used  interventions  confronting  smokers  with  their  lung  damage  to  aid   82 
behaviour change. 
 
Have  the  numerical  results  been  interpreted  with  common  sense 
and due regard to broader aspects?  
As  all  the  included  studies  were  randomised  controlled  trials  Bize  et  al 
converted the results into odds ratios for smoking cessation up to the longest 
recorded follow-up time (six to twelve months) between intervention and control 
groups,  with  their  95%  confidence  intervals.  Mostly  they  were  unable  to 
combine results because the interventions were too diverse.  In the two studies 
they were able to combine for a mini meta-analysis the effects were in opposing 
directions and more or less cancelled each other.
152;153 They questioned the 
external validity of the only study with a statistically significant positive odds 
ratio  as the  sample was  made  up  predominantly of  male  light  smokers  in  a 
developing country (average 10 to12 cigarettes a day).
154 Moreover, from the 
perspective of this thesis that study had little relevance as the intervention was 
about confrontation with evidence of arterial damage rather than lung damage. 
 
However the reviewers could not say with certainty that there is no effect from 
using biological markers.  Several of the studies had odds ratios greater than 
one,  which  therefore  favoured  the  intervention  group,  but  with  confidence 
intervals that straddled zero and therefore reduced the likelihood that the real 
result was positive. Any effect may be hidden by a serious lack of power to 
detect small but significant changes in smoking behaviour. Remarkably, only 
one of the studies included in their final selection had documented a power 
calculation  estimation  of  sample  size  prior  to  recruitment.
155  Moreover,  that   83 
estimate was based on a quit rate of 25% in the intervention group and 10% in 
the control group. In the light of other interventions for smoking cessation this 
was probably a rather optimistic estimate of the possible effect of intervention.  
 
Another possible explanation for the absence of effectiveness of biomedical risk 
assessment could be the potentially counterproductive effect of communicating 
normal  results  to  smokers.  Only  one  of  the  studies  included  in  the  analysis 
provided some insight about smoking cessation rates according to spirometric 
test results. Sippel did not find any correlation between smoking cessation and 
abnormal spirometry results.
155 These particular questions, and the best way to 
handle and communicate normal results, remained unanswered. 
 
It  is  clear  that  there  are  some  serious  methodological  shortcomings  in  the 
studies that were included in the review. Even if the results of the statistical 
analysis  had  pointed  towards  a  useful  effect  of  the  intervention  these 
methodology problems would have created serious doubt about their usefulness 
and generalisability. 
 
Therefore it is possible that with better methodology with improved numbers of 
participants,  adequate  length  of  follow  up  and  experimental  rigour  these 
interventions could be re-investigated for their possible effectiveness. In these 
circumstances isolating a small but critical improvement to smoking cessation or 
uptake of smoking cessation treatments would be more likely.  
 
Elsewhere I have outlined the study by Etter et al. (see Section 4.7, p. 141) of   84 
tailored information given to smokers according to personal data from a pre-
intervention  questionnaire.
156  It  seems  clear  that  the  effect  of  such  brief 
interventions will be limited, subtle but possibly important especially if clinicians 
are  to  ‘capture’  those  smokers  who  would  not  normally  attend  a  smoking 
intervention because they are not (yet) motivated to do so.  
 
It  is  already  fairly  clear  what  support  and  pharmacological  treatments  help 
smokers  to  quit  when  they  are  seriously  intending  to  do  so.  The  systematic 
review did not reveal strategies to help the reluctant but damaged individuals or 
to establish a role for the routine use of biomarkers in smoking cessation policy. 
However, the authors concluded that due to a lack of good quality evidence 
they  could  not  make  any  definitive  statements  about  the  effectiveness  of 
biomedical risk assessment as an aid for smoking cessation. 
3.4.3 Smoking cessation in the presence of lung damage 
Several researchers have tried to find an association of abnormal lung function 
with  improvement  in cessation  rates. A  large  non-randomised  study  of 4500 
Polish  men  and  women  smokers  found  that  those  with  lung  damage  from 
smoking were more likely to respond to stop smoking after being confronted by 
information about their lung damage compared to those who had no detectable 
damage at baseline.
157 At the time of screening all subjects received simple 
smoking  cessation  advice.  Those  with  abnormal  lung  function  were  told  that 
they had COPD and that smoking cessation would halt rapid progression of 
their lung disease. They were shown a graph adapted from Fletcher and Peto’s 
classic  diagram  demonstrating  deterioration  with  age  in  susceptible  smokers 
(see  Figure  1,  p.  44),
6  and  their  FEV1  was  superimposed  on  the  diagram   85 
showing the  expected  future  decline and  the  benefit  of  stopping.  They  were 
strongly encouraged to stop smoking and given a booklet about health risks of 
smoking and benefits and methods of stopping. 
 
The  validated  smoking  cessation  rate  in  those  with  airway  obstruction  was 
16.3%  compared  with  12.0%  in  those  with  normal  spirometric  parameters. 
Although they did not use lung age as a concept to explain their results use the 
idea of showing a graphic and giving individualized advice is a similar idea. The 
study has a number of shortcomings. The control group quit-rate in those with 
normal lung function is considerably higher than expected which lead to some 
doubts  about  how  generalisable  the  results  can  be.  The  participants  were 
allocated  and  not  randomised.  The  characteristics  of  the  two  groups  are 
therefore very different and other unidentified confounders may be influencing 
the results. Of note the measure of pack-years, age and of course (by definition) 
percent of predicted FEV1 was different. Success in smoking cessation was 
associated  with  lower  lung  function,  lower  nicotine  dependence,  and  lower 
tobacco exposure.  This study would not have been included in the Cochrane 
analysis but adds some further evidence of a possible use of graphic displays 
and explaining deteriorating lung function to smokers. The implication from the 
Bednarek  study  is  that  individuals  can  be  presented  with  understandable 
individualized,  graphic  information  that  creates  concerns  about  the  future 
deterioration of function, which can translate into possible concern about health, 
negative thoughts about smoking, and action to quit. 
 
Conceptualizing  and operationalising  (measuring)  these psychological  factors   86 
have  proved  more  difficult  and  have  not  thrown  more  light  on  any  possible 
mechanism.  In  a  small,  randomised  controlled  trial  of  124  smokers  the 
perceived risks and feedback about lung age did not correlate with desire to 
quit.
56 This study also would not have been included in the Cochrane review 
above because the primary outcome measure was ‘desire to stop smoking’ not 
smoking cessation. Furthermore, the participants were college students with a 
mean age of 20 years and therefore not representative of the usual group of 
smokers in the community, and the numbers were too small for any statistically 
significant conclusions to be made.  One surprising feature was that 75% of the 
students had a lung age greater than chronological age (the mean lung age was 
35).  Most  previous  research  indicates  that  20  pack  years  of  smoking  are 
required before lung damage is detectable.
32 This discrepancy casts doubt on 
the reliability of the testing. 
 
Several  other  studies  published  since  the  Cochrane  review  of  2005  have 
produced  mixed  results.  A  prospective  primary  care  study  in  Sweden  used 
annual  spirometry  and  brief  advice  over  an  impressive  three  years  of  follow 
up.
158  They  identified  those  with  COPD  and  compared  them  to  a  group  of 
smokers with normal lung function. This was not a randomised controlled trial 
and the groups were different by definition. The authors also suspected higher 
motivation  due  to  the  recruitment  process  of  advertising  a  free  lung  test  for 
smokers  between  40  and  55  years.  The  abstinence  rates  were  significantly 
higher in the smokers with COPD than in smokers with normal lung function. 
Smoking  cessation  rates  among  smokers  with  normal  lung  function  did  not 
increase with increasing number of follow-ups. Despite its limitations the 3-year   87 
cessation rates of 25% in the COPD group (v 9% in those with normal lung 
function, p< 0.001)
f give some support to the value of annual spirometry and 
discussions  about  abnormal  lung  function.  They  concluded  that  smokers 
diagnosed with COPD stopped smoking significantly more often than those with 
normal lung function.
158 Two major weaknesses of the study cast some doubt 
over the results. First the smokers were not randomised and therefore there 
may  have  been  some  unknown  confounding  variables  and  secondly  the 
reliability  of  their  impressive  quit  rates  is  questionable  as  these  were  self-
reported and not validated by biochemical testing. 
 
Finally, the study that comes nearest in methodology to the lung age study was 
a randomised controlled trial in primary care in Belgium.
159 One major difference 
was  that  their  study  excluded  those  in  pre-contemplative  and  contemplative 
groups. They selected only preparation and action stage smokers who were 
randomised  by  a  toss  of  a  coin  and  used  spirometry  results  as  part  of  the 
intervention. All 221 participants tried to quit, a random sample were confronted 
with spirometry results.  They report that they found no significant difference in 
those  with  normal  or  abnormal  results  or  those  with  spirometry  versus  no 
spirometry.  Their interpretation is based on 24 month quit rates of 19% v 14% 
but no detailed statistical analysis was presented. They also did not include a 
power  calculation  and  failed  to  document  levels  of  co-morbidity  or  specify 
exclusion  criteria  (except  stage  of  change).  In  comparison  to  long-term  quit 
rates in other studies their rates seemed fairly respectable. However, I believe 
their study is inconclusive and incomparable with the lung age study for several 
                                            
f No CI reported   88 
important  reasons.  First  the  study  was  not  sufficiently  powered  to  detect  a 
difference  (a  five  percent  difference  in  smoking  rates  was  said  to  be  non-
significant) and secondly their sample was highly selected as far as motivation 
to change.  
 
In summary, my overall conclusions from the research published since 2005 
Cochrane meta-analysis is that the jury is still out about the use of confronting 
smokers with their spirometry results however that is done. More and better 
quality research is required to establish the role of using spirometry in screening 
and in motivating all smokers towards behaviour change.    89 
     
4  Literature review 2: Theories of behaviour change 
4.1  Introduction to behaviour theories 
It  is  beyond  the  scope  of  this  thesis  to  cover  all  behaviour  theories.  Out  of 
hundreds of possible theories of behaviour change I have chosen to focus on 
several for detailed discussion. They are the theory of planned behaviour (TPB), 
catastrophe  (chaos  or  complexity)  theory  (CCC),  the  trans-theoretical  model 
(TTM), and the health belief model (HBM). 
 
My  reasons  for  choosing  these  particular  theories  for  further  discussion  are 
mostly pragmatic. As a non-psychologist I take an outsider’s view and cannot 
be  exhaustive  in  covering  the  discipline  of  behavioural  psychology.  I  have 
therefore chosen theories that: 
 
•  Are  frequently  cited  in  the  health  research  literature  in  the  context  of 
smoking, addiction and health related behaviour change;  
•  Appear to have some significant differences to each other, and therefore 
provide an opportunity to explore the range of ideas and constructs used 
in theories; 
•  Seem to have significant overlap in constructs and terminology, which I 
compare and contrast.  
 
For  each  of  the  selected  theories,  I  outline  the  fundamental  structure, 
assumptions, how they work, the terminology, some research background, and   90 
the usefulness of each model in relation to smoking. 
4.1.1 What are theories of behaviour for? 
The development of different theories in western medical practice reflects the 
positivist  approach  to  most  biomedical  research  and  intervention.  Positivism 
assumes that there exist constant, replicable and testable facts. Positivism and 
the scientific method are inextricably intertwined. The scientific method depends 
upon gathering observable, empirical measurable evidence. Even though many 
research articles are concerned with facts and results and may not pay attention 
to an underlying theory there is an assumption (even if unacknowledged) that 
such fundamental rules underpin modern scientific enquiry.
160 
 
Most of the models of behaviour indicate that their primary objective is to predict 
behaviour.
161 Stepping back one stage further it is clear that there are two basic 
assumptions  that  justify  the  study  of  health  behaviours.  First,  that  a  large 
proportion of morbidity and mortality (particularly in industrialised countries) is a 
consequence  of  certain  behaviour  and  second,  that  these  behaviours  are 
amenable to manipulation and change.  
 
Another  important  objective  of  developing  models  is  to  explain  observed 
behaviour in such a way that the knowledge can then be used to develop new 
strategies to promote desired behaviour change using that information as the 
underpinning  foundation  for  new  interventions.  Finally,  although  cognitive 
theories are mainly used to predict behaviour they may have a sensitising role, 
generate ideas and concepts that help understanding.
92  
   91 
4.1.2 Difficulties navigating behaviour theories 
One  of  the  many  difficulties  for  those  who  approach  the  broad  subject  of 
behaviour theory in the context of predicting and changing health behaviour is 
the  vast  and  inconsistent  use  of  new  vocabulary.  The  terminology  does  not 
necessarily have inherent or intuitive meaning and words used for constructs 
from different theories may seem similar or have overlapping meaning without 
actually being truly interchangeable. Many of the social cognitive models fail to 
supply clear construct definitions.
161 When comparing different social cognitive 
models there are some constructs, which are very similar (if not identical) to 
each other but are given a different label. Moreover when definitions of terms 
are  supplied  they  often  use  new  and  equally  impenetrable  words  in  the 
explanation. 
 
In common with all theories of behaviour, the development of these theories is, 
to use a metaphor, a map of the territory rather than being the territory itself. 
Each construct is a symbol or landmark on the map rather than the actual thing 
it purports to represent. Maps are useful to help guide us through a landscape 
and it may be that a poorly drawn map is better than none. Unless each of the 
maps uses terminology that is understandable and interchangeable, then the 
travellers are likely to get confused and lost. However it is important to realise 
that with every new journey if new discoveries of ‘facts’ are made the map may 
need to be modified or otherwise it will become less and less useful. If a new 
feature (from research or observation) cannot be incorporated into or explained 
by the map as it stands it may be that the map is the wrong tool for pointing the 
right direction. In practice where there is a discrepancy between the theory and   92 
observation usually some explanation or addition is offered for the difference 
rather rejection of the theory. To persist with the metaphor, if a train appears on 
the landscape, their presence may not be explicable by the ordinance survey 
map  made  ten  years  ago  but  could  be  explained  by  a  calendar  and  the 
timetable of the local train service (predictable, manmade conforming to some 
complex pattern), whereas a major flood (catastrophe/unpredictable event) may 
destroy landmarks and make watery chaos of geography and other features 
may disappear.  
 
Therefore theories may be able to describe or predict patterns of behaviour but 
sometimes  even  a  detailed  or  well  established  theory  may  fail  due  to  the 
excessive number of variables or complexities of the determinants of human 
behaviour. 
4.1.3 What are cognitive factors? 
Behaviour  may  be  determined  by  intrinsic  factors  and  extrinsic  factors  (see 
Figure 2, p. 93). Broadly speaking extrinsic factors are external to the individual 
and consist of incentives (e.g. subsidies) or disincentives (e.g. taxes) and legal 
structures.    Intrinsic  factors  include  individual  circumstances, personality  and 
cognitive factors.  
 
The  dictionary  definition  of  cognition  is  ‘when  you  think  or  use  a  conscious 
mental process’.  However the psychological definition refers to all processes 
by  which  the  sensory  input  is  transformed,  reduced,  elaborated,  stored, 
recovered, and used. Psychologists have concentrated their attention on these 
cognitive  factors  as  they  believe  them  to  be  very  important  determinants  of   93 
behaviour  and  far  more  likely  to  be  amenable  to  change.  As  proximal 
determinants of change these cognitive factors are assumed to be important 
causes of behaviour, which mediate the effects of other determinants such as 
social class. They are also assumed to be more open to change than other 
factors such as personality.
161  
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Figure 2 Intrinsic and extrinsic factors in change. 
 
Social cognition models have been developed to describe the processes of 
how  cognitive  factors  produce  behaviour  in  a  social  context.  They  regard 
cognition as being shared by individuals within the same society.
162 Social 
cognition models have their origins in the work of Bandura which suggested 
that  behaviour  is  determined  by  expectancies,  incentives  and  social 
cognitions.
163 The difference between cognition models and social cognition 
models is that social cognition models include the influence of other people 
and  the  society  within  which  the  individual is  functioning.  For example,  in   94 
practice  this  is  conceptualised  in  the  construct  of  ‘normative  belief’:  ‘My 
children want me to stop smoking and their opinion is important to me’. 
 
Many models have been developed, some have faded, some have persisted 
but  none  have  been  universally  accepted.  Theories  in  psychology  often 
continue to persist unchallenged even when major observations do not fit the 
theory or there are major discrepancies. Meehl (1978) observed that theories 
are  neither  refuted  nor  corroborated  but  fade  away.
164  When  a  model  is 
tested in research to predict behaviour or outcomes of an intervention there 
is usually a gap between those expected and observed outcomes. Indeed a 
good  theory  should  consist  of  constructs  that  are  specific  enough  to  be 
testable  and  be  useful  for  designing  intervention  and  be  able  to  predict 
behaviour  with  reasonable  accuracy.
165  The  discrepancies  between  the 
predicted and observed outcomes are often explained away rather than used 
to reject or refine the theory.  
 
The  gap  between  prediction  (from  theory)  and  observed  behaviour 
demonstrates  significant  failings  of  theory  to  predict  outcomes  or 
observations in the real world.  Psychologists call this gap ‘variance’. This is 
not the only discrepancy between theory and reality in what I have called the 
prediction-intention-behaviour deficit (see Figure 3, p. 95).  Models of health 
beliefs  only  predict  between  40  and  50%  of  behavioural  intentions.
166;167 
Furthermore, having an intention to behave in a certain way does not reliably 
predict  behaviour.  Intentions  may  explain  between  19  and  38%  of  the 
variability in behaviour.
162;162;168   95 
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Figure 3 The prediction-intention–behaviour deficit 
 
 
Thus there is a progressive fall-off in observed (or reported) change from the 
predictions  made  by  a  theory  to  intention  to  behave  in  a  certain  way  and 
between that and actual behaviour. ‘Intention’ therefore becomes equivalent to 
a  surrogate  measure  of  outcomes  and  is  not  a  reliable  indicator  of  actual 
behaviour 
 
A number of ‘get-out clauses’ are used in reports of studies that are less than 
conclusive. For example statements that ‘the variables were not operationalised 
properly’ may disguise either methodological or theoretical deficiencies. Usually 
they mean that the questions did not test what the researcher hoped they would 
test.  In other studies demonstrating limited success in predicting outcomes the 
explanation may be ‘sample characteristics’.  Of course they will only consider 
explanations that are within the paradigm of their own behaviour theory and   96 
philosophy  of  knowledge  and  may  therefore  overlook  other  explanations. 
Further discussion of this possibility is beyond the scope of this PhD thesis. 
4.1.4 How are theories tested? 
A  number  of  different  research  designs  are  commonly  used  to  test  these 
theories.  Cognitive  theories  are  mostly  tested  by  cross-sectional  design.
169 
Each construct within the theory is measured. The most common measure is by 
questionnaire (but could be by structured face-to-face or telephone interviews) 
using questions designed to test the extent of a particular construct. After a 
period of time the outcome behaviour is recorded (e.g. by observation, medical 
records or self reporting). An attempt is then made to determine to what extent 
each  of  the  construct  variables  has  predicted  the  outcome  change  in 
behaviour.
169 
 
For example, stage based theories can be tested using cross-sectional surveys 
where the participants are classified into their stages and compared according 
to the relevant variables that are theoretical determinants of change between 
stages.
161 Examination of stage sequences and longitudinal prediction of stage 
transition  are  used  to  test  whether  different  variables  successfully  predict 
transition from one stage to another.  
 
The strongest evidence for a stage-based theory would be from experimental 
studies  of  stage-matched  interventions.  In  other  words,  behaviour  change  in 
one group after an intervention (designed to target a determinant of behaviour 
change  which  is  theoretically  active  at  one  stage  rather  than  another)  is 
compared with another group where the intervention is not matched. Currently a   97 
review  has  been  designed  and  is  being  conducted  by  the  Cochrane 
collaboration to determine if there is any strong evidence for the impact of stage 
based interventions on smoking.
170   98 
 
4.2  Theory of planned behaviour (TPB) 
This sub-section also includes the related theories of the theory of reason action 
and behaviour prediction theory) 
 
The theory of planned behaviour is one of a number of social cognition theories.  
It is an extension of the theory or reasoned action which arose from work by 
Fishbein and Azjen who published ‘Belief, Attitude, Intention, and Behavior: An 
Introduction  to  Theory  and  Research’.
171  The  theory  became  known  as  the 
theory of reasoned action but after several changes was known as the theory of 
planned  behaviour.  Changes  were  made  to  account  for  other  observed 
outcomes.  The addition  of  ‘perceived  control’  over  the behaviour  altered  the 
name to the theory of planned behaviour.
172 
4.2.1 Fundamental structure  
According to the theory, behaviour is influenced by the intention to behave in a 
certain way. Intention is determined by three major variables called subjective 
norms, attitudes and self-efficacy (also called perceived behavioural control).  
Self-efficacy  had  been  added  to  account  for  times  when  people  have  the 
intention  of  carrying  out  a  behaviour,  but  the  actual  behaviour  is  ‘thwarted 
because they lack confidence or control over behaviour’.
173 
 
The theory of planned behaviour suggests that a person's behavioural intention 
depends on the person's attitude about the behaviour and subjective norms. If a 
person intends to ‘do a behaviour’ then it is likely that the person will do it.   99 
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Figure 4 Theory of planned behaviour 
 
Behavioural  intention  measures  a  person's  relative  strength  of  intention  to 
perform a behaviour. Attitude is comprised of beliefs about the consequences of 
performing  the  behaviour  multiplied  by  his  or  her  valuation  of  these 
consequences.  
 
Subjective  norm  is  seen  as  a  combination  of  perceived  expectations  from 
relevant  individuals  or  groups  along  with  intentions  to  comply  with  these 
expectations. In other words, ‘the person's perception that most people who are 
important to him or her think he should or should not perform the behaviour in 
question’ (Azjen and Fishbein, 1975).
171 To put the definition into simple terms: 
a  person's  voluntary  behaviour  is  predicted  by  their  attitude  toward  that   100 
 
Example: 
A 50 year old smoker and his wife have been considering their smoking for 
some  time  (motivation  to  comply).  Their  teenage  children  have  always 
disapproved  of  their  parents’  habit  (normative  belief).  The  nagging  has  not 
lessened over time. Mr X is confident he can stop at any time that he wants to; 
he is in control of his habit and believes that he does it because he enjoys the 
sociable side of life and fits with his friends (subjective norms). 
 
Recently his wife has been getting anxious about the health issues. A friend of 
Mrs X has told her about her brother who recently had a heart by-pass. She has 
a  cough  and  gets  puffed  on  the  stairs,  which  she  thinks  could  be  due  to 
smoking or just lack of fitness. She is not sure she has the will power to stop 
easily  (control  belief=  perceived  likelihood  of  constraining  and  facilitating 
conditions)  and  her  biggest  worry  is  putting  on  more  weight.  She  already 
struggles with her weight (constraining condition) and her friend put on 2 stone 
when she stopped last year. The friend’s husband believes it is better to be slim 
and look good than to be a fat non-smoker (subjective norms). However she 
thinks  that  if  there  are  no  fags  in  the  house  and  her  husband  stops  too 
(facilitating  condition)  –  maybe  she  can  succeed  (control  belief  x  perceived 
power= perceived behavioural control) 
 
Both Mr X and Mrs X intend to stop (behavioural intention) smoking but will this 
translate into action and change of behaviour? 
Motivation to comply x normative belief = subjective norm  
 
Control belief x perceived power=perceived behaviour control (efficacy) 
 
Behavioural belief x evaluation of behavioural belief = attitude 
Box 2 Example of TPB and smoking.   101 
 
behaviour and how they think other people would view them if they performed 
the behaviour. A person’s attitude, combined with subjective norms, forms their 
behavioural  intention.  However,  Fishbein  and  Ajzen  state  that  attitudes  and 
norms are not weighted equally in predicting behaviour. ‘Indeed, depending on 
the individual and the situation, these factors might have very different effects 
on behavioural intention; thus a weight is associated with each of these factors 
in the predictive formula of the theory. For example, you might be the kind of 
person who cares little for what others think. If this is the case, the subjective 
norms  would  carry  little  weight  in  predicting  your  behavior’.
173  Miller  (2005) 
defines each of the three components of the theory as follows.
173 (I have used 
different examples to illustrate aspects of the theory): 
Attitudes:  
Attitudes are the accumulation of beliefs about a particular behaviour weighted 
by evaluations of these beliefs. Someone may believe that exercise is good for 
health, that exercise improves looks, but that exercise takes too much time, and 
that exercise  is uncomfortable.  Each  of  these  beliefs  can be  weighted  (e.g., 
health issues or looks might be more important to an individual than issues of 
time or comfort).  
Subjective norms:  
Subjective norms refers to the influence of people in their social environment on 
their behavioural intentions; different opinions or beliefs of different people will 
influence a person’s behavioural intention to varying degrees. In the example 
(Box 2, p. 100) Mrs X’s children have some influence but the belief of a friend 
about weight gain (after smoking cessation) and another about health risks will   102 
be weighed against each other to determine behavioural intention which will 
lead to stopping or failure to stop smoking. 
Behavioural intention:  
Behavioural  intention  is  a  function  of  both  attitudes  toward  a  behaviour  and 
subjective norms toward that behaviour, which has been found to predict actual 
behaviour.  
4.2.2 Research background 
The  theory  of  planned  behaviour  continues  to  be  used  very  widely  in  many 
different cultural contexts in health and other psychological research to predict 
and explain a diverse range of behaviours, including health-relevant behaviours 
such as smoking,
174 condom use, exercise and diet as well as non health issues 
such as use of the internet and accessing services or breaking driving rules.
175-
180  Many  prediction  studies  are  aimed  towards  identifying  beliefs  that  could 
subsequently be targeted by a persuasive message.  
 
The process of developing a prediction study typically follows three steps. 
Firstly, the most frequent important beliefs are elicited from a sample of the 
target group. Secondly, a questionnaire is constructed to assess beliefs that 
distinguish intenders from non-intenders, and to identify the relative contribution 
of the attitudinal or normative component. Finally, an intervention is designed to 
change the key beliefs identified. 
 
Ogden reports a search of four major psychology journals for articles published 
over the previous five year period, which purported to test or apply one or more   103 
social cognition theories.
165 She concluded that the majority of the articles did 
not  strongly  support  the  models  being  used.  In  particular  there  was  little 
evidence for the expected associations between variables or for the models’ 
ability  to  predict  the  particular  outcome  being  studied.  All  of  the  articles 
examined  left  much  of  the  variance  unexplained,  with  explained  variance 
ranging from 1% to 65% for behavior and 14% to 92% for behavioral intentions. 
But, even though the variables were not predictive and the variance explained 
was low, the research data were not used to dismiss or disprove the validity or 
reliability of the particular models tested. This emphasizes the general criticism 
of behavioural models that they are not disproved or rejected but are simply 
allowed to fade. 
 
When constructs are not defined or are too vague, precise testing is impossible, 
and a theory cannot be ‘disproved’. In practice this means that if one out of the 
three main variables (subjective norms, perceived behavioural control, attitudes) 
does not appear to have any predictive value, several explanations are offered 
but no data are collected to demonstrate that the model is wrong. Therefore the 
theoretical basis remains unchallenged.
165
 
 
However, in response to these objections, Azjen argues that ‘there is nothing in 
the theory (of planned behaviour) to suggest that attitude, subjective norm and 
perceived behavioural control will each make a significant contribution to the 
prediction of intention. The relative importance of these three factors is likely to 
vary from one behaviour to another and between populations’.
181 This highlights 
the importance of precise definitions and ability to test precisely and reliably. In   104 
situations  where  the  theory  has  failed  to  accurately  predict  behaviour  the 
investigator may give explanations while failing to reject the theory 
182 or be 
tempted to add a variable such as ‘habit’, ‘ambivalence’, moral obligation and 
self efficacy.
183 
 
In  a  thorough  systematic  review  of  the  application  of  the  theory  of  planned 
behaviour  in  interventions  for  behaviour  change  Hardeman  et  al  found  30 
papers  describing  24  distinct  interventions.
184  Methods  of  change  generally 
involved persuasion, information, skills development and goal setting. In one 
half of the studies the theory was used to develop the intervention and in the 
remainder  the  theory  was  used  to  assess  changes.  Approximately  half  of 
those studies involving an intervention reported a change of intention but the 
effect  size  was  small.  TPB  was  mostly  used  to  measure  the  process  and 
outcomes rather that to develop the intervention but studies were rarely explicit 
about the use of TPB.  
4.2.3 Critique of the theory of planned behaviour  
Sheppard et al. suggest ‘that more than half of the research to date that has 
used the model has investigated activities for which the model was not originally 
intended’.
185 In other words the model is frequently applied to target behaviour 
and situations where the subject does not have voluntary control, choice is not a 
reality or intentions are assessed where it is impossible for all the necessary 
information to be available. Many of the studies in their meta-analysis involved 
goals  and  choosing  alternatives.  Goals  were  judged  by  the  presence  of 
significant barriers to their fulfillment e.g. resources, training or the cooperation 
of  others.  Their  expectation  was that the model  would  not  fare  well  in  such   105 
situations.  However,  they  found  the  model  ‘performed  extremely  well  in  the 
prediction of goals and in the prediction of activities involving an explicit choice 
among alternatives’. Thus they concluded that the model ‘has strong predictive 
utility, even when utilized to investigate situations and activities that do not fall 
within the boundary conditions originally specified for the model. That is not to 
say,  however,  that  further  modifications  and  refinements  are  unnecessary, 
especially when the model is extended to goal and choice domains’.
185 
 
Hale et al. also echo these views when they state ‘The aim of the TPB is to 
explain volitional behaviours. Its explanatory scope excludes a wide range of 
behaviours such as those that are spontaneous, impulsive, habitual, the result 
of  cravings,  or  simply  scripted  or  mindless.  Such  behaviours  are  excluded 
because their performance might not be voluntary or because engaging in the 
behaviours might not involve a conscious decision on the part of the actor’.
186 
 
Sheppard et al. (1988)
185 are supportive of the theory of planned behaviour but 
make exceptions for certain situations when they say ‘a behavioural intention 
measure  will  predict  the  performance  of  any  voluntary  act,  unless  intent 
changes  prior  to  performance  or  unless  the  intention  measure  does  not 
correspond to the behavioural criterion in terms of action, target, context, time-
frame  and/or  specificity’.  So,  for  example,  if  a  smoker  learns  they  have  a 
medical condition made worse by putting on weight (e.g. back pain), and they 
believe  they  will  put  on  weight  after  stopping  smoking,  this  may  affect  their 
behavioural intention (about quitting).  
   106 
Sheppard et al. (1988) propose that there are three limiting conditions on the 
use  of  attitudes  and  subjective  norms  to  predict  intentions  and  intentions  to 
predict the performance of behaviour: 
1.  Goals versus behaviours:  
There is a distinction between a goal intention (cutting smoking from 30 to 20 
per day) and a behavioural intention (taking nicotine replacement therapy). 
2.  The choice among alternatives:  
The presence of choice may dramatically change the nature of the intention 
formation process and the role of intentions in the performance of behaviour. 
3.  Intentions versus estimates:  
There are occasions when what a person intends to do and what they expect to 
achieve are different. 
4.2.4 Smoking cessation and TPB 
Two  basic  assumptions  cast  doubt  on  the  validity  of  TPB  in  the  context  of 
smoking cessation. The first assumption is that (undesirable) behaviour is under 
voluntary control.  However much mankind believes that he is in control, the 
evidence  from  clinical  and  practical  life-experience  demonstrates  that  self- 
control  is  difficult  and  inconsistent.  Even  without  chemical  dependence  the 
behaviour under investigation may be habitual or have deep psychological roots 
in a person’s life journey or as a personality trait. 
 
The second assumption is that people are rational. If that were so then open 
access to facts about the consequences of certain behaviour would translate 
into  safer  conduct  in  all  spheres  of  life.  However  people  are  capable  of 
dismissing information or weighing up the pleasurable effects of the ‘here and   107 
now’  which  may  undermine  any  logical  conclusions.  People  may  take 
extraordinary  risks  with  personal  health  or  safety,  for  short-term  gains  or 
experiences (see Section 3.2.2, Addiction, p. 50). 
 
TPB has been used as the theoretical basis of a number of smoking research 
studies.
174;187;188  Coleman  et  al.  used  questionnaires  to  collect  data  on  the 
intentions  of  about  a  1000  smokers  attending  general  practice.  Using  the 
theoretical  framework  of  TPB  they  concluded  that  where  smokers  perceived 
that their problems were smoking related they were more likely to have tried 
stopping  in  the  past  (odds  ration  1.78,95%  CI  1.26-2.67),  to  want  to  stop 
smoking (OR 1.83,CI 1.15-2.9) or to intend to stop in the near future.
188 In other 
words, in the language of TPB, behavioural intention is formulated by beliefs 
about health and the attribution to the behaviour. The study did not report any 
plan to follow up the smokers to confirm whether or not the intensions were 
translated into successful behaviour change.  
 
The study by Black et al. was a telephone survey of the attitudes and control 
beliefs of nearly 200 American university campus students who smoked.
187 Only  
two  components  of  TPB  (attitudes  and  control  belief)  were  measured  with 
questions designed to assess their interest in involvement in different types of 
smoking cessation programmes. There was no actual intervention and duration 
of follow up and change in intention or behaviour was not reported. Therefore, it 
is  difficult  to  make  any  firm  conclusions  about  how  useful  the  model  is  the 
context of smoking behaviour. 
   108 
There is now plenty of evidence that many decisions about change in behaviour 
are not necessarily planned. The trigger may be sudden and unexpected and 
the change equally ‘out of the blue’.
189 In the case of smoking cessation West et 
al found that in their sample half of people who tried to quit did so without any 
pre-planning.  A  greater  proportion  of  them  were  still  non-smokers  after  six 
months than those who had planned a quit attempt. These results are used to 
argue that the trans-theoretical model is also deficient. 
 
Existing  theories  do  not  predict  behaviour  particularly  well.  Some 
unpredictability will remain even if the theories are improved. TPB continues to 
be  used  widely  in  consumer  and  health  research  and  has  the  potential  to 
underpin  smoking  cessation  strategies  with  appropriate  modifications  where 
choice  and  resources  and  goals  are  considered.  The  theory  accounts  for 
changes in intention and a minority of research has clarified the usefulness of 
the theory in predicting successful behaviour change.   109 
 
4.3  Health belief model (HBM) 
The health belief model (HBM) was developed by Rosenstock in the 1950s for 
studying and promoting the uptake of services offered by social psychologists 
and in particular health education programmes. Subsequent amendments to the 
model  were  made  as  late  as  1988,  to  accommodate  evolving  evidence 
generated  within  the  health  community  about  the  role  that  knowledge  and 
perceptions  play  in  personal  responsibility.  It  was  recognised  that  effective 
health  education  was  needed  to  target  potentially  modifiable  characteristics 
which determine behaviour.  
 
The relationship between health beliefs and behaviour was conceptualised in 
terms of ‘valence’. Valence is the concept of making behaviour more or less 
attractive.  Derived  from  value  expectancy  theory,  the  HBM  has  been  widely 
applied to many different preventive health behaviours as well as actions taken 
to seek medical attention for illnesses.
190  
4.3.1 Fundamental structure of health belief model  
The  original  model  postulated  that  preventive  health  behaviours  may  be 
predicted by the following key beliefs that shape health behaviour: 
1. The likelihood of experiencing a health problem (e.g. perceived susceptibility 
to tuberculosis) 
2. The severity of the consequences of that problem (tuberculosis) 
3. The perceived benefits of particular health behaviour (belief that TB could be 
asymptomatic and screening could detect it early) (see Figure 5, p. 110)   110 
 
The  factors  influencing  behaviour  may  be  divided  into  threat  perception  and 
behavioural evaluation. As above the threat perception is about how much the 
individual thinks they will get the condition and the consequences of getting it. 
Behavioural evaluation distinguishes between the benefits of change (efficacy) 
and  the  personal  cost  which  may  be  physical,  psychological  or  financial 
(barriers).
191 There is no formula for weighing the balance between cost and 
benefit  (belief)  and  therefore  the  construct  includes  these  as  separate 
(independent) variables.
169  
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Figure 5 Health belief model 
 
Even when an individual believes in a health behaviour there still may need to 
be a cue or a trigger to activate the behaviour. Later additions to the model 
include readiness (to be concerned about health matters) and perceived control 
over the behaviour (see Figure 5, p. 110).   111 
4.3.2 Research background 
The initial prospective research demonstrated correlation between three factors 
or constructs:  
•  likelihood of experiencing a health problem  
•  the severity of the consequences of that problem and  
•  the perceived benefits of a health behaviour 
and the uptake of the health behaviour (screening) and therefore were believed 
to be predictors of behaviour.  
 
Further research demonstrated that a health education intervention designed to 
increase  perception  of  susceptibility,  severity  and  anticipated  benefits, 
increased health improving behaviour.
192-194 A meta-analysis of studies using 
this model in adults highlighted some of the problems with definitions of the 
construct variables.
191 Interestingly they identified over 200 published studies 
for analysis but only 16 fulfilled their criteria for inclusion by measuring all the 
major components of the theory (now increased to four- susceptibility, severity, 
benefit and barriers). The authors concluded that ‘the weak effect sizes and lack 
of  homogeneity  indicate  that  it  is  premature  to  draw  conclusions  about  the 
predictive validity of the HBM as operationalised in these studies’. 
  
Two constructs were later added. Perceived efficacy which is an individual's 
self-assessment of ability to successfully adopt the desired behaviour and cues 
to  action  which  are  external  influences  promoting  or  triggering  the  desired 
behaviour.
195 The second addition was cues to action which can include internal 
cues such as perception of body states and external cues such as interpersonal   112 
interaction and mass media communication.
191 
 
As with the other models already described the HBM has been used in a wide 
variety of settings including the study of uptake of healthy related behaviour by 
uptake of   tuberculosis screening, vaccinations, cervical cancer screening and 
preventative dentistry.
169 
 
Some  studies  have  given  support  to  the  model  especially  when  applied  to 
individual components. In other words if each construct is examined in isolation 
they are shown to be predictors of health behaviour in selected areas of study. 
This  is  especially  so  in  the  area  of  health  screening  where  ‘barriers’  and 
‘perceived  susceptibility’  were  found  to  be  the  best  predictors  of  healthy 
behaviour.  For  example,  knowledge  about  breast  cancer  is  correlated  with 
breast self-examination and having regular mammograms.
162 
4.3.3 Critique of the health belief model (HBM) 
There  is  a  difference  between  demonstrating  that  individual  components  of 
HBM  predict  behaviour  and  showing  that  the  combination  of  constructs  is  a 
useful predictor of behaviour. For the HBM to be validated as an integrated 
model of behaviour each of the dimensions has to fit with each other and the 
research needs to demonstrate the relative importance of each as well as their 
interactions with one another. In other words the theory must be demonstrated 
in practice and in research.
191 As discussed above, reviews of research studies 
using HBM show only weak correlations and their heterogeneity mean that it is 
difficult to draw conclusions about the predictive value of the HBM. Few studies 
meet minimal criteria for valid representation of the HBM components indicating   113 
that future studies should focus more on systematic analysis of the constructs of 
HBM.
191 
 
Conflicting findings are found in some studies which confuse matters.
189;190 For 
example  it  would  be  reasonable  to  predict  that  high  susceptibility  would  be 
correlated  with  health  seeking  behaviour  whereas  some  studies  found  the 
opposite.
162  Other  studies  showed  that  benefits  of  carrying  out  a  health 
behaviour  (stop  smoking,  save  money)  and  perceived  severity  of  the 
consequences (lung disease) were not related. Furthermore, the model focuses 
on conscious decision making. It makes no allowances for other external forces 
such as social pressure or perceived controls or influences from other people 
and  finally,  there  is  no  clear  indication  of  the  relationships  between  the 
components.  
4.3.4 Smoking and the health belief model  
The HBM has been used to develop programmes or to predict outcomes in a 
number of studies about smoking cessation interventions.
97;196-202. Previously, 
the  dubious  quality  of  studies  has  been  a  real  problem  in  determining  the 
usefulness in smoking cessation. The meta-analysis by Harrison et al in 1992 
not only found few studies which met their strict quality criteria but also failed to 
identify any well conducted studies that related to smoking behaviour.
191  
 
Few studies using HBM have been of sufficiently clear design to separate out 
the influence of the different components or have been criticised for not fully 
operationalising  the  variables.
203-207  One  study  combined  the  two  constructs 
benefits and barriers into a single ‘index’.
169 The prospective study by Mullen et   114 
al was a comparison of three different health models in four different health 
areas (smoking, exercise and consumption of fried and sweet foods).
208 As far 
as  smoking  is  concerned  they  confirmed  that  the  construct  susceptibility  to 
serious illness over the next ten years was associated with an attempt to quit 
smoking and a reduction of cigarettes smoked. They concluded that in such 
areas  as  smoking,  where  health  risks  are  widely  known,  personalization  of 
consequences  may  be  important  in  influencing  behaviour.
208  The  construct 
barriers was operationalised as ‘attachment to aesthetic pleasures of smoking’. 
This did not directly predict change in behaviour in this study. 
 
Those with pre-existing morbidity, either caused by smoking or made worse by 
smoking, are a special risk group. A prospective questionnaire survey of nearly 
400 patients attending a clinic for respiratory diseases measured health beliefs, 
smoking  history  and  patient  predictions  of  future  smoking  behaviour.
205  Quit 
rates were low and predictions had low accuracy. Very few firm conclusions 
about  the  constructs  of  HBM  could  be  drawn  but  the  study  confirmed  the 
experience  and  perceptions  of  clinicians  that  smokers  with  lung  disease 
represent a group resistant to change.  
 
A small retrospective study of diabetics comparing the variables of the HBM 
among  smokers  and  ex-smokers  concluded  that  perceptions  of  severity, 
perceptions  of  susceptibility,  cues  to  action,  and  the  modifying  factor  social 
support  were  useful  predictors.
206  However,  they  point  out  that  recall  of 
physician advice may not be reliable, as it seems unlikely that less than half of 
the diabetic patients were advised to stop smoking. The most likely explanation   115 
is a combination of failure of retrospective data and memory and resistance or 
denial. Those with chronic diseases made worse by smoking are resistant to 
change and may build up a strong resistance to professional advice.  
 
In conclusion, despite having intuitive appeal and face validity, the HBM model 
has been shown empirically to be a poor predictor in the context of smoking 
behaviour and cessation.    116 
 
4.4  Trans-theoretical model (TTM) 
Among the stage theories of behaviour change the trans-theoretical model is 
probably  the  best  known  and  most  widely  used  in  addiction  and  smoking 
research. It is beyond the scope of this thesis to discuss all the stage theories 
but I will put the trans-theoretical model into context of stage theories in general. 
 
At the simplest level any stage theory would have two discrete stages with the 
ability to move from the first to the second under the influence of independent 
variables.  The  transitions  are  the  dependent  variables.  The  subject  either 
remains the same or moves (dichotomous stages). A three-stage model would 
have three separate states or stages with independent variables between each 
stage.  The  independent  variables  may  act  alone  or  via  others  at  different 
stages. Complexity may increase with the numbers of stages and the ability to 
move in either direction and to skip stages. 
 
The trans-theoretical model (TTM) was originally developed by psychologists 
Prochaska and Diclemente over 30 years ago and has been developed and 
used widely in researching the process of change.
209-211 The model has been 
applied to a wide range of behaviours including smoking, drinking, drug use, 
uptake  of  mammography  screening,  and  healthy  activities  (exercise,  healthy 
eating, safe sex). 
 
The name ‘trans-theoretical’ arises from the fact that the model incorporates 15   117 
theoretical  constructs  and  was  an  attempt  to  draw  these  into  a  single 
framework.
212 It has been modified several times since its original development. 
4.4.1 Fundamentals of trans-theoretical model  
The exponents of this model describe five stages (Box 3 and Figure 6, p.120). 
 
1.  Pre-contemplation: not intending to make any changes 
2.  Contemplation: considering a change.   
3.  Preparation: making a small change.  
4.  Action: actively engaging in a new behaviour. 
5.  Maintenance: sustaining the change over time. 
Box 3 General meaning of stages 
 
The  pre-contemplative  stage  corresponds  to  that  period  where  there  is  no 
intention to change in the foreseeable future and the person has no faith in their 
ability to change and suppresses any thoughts about change. They may or may 
not  have  sufficient  information  about  the  risks  of  their  behaviour  but  avoid 
engaging in dialogue about their habit and its effects. There is a tendency to 
overestimate  the  benefits  of  the  behaviour  (e.g.  pleasure  of  smoking)  and 
underestimate  the  hazards.  It  is  unlikely  that  this  group  will  volunteer,  or 
respond  to  an  invitation,  to  engage  with  smoking  cessation  treatments  or 
educational programmes to discover more about risks to their health. They may 
regard  change  as  pointless  as  they  may  doubt  their  ability  to  change. 
Researchers often exclude this category from intervention studies.    118 
 
Commentators  of  this  model  have  identified  different  aspects  of  the  pre-
contemplation  stage.  This  has  been  termed  ‘resistance  and  the  four  Rs’. 
Reluctant pre-contemplators are those who through lack of knowledge or inertia 
do not want to consider change. Knowledge and empathy are most helpful for 
them.
142 There is reluctance rather than resistance and is this not particularly 
conscious.  Rebellious  pre-contemplators  have  a  heavy  investment  in  the 
behaviour and resist any attempt to being told what to do. They will be hostile 
and resistant to change. If they are recruited to any programme they will insist 
that they are not going to change and make it clear that they will energetically 
resist. Resigned pre-contemplators do not have that energy and do not feel in 
control.    They  have  given  up  the  possibility  of  successful  change  and  feel 
overwhelmed. They often have a track record of multiple attempts with different 
techniques. The rationalising pre-contemplator has all the answers, and counter 
arguments to personal risk and is not considering change.
142 
 
Contemplation equates with a stage of serious thought about changing within 
the foreseeable future (often said to be six months). The pros and cons of the 
habit  become  fairly  equal  although  there  is  still  doubt  about  the  benefit  and 
continuing to think about change may be a substitute for action. This stage may 
become prolonged.  
 
The preparation stage is said to exist when there is an intention to change in the 
very near future (often within the next month). They usually have tried to change   119 
over the previous twelve months and are making moves to delay and reduce 
the  harmful  behaviour.  They  already  regard  the  hazards  the  behaviour  as 
greater than the benefits. 
 
The  final  two  stages  are  action  and  maintenance  of  the  new  behaviour. 
Unfortunately people are most likely to relapse in the action stage but as people 
move  towards  maintenance  of  the  behaviour  (e.g.  not  smoking)  they  will 
increasingly  use  strategies  to  avoid  high  risk  situations  by  working  on  a 
healthier  lifestyle  and  modifying  their  environment  to  reduce  exposure  to 
temptation.
210;213 
4.4.2 Constructs of the trans-theoretical model  
The trans-theoretical model of stages of change has been further developed 
using a number of different constructs. Instead of the point prevalence (e.g. of 
non-smoking)  being  used  to  measure  success  of  an  intervention,  Velicer  et 
al.
213  propose  a  three-construct  outcome  model  (habit  strength,  positive 
evaluation  strength,  and  negative  evaluation  strength),  where  different 
constructs are sensitive to change for different aspects of the change process 
over time. This is a complex model which looks at the presence or absence of 
certain psychological and environmental or physical factors and how each one 
will  influence  an  individual  depending  on  their  stage  in  the  trans-theoretical 
model (pre-contemplative, contemplative etc). A simple way of looking at their 
construct is to say that how a person is influenced by any given internal or 
external factor is determined by their stage of change in behaviour (see Figure 
6, p. 120).   120 
Habit strength 
For example ‘habit strength’ is one of the three constructs. A pre-contemplator 
will  be  immune  to  environmental  influences.  However,  recent  introduction  of 
laws to ban smoking in certain places may determine where they go but not 
their  smoking  status.  It  is  not  clear  whether  this  sort  of  legislation  helps  or 
hinders  change  for  pre-contemplators  as  they  may  simply  become  more 
entrenched in their own belief in a right to choose their lifestyle and habits. A 
contemplator or action stage person will be very influenced by environment and 
will attempt to avoid certain situations in order to maintain resolve. They are 
however vulnerable to situations where they are not in control and may relapse. 
The  maintenance  phase  is  much  less  sensitive.  These  ideas  are  mostly 
intuitive. 
 
Trans-theoretical model - spiral of change
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Figure 6 Trans-theoretical model spiral of change. 
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Evaluation strength 
However  the  other  two  constructs  are  less  easy  to  understand.  The  idea  of 
‘positive evaluation strength’ is concerned with belief about the behaviour and 
how  the  individual’s  belief  changes  or  is  influenced  by  information.    This 
construct demonstrates a positive attitude to the benefits of change until what 
the  authors  have  called  a  ‘conviction  threshold’  is  met  and  therein  lies  the 
opportunity for change. Dipping through the conviction threshold into a position 
where  information  is  received  and  processed  conceptualises  a  teachable 
moment in an otherwise resistant individual. In contrast the most sensitive time 
for  processing  information  is  during  the  action  stage.  Negative  evaluation 
strength is in a sense the reverse image of the positive evaluation strength. The 
important difference is that when contemplating negative aspects of smoking 
the individual may ignore it because of indifference or from lack of conviction. 
Pre-contemplators  and  people  in  maintenance  are  both  indifferent  whereas 
those in the contemplation phase are still not convicted fully of the negative 
influences of their smoking but if and when they do move into the Action stage 
they  are  not  indifferent  and  start  becoming  convicted  and  are  open  to 
processing information that will help them on their journey to cessation.  
 
Other constructs 
Prochaska et al have introduced other constructs.
214 Self-efficacy is said to be a 
balance  of  confidence  and  temptation.  That  is,  the  confidence  that  one  can 
engage  in  the  healthy  activity  or  the  temptation  to  engage  in  the  unhealthy 
activity across different challenging situations. Decisional balance is divided into 
the  pros  and  cons  of  benefits  and  change.  It  is  unclear  how  the  original   122 
constructs (Figure 6, yellow box) (p. 120) and the more recent constructs and 
processes of change (Figure 6, blue boxes) are related or whether the more 
recent work supersedes the former. 
 
They  have  identified  ten  processes  of  change  (Figure  6,  blue  boxes), 
subdivided  into  the  experiential  processes  (such  as  consciousness  raising, 
dramatic  relief,  self  re-evaluation,  environmental  re-evaluation  and  self 
liberation) and behavioural processes. Consciousness-raising encompasses the 
influence of new facts and ideas that support the healthy behaviour change. 
Dramatic relief is a term, which paradoxically indicates the unpleasant negative 
emotions  from  the  perception  of  risk  from  the  unhealthy  behaviour.  Self  re-
evaluation  is  about  the  realisation  that  ones  identity  includes  behaviour 
(change), whereas environmental re-evaluation is about the negative or positive 
impact on ones social or physical environment of behaviour. Self-liberation is a 
positive commitment to change. 
 
Behavioural processes are more concerned with social, external interactions. 
They  are  categorised  into  helping  relationships,  counter-conditioning, 
reinforcement management, stimulus control and social liberation. For example 
these  include  the  following;  seeking  and  using  social  support  (helping 
relationships), substituting healthy alternatives (counter conditioning) or rewards 
(reinforcement  management)  for  the  healthy  behaviour,  removing  reminders 
and decreasing rewards (reinforcement management) for unhealthy behaviour 
(stimulus  control).  Social  liberation  is  the  realisation  that  social  norms  are 
changing towards support for the healthy behaviour change.   123 
 
In summary, the stages of change may be represented as a dynamic spiral 
rather than simply as linear progression from one stage to another in orderly 
fashion.
161 People start at the bottom of the spiral, in pre-contemplation. They 
then  move  through  the  stages  (contemplation,  preparation,  action,  and  then 
maintenance)  but  will  typically  relapse  back  into  an  earlier  stage.  They  may 
cycle and recycle through the stages several times before reaching the top of 
the spiral and achieving successful long-term behaviour change. On a practical 
level the authors claim that people can be categorised into the stages by the 
use of three simple questions of intention. 
4.4.3 Critique of the trans-theoretical model  
The usefulness of this model has been seriously challenged in recent years by 
a number of authors.
161;165;215 The biggest objection to this model is the arbitrary 
division into stages based on a time of intention. The stages are assumed to be 
discrete  whereas  in  reality  they  usually  represent  a  continuum  of  personal 
experience and behaviour. The theory should allow for a jump between non-
adjacent groups but the assumption is that one moves through or spirals round 
the stages.  
 
At  first  glance  this  model  may  have a  logical  appeal  and  seem  theoretically 
plausible  but  practical  experience  and  research  has  shown  big  changes  in 
behaviour  may  occur  without  a  stage  shift.  When  defined,  by  intention  and 
attempts at change, the groups would appear to be homogenous. In reality this 
is far from true. As I have explained the concept of ‘stage’ is not as simple as it   124 
first appears as each level includes numerous variables. If a smoker declares 
that they intend to stop smoking in the next four weeks an external observer 
might reasonably expect that they are likely to be more successful at cessation 
than the person who says that they are not considering any change. However, 
West et al have found that nearly 50% of quit attempts happen in an unplanned 
way and that these unplanned event have better long term success than those 
which  are  planned.
189  Furthermore  there  is  little  consistent  evidence  of 
progression between stages to support the theory.
216 At its simplest the five-
stage model (see Box 3, p. 117) could be replaced with a simple question ‘are 
you planning to change?’ A continuum rather than distinct states is more likely.  
 
A further objection to this model is that the creators have not established a clear 
cause and effect relationships between different variables. Studies have been 
done  using  cross-sectional  surveys  to  determine  stages  and  compare  the 
presence  of  relevant  variables  that  are  theoretically  active  determinants  of 
change between stages. It is still unclear whether or not the stages are truly 
‘predictive’ of behaviour and whether or not interventions can be targeted at a 
given stage.
213 
 
Cross-sectional  surveys  do  not  allow  conclusions  to  be  drawn  about  the 
individual role of presumed causative variables. Sutton reviewed the research 
designs  that  have  been  used  to  test  predictions  from  stage  models  (cross-
sectional  comparisons  of  people  in  different  stages;  examination  of  stage 
sequences; longitudinal prediction of stage transitions; and experimental studies 
of matched and mismatched interventions) and concluded that evidence for the   125 
model is inconsistent.
212 Experimental and longitudinal designs would give more 
information but are rarely done.  
 
So-called ‘stage-based’ interventions would be very useful in a treatment setting 
if they are valid.
216 If different variables are active and causative at a certain 
‘stage’ then treatments or interventions would be more effective if targeted at 
the  correct  stage.  There  would  be  a  great  benefit  if  interventions  could  be 
targeted towards particular groups based on psychological factors, which would 
give cost effective interventions. In theory this would save time and money by 
avoiding using methods that are ineffective for certain groups and maximising 
positive change, and perhaps minimising potential harm by using inappropriate 
methods in the ‘wrong’ contexts.  However, so far evidence is lacking for this 
approach 
 
Finally  the  model  focuses  on  conscious  decision-making  and  assumes  that 
people make clear plans, which they are able to act upon. Although we like to 
believe  that  we  are  rational  decisive  beings  the  evidence  is  contrary  to  this 
notion.  Crises,  sudden  changes  of  mind  and  life  events  may  cause  sudden 
shifts and spur of the moment changes.
189 
4.4.4 Smoking and the trans-theoretical model  
For non-psychologists, the simplicity of application of the TTM in classifying the 
‘stage of change’ of smokers is probably the greatest attraction of this model. 
Many  researchers  have  used  this  model  as  another  measure  of  baseline 
characteristics of participants rather than as a means of testing the model for its 
value  at  predicting  behaviour  change.
56;155;159;217;218  However,  very  little   126 
prospective  randomised  research  has  used  the  model  to  test  stage  based 
targeted interventions. 
 
Those with chronic diseases attributable to smoking can be classified into the 
stages of the TTM. In some studies a particular stage has been correlated with 
how  susceptible  they  are  to  change  in  behaviour.  In  a  study  of  those  with 
established heart disease people who were classified to the preparation stage 
were four times as likely to have quit six months later than those who were in 
the  contemplative  stage.  There  was  even  a  doubling  of  quit  rate  of  those 
starting in the contemplative stage compared to the pre-contemplative.
211 
 
The  idea  of  stage  of  change  can  also  be  conceptualised  in  the  theoretical 
framework  proposed by  Glass et  al –the  nested  hierarchy of  systems  which 
allows for a theoretical heightened sensitivity to exposure.
219 Other researchers 
have explored the possibility of a ‘window of opportunity’ such as during hospital 
admission.
123;220  If  attempts  are  made  to  induce  change  in  behaviour  at  the 
wrong time or context the result may be confrontation and failure.
142 This may 
go some way to explain the conclusion of the Cochrane review that community 
based interventions have not shown any reduction in smoking or indeed may 
have negative affects.
116 
 
As far as stage based interventions and smoking are concerned van Sluijs et al, 
conducted a systematic review of stage based controlled trials which had been 
initiated in primary care with the purpose of behaviour change in three specific   127 
areas- smoking, physical activity and diet.
221 Using an explicit ten point scoring 
system they judged methodological quality of each of the studies. Among the 
studies judged to be of sufficient methodological quality to analyse in detail, 
fourteen  of  the  studies  were  aimed  at  smokers.  They  excluded  studies  that 
combined behavioural and pharmacological interventions such as NRT. All the 
interventions were aimed at altering behaviour.
222 Their conclusions were not 
encouraging. The results for smoking were at best indicating a ‘positive trend’ 
but  without  strong  evidence  for  stage  based  interventions.  The  trends  were 
shifts in one stage or increased quit attempts without conclusive evidence in 
significant behaviour change in the long term. 
 
Despite the reservations and limitations of this theory the TTM may still remain 
a useful and very practical framework. Until there is stronger evidence against 
the  TTM  and  a  better  and  more  user-friendly  alternative,  I  believe  many 
researchers are likely to continue to use it at least as a comparative baseline 
measure  in  controlled  trials  and  possibly  as  the  theoretical  basis  of  other 
intervention trials.  
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4.5  Catastrophe, chaos and complexity theory (CCC) 
‘What we call chaos is just patterns we haven't recognized yet’.  
Chuck Palahniuk
g 
4.5.1 Basic concepts of catastrophe, chaos and complexity theory
h 
Chaos  theory  is  a  branch  of  mathematics  that  deals  with  the  way  in  which 
tensions develop in systems so that even small triggers can lead to sudden 
changes.  During  the  past  two  decades,  a  mixed  group  of  physical,  social, 
biological,  and  computer  scientists  have  devoted  increasing  attention  to  two 
related disciplines: chaos theory and complexity theory. Often termed non-linear 
dynamics because they seek to understand systems that change in ways that 
are  not  amenable  to  the  linear  cause  and  effect  models  these  theoretical 
perspectives are thought to have application across a wide range of scientific 
and social scientific disciplines.
223 
 
Much  of  the  study  of  change  in  health  behaviour  has  been  based  on  the 
cognitive-rational  paradigm  in  which  change  is  conceptualised  as  a  linear, 
deterministic  process.  Determinism  is  understood  as  the  proposition  that  a 
chain  of  events  or  rational  thought  determines  everything,  including  human 
cognition, behaviour, decision and action. Cognitive behaviour models mostly 
assume  a  linear  process  of  individuals  deciding  about  change  based  on 
                                            
g 20
th Century American writer- http://en.wikipedia.org/wiki/Chuck_Palahniuk 
h CCC is used to refer to catastrophe &/or chaos &/or complexity theory –some purists would 
not agree that they are the same but for the purpose of this thesis they are regarded as such as 
the medical literature often uses the terms interchangeably.   129 
judgments of benefits and disadvantages of their actions. Such a view, fails to 
account  for  non-linear,  quantum  influences  on  human  thought  and  action. 
According to the CCC (relevant to understanding health behaviour-change):  
1)  Chaotic  systems  can  be  mathematically  modelled  but  are  nearly 
impossible to predict;  
2) Chaotic systems are sensitive to initial conditions;  
3) Complex systems involve multiple component parts that interact in a 
non-linear fashion; and  
4) The results of complex systems are often greater than the sum of their 
parts.  Therefore,  small  changes  in  knowledge,  attitude  or  efficacy  may 
dramatically alter motivation and behavioural outcomes.
224 
 
Advantages  of  this  model  over  cognitive  behaviour  models  are  found  in  the 
frustration encountered in trying to explain variance as illustrated and discussed 
in Section 4.1.3 (see Figure 3, p.95) and Section 4.6 (p. 134). Those linear 
models resort to dismissing or explaining such problems as errors. The chaotic 
view  allows  for  the  unpredicted  and  unpredictable  aspects  seen  in  human 
behaviour.  However,  the  linear  and  chaotic  paradigms  are  not  mutually 
exclusive,  as  behaviour  change  may  include  both  chaotic  and  cognitive 
processes.  Studies  of  addiction  suggest  that  many  decisions  to  change  are 
sudden  and  unplanned  (so  called  ‘quantum’).  Any  model,  which  hopes  to 
endure and gain credibility, must include both aspects of observation of human 
behaviour change. 
 
The trigger for change may also be conceptualised as a ‘tipping point’. This idea   130 
was  popularised  in  The  Tipping  Point:  How  Little  Things  Can  Make  a  Big 
Difference  by  Malcolm  Gladwell.
225  Tipping  points  are  dramatic  changes  in 
social behaviour that arise quickly and usually unexpectedly. These come in a 
variety  of  guises,  including  advertising  slogans  or  tunes,  political  ideas  or 
shocks  in  the  stock  market,  and  most  are  impossible  to  predict.  However, 
retrospectively analysis may produce a variety of possible rational explanations 
for  the  phenomena.  In  a  similar  way,  smoking  may  stop  or  restart  in  an 
unpredictable manner with some plausible explanation when viewed with the 
benefit  of  hindsight.  In  the  same  way  as  these  phenomena  may  be 
unpredictable but explicable in hindsight, some interventions may work through 
mechanisms that cause a shift in behaviour in a particular direction. 
4.5.2 Research and biomedical application  
CCC has been applied to the study of health related behaviour for at least 40 or 
50  years.  However,  compared  to  many  other  theories  within  the  field  of 
psychological and biomedical research there are far fewer references to this 
model.  
 
A database search of the literature using the search terms catastrophe or chaos 
or  complexity  theory  and  their  use  in  biomedical  or  psychological  research, 
delivers a small group of papers. Within this group are a wide variety but limited 
number of studies including research of; relapse in alcoholics
226;progression of 
leprosy
227; clinical course of patients in an intensive care unit
228 and analysis of 
sudden unplanned smoking cessation.
189 
 
The CCC model was found to predict the largest proportion of the variance in   131 
both  alcohol  and  marijuana  use  among  adolescents.  Results  suggest  that  a 
CCC model of adolescent behaviour can provide an important and new way of 
conceptualising  risky  behaviour.
229  However,  their  analysis  of  smoking 
interventions for adolescents did not find the model very useful compared to 
interventions for other types of risky behaviour.
230 Recently this idea has been 
revisited by a number of researchers who have become dissatisfied with the 
other established and overused theories (in particular TTM) and are looking for 
a better way of predicting or explaining behaviour change in smoking and other 
addictive behaviours.
231 
4.5.3 Critique of catastrophe, chaos and complexity theory  
The practical usefulness of any theory is in its ability to predict outcomes of 
psychological interventions and then to be able to design interventions based 
on  that  theory  to  promote  desirable  change.  Small  changes  in  knowledge, 
attitude  and  efficacy  may  dramatically  alter  motivation  and  behavioural 
outcomes and the interaction of such variables can yield almost infinite potential 
patterns  of  motivation  and  behaviour  change.  Chaotic  systems  can  be 
mathematically modelled but are nearly impossible to predict. 
 
The CCC model may help to conceptualise the behaviour of some people some 
of  the  time  but  is  insufficient  by  itself  to  explain  or  predict  other  behaviour 
related to addiction and transition from the addicted to the non-addicted state. 
Triggers for stopping the behaviour and for relapse may not conform to a set 
pattern and therefore to that extent the sequence of events may follow a chaotic 
pattern.
92  
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Undoubtedly for some people a linear change does occur and the process of 
change may well conform to a more logical sequence from balancing pros and 
cons,  external  pressures  and  decisions  to  change  leading  to  setting  of  quit 
dates and progression to cessation. Any theory of behaviour change needs to 
incorporate a random, sudden shift of position, which may defy logic, planning, 
and  any  prediction  model.  A  ‘mixture  model’  of  both  chaotic  and  linear 
progression may be one that helps us best understand change.
224 
 
However,  because  chaotic  systems  can  be  mathematically  modeled  but  can 
rarely be predicted the theory has very limited use in designing interventions. In 
many  ways  it  becomes  the  equivalent  of  the  ‘error’  of  other  models  and 
therefore the ultimate in ‘get-out’ clauses.  
4.5.4 Smoking cessation and the catastrophe, chaos and complexity 
theory (CCC) 
In relation to smoking cessation, several studies have highlighted the fact that a 
large proportion of smokers and ex-smokers report that their quit attempts are 
not planned but are apparently ‘spur of the moment’.
189;214  Larabie found that 
37% of current smokers reported that their most recent quit attempt had been 
unplanned and amongst ex-smokers 51% had not planned their successful quit 
attempt.
214 These results were supported by further studies by West et al.
189 
CCC had not been used to devise their study but the authors proposed that the 
results were in accord with it. 
 
Potentially these observations have profound implications for clinical work and 
smoking cessation research. First there is there is a fundamental instability in   133 
the  position  of  smokers,  which  may  be  exploited  to  greater  benefit,  and 
secondly quitting opportunities or ‘moments’ can appear at any time. It is not 
known what key interaction of environment or people can tip the balance for a 
person to quit smoking. Therefore, it makes sense to encourage smokers to 
both recognise and act upon ‘abrupt’ opportunities. Moreover, it is possible that 
policy makers and health professionals can extrapolate these results. Under this 
theory the idea that strategies should be targeted to those who are ‘ready for 
change’ would be false for at least a third of smokers. Surprisingly, smokers 
who make unplanned quit attempts are more likely to persist with abstinence.  
 
These findings encourage strategies that are not ‘stage related’, but take the 
opportunities when they arise. West proposes that beliefs, past experiences, 
and the current situation create varying levels of ‘motivational tension,’ in the 
presence  of  which  even  quite  small  ‘triggers’  can  lead  to  a  renunciation  of 
smoking. However if they lead to a ‘plan’ for later action, this may indicate a 
lower level of commitment to change. This concept has been incorporated in a 
general  theory  of  motivation  and  its  application  to  addictive  behaviours.
189 
Furthermore these authors propose that public health campaigns should focus 
on the ‘3 Ts’: creating motivational tension, triggering action in smokers who are 
on the ‘cusp’ of a change, and immediate availability of treatment. 
 
In conclusion the CCC model is a helpful conceptual tool to help explain events 
but because it relates to the uncertain and unpredictable, it would be inherently 
illogical to attempt to use it prospectively to predict the success of any particular 
intervention.   134 
 
4.6  Generic problems with theories  
Theories in ‘soft’ areas of psychology lack the  cumulative character of 
scientific knowledge. They tend neither to be refuted nor corroborated, 
but instead merely fade away as people lose interest 
164 
There are plenty of problems within individual theories, making comparisons of 
one theory with another and with making generalisations about their utility. The 
problems  with  theories  that  I  have  encountered  will  be  discussed  under  the 
headings of: 
•  Assumptions 
•  Study design  
•  Instruments – including construct and content validity   
•  Transferability – external validity 
4.6.1 Assumptions 
The social cognition and cognition theories assume that behaviour is largely 
under  voluntary  control  (TPB  and  HBM)  with  predictable,  planned,  rational 
behaviour. These assumptions tend to ignore risky, involuntary or personality 
driven responses.  Furthermore some major changes in behaviour may not only 
be  unplanned  but  may  be  induced  by  apparently  brief  or  small  triggers. 
Addictive responses are also hard to factor-in to theories where benefits and 
gain are dependent on individual experience, perceptions or susceptibility rather 
than generalizable attitudes, experience or expectations.  
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4.6.2 Study design  
The ideal method of testing a health behaviour theory is using experimental 
research  design.  However  many  studies  rely  on  other  methods  including 
retrospective, questionnaire and cross-sectional design. 
 
Retrospective  studies  rely  heavily  on  self-reported  memory  of  past  health 
beliefs and behaviour which may not be reliable. Cross-sectional studies assess 
behaviour  and  belief  simultaneously,  cannot  determine  causation  but  only 
associations. Therefore experimental designs are preferable to determine the 
relationships between variables.  
 
Probably the commonest method of testing theories is to use questions, which 
are assumed to test a certain area of cognition. Some researchers believe that 
the process of asking the questions may actually alter behaviour.
165 Application 
of  a questionnaire  may  create  rather  than measure  cognitions. Experimental 
research design is required to address some of these difficulties. Many of these 
issues would be resolved by more extensive use of prospective observational 
research. 
 
Measurement and recording of behaviour or intention present some interesting 
challenges.  There  are  fundamental  problems  with  dividing  the  continuum  of 
behaviour for measurement purposes. It is difficult to measure the spectrum of 
human behaviour or attributes with Likert scales or other intervals. Constructs or 
variables are often measured indirectly by questions, which may or may not 
give consistent or reliable results. Many ‘operational definitions’ of psychological   136 
terms have been made, but they are often not generalizable. Thus there are 
difficulties in interpreting, understanding and comparing research and results. 
4.6.3 Instruments –construct and content validity 
To be useful in comparing research results and in the real world the theoretical 
constructs (abstract concepts of active components) held within any theory of 
behaviour  change  must  not  only  be  sufficiently  defined  for  comparison  with 
other studies and other theories but also be testable in a consistent manner 
both  within  the  study  in  question  and  then  applicable  to  other  contexts  and 
studies. The techniques used for testing or measuring (e.g. questionnaire) need 
to establish that they are consistently testing (operationalising) the constructs 
that are thought to be active (internal validity) and that these can be reproduced 
in other studies and thence to real life situations (external validity).  It is not 
sufficient for a theory or construct to simply look reasonable (face validity), it 
has to have internal and external validity to be transferable to other situations in 
the real world of clinical understanding and intervention.  
 
Construct validity refers to the extent to which attempts at measurement of a 
theoretical  construct  or  variable  (operationalisation)  are  ‘demonstrated  to  be 
consistent  with  the  theoretical  constructs  on  which  those  operationalisations 
were based’.
232 An alternative definition is that ‘construct validity shows how 
well  a  test  links  up  with  a  set  of  theoretical  assumptions  about  an  abstract 
construct’.
233 Construct validity is a prerequisite to external validity but the two 
are  not  the  same.  Furthermore  some  authors  regard  construct  validity  as  a 
necessary umbrella under which other types of validity sit.  
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External validity involves generalizing from one study to other contexts (people, 
places  or  times),  whereas  construct  validity  involves  generalizing  from  a 
programme or measures to the concept of the same programme or measures. 
 
For example HBM proposes that perceived susceptibility and severity are two of 
the active theoretical construct variables. Good construct validity exists when a 
measure (instrument) can reliably demonstrate a good correlation between the 
variables that are (theoretically) active and the construct (theoretically) being 
measured. Some studies show fairly good correlation
162 and some show only 
weak correlation.
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Many  construct  measurements  in  behaviour  theories  include  questionnaires 
with questions aimed at determining if an attribute is active. There is a need for 
tests of consistency and reliability to establish construct validity. There is also a 
great  need  for  consistent  terminology.  Part  of  the  test  of  consistency  and 
thereby construct validity is the ability to translate terminology from theory to 
practice and between theories. 
 
The nomological network was originally Cronbach and Meehl's view of construct 
validity. That is, ‘in order to provide evidence that your measure has construct 
validity Meehl argued that you had to develop a nomological network for your 
measure. This network would include the theoretical framework for what you are 
trying to measure, an empirical framework for how you are going to measure it, 
and specification of the linkages among and between these two frameworks’.
232  
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Content validity also sits under the umbrella of construct validity and ‘seeks to 
establish that the item or questions are a well balanced sample of the content 
domain to be measured’.
233 This is more than face validity which is fairly low in 
the hierarchy of features determining how well an instrument measures what it 
is intending to measure. 
 
Furthermore,  the  lack  of  consistent  classification  or  naming  of  different 
behaviours or responses presents major obstacles. For example the construct 
‘confidence’ in trans-theoretical model is similar to Bandura’s ‘self-efficacy’.
161 
Some constructs are not sufficiently specific to allow them to be tested.
165 If a 
concept has not been defined in one theory then any attempt at establishing 
construct validity, content validity or external validity will be flawed. Therefore 
the instruments of measurement cannot be applied to more than one theory and 
any legitimate application to other studies is impossible.  
 
The inevitable conclusion is that constructs need clear transparent definitions. 
How the instruments have been operationalised need to be clear and available 
to other researchers. In other words what questions (or other measuring tools) 
are  used  and  what  construct  they  are  supposed  to  be  testing  needs  to  be 
clearly explained. 
4.6.4 Transferability 
External validity is essential for results to be applicable to other contexts and 
populations. However there may be other features which conspire against the 
results or theory being applied outside a particular study.  
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There  are  methodological  controversies  regarding  the  difference  between 
idiographic and nomothetic methods in psychology. In the study of psychology, 
idiographic describes the study of the individual, who is seen as an entity, with 
properties  setting  him  apart  from  other  individuals.  Nomothetic  refers  to  the 
study  of  a  cohort  of  individuals.  Here  the  subject  is  seen  as  representing  a 
group or population and their personality traits and behaviours. In a nutshell 
research  in  creating  generalisable  theories  is  attempting  to  predict  the 
behaviour of individuals.  
 
A  number  of  other  features  may  reduce  the  possible  success  of  predicting 
behaviour.  Personality  differences  may  be  due  to  unknown  and  unknowable 
critical  events  in  an  individual’s  development  which  cannot  be  predicted  or 
generalised. Moreover the change in personality due to neurosis or depression 
may change the cognitive-affective voluntary actions of individuals. Differences 
may not be predictable or logical but simply due to luck or ‘random walk’ with no 
rational explanation.
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If each and every variable is small and independent the problem of creating a 
useful  theory  would  not  be  so  problematic.    However  when  there  are  large 
numbers  of  variables,  which  interact  with  each  other,  and  contribute  to 
idiographic  development  with  unpredictable  directions  of  action,  the  task  of 
developing a good theory is very difficult. 
 
There  may  be  considerable  overlap  of  cultural  factors  with  other  influences. 
Cultural differences may be mediated through related but changeable factors   140 
(like  diet,  poverty,  and  exposure).  Cultural  differences  may  also  influence 
mental  health,  reactions  to  situations  and  environment,  and  a  person’s 
worldview, which in turn may alter behaviour. Researchers therefore have to be 
careful not to make inappropriate generalisations from one context or culture to 
another. 
 
Cognition theories make a link between the intention to act and the behaviour 
under study. Follow up studies have demonstrated that there is a large gap 
between intention to behave or change and actual behaviour.  These gaps are 
often  referred  to  as  variance,  which  rarely  lead  to  rejection  of  a  theory  and 
create difficulties with generalising the results. 
 
Many ‘operational definitions’ of psychological terms have been made, but they 
are often not generalizable. This is particularly difficult for non-psychologists. 
Thus  there  are  difficulties  in  interpreting  and  understanding  research  and 
results.  
 
In conclusion there are many areas in which these models cause theoretical 
and  operational  difficulties.  Despite  these  differences  and  difficulties  there  is 
potential to build on the work that has already been done and use any insights 
and  ideas  to  better  understand  the  rich  diversity  of  human  cognition  and 
behaviour and use this information for improving health outcomes.  
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4.7  Tailored design 
Although tailored design is not classified as a behaviour theory in its own right it 
does draw on ideas from different theories and I have chosen to include a brief 
description in this section. Tailoring interventions has great intuitive appeal and 
since  the  advent  of  computer  technology  has  the  potential  to  be  a  practical 
option for some interventions. 
 
Strecher et al used a randomised study to investigate the effect of computer 
tailored letters to aid smoking cessation.
234 Individualised letters were sent to 
people in the intervention group according to data collected at recruitment using 
the constructs of HBM as the theoretical framework. The control group were 
sent  standard  information  about  smoking  cessation.  Rates  of  cessation  in 
moderate  to  light  smokers  in  the  intervention  was  improved  (19%  v  7%) 
significantly compared to the control group (P< 0.5)
i.  
 
Taking  advantage of modern  computer  technology  the  Etter  et al  tested  the 
hypothesis  that  computer-tailored  counselling  letters  (and  stage  matched 
booklets)  would promote better  intentions  to  quit than  non-tailored  advice.
156 
They based their intervention on a combination of behaviour models including 
the stage of change (TTM), and the theory of planned behaviour (TPB). Nearly 
3000 smokers were recruited by random mailing of 20 000 addresses from a 
population register. Their power calculation required 2000 participants and they 
                                            
i No confidence intervals were given in the paper.   142 
estimated a 10% response rate to the mailing. Respondents were randomised 
into intervention and control groups. Personalised letters sent to the intervention 
group used the level of tobacco dependence, attitudes toward smoking, self-
efficacy,  and  intention  to  use  nicotine  replacement  therapy.
156  They 
demonstrated a significantly improved rate of cessation in the intervention group 
in  all  categories  (5.8%  v  2.2%)  (P=  0.001).  Abstinence  was  not  verified  by 
biochemical testing. A large proportion of the participants were not considering 
quitting  at  the  start  of  the  study  and  even  those  in  the  group  of  pre-
contemplators faired better with tailored information (3.8% v 0.8%).  
  
Computer technology allows for personalised relevant targeted information to 
be given to an individual smoker. There is some evidence that this targeted 
approach is a useful method to help some smokers to quit. 
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5  Methodology  
In order to evaluate the impact of lung age information we need to measure key 
variables. In this section I outline some of the common instruments in use and 
discuss their advantages and disadvantages. I also seek to explain the reasons 
for choosing the instruments used in this study. 
 
5.1  How to measure smoking status 
It  is  important  to  decide  on  the  meaning  of  smoking  cessation  and  what 
constitutes a successful intervention. The Cochrane study of NRT interventions 
aimed  to  select  studies  which  had  biochemical  validation  of  smoking 
cessation.
141 Within their review the definitions of abstinence varied. They found 
that  the  meaning  of  sustained  abstinence  included  at  least  three  different 
interpretations: continuous abstinence without one cigarette since the quit day, 
repeated  point  prevalence  at  repeated  telephone  or  direct  contact,  and  self 
reported  abstinence  for  a  prolonged  period.  A  quarter  of  the  studies  in  that 
review only reported the point prevalence at the longest period of follow up. The 
reviewers stated that they preferred the use of sustained cessation rather than 
point prevalence and excluded studies, which did not have cessation data for at 
least six months following the intervention.  
 
There are problems whichever measure of cessation is used. Point prevalence 
is  not  necessarily  stable;  continuous abstinence  inevitably  reduces  with  time   144 
and measuring prolonged abstinence requires lengthy follow up. The desirability 
of  using  point  prevalence  is  that  it  is  the  only  state  that  can  be  confirmed 
biochemically.  Repeated  point  prevalence  with  confirmation  of  cessation  by 
biochemical  monitoring  helps  to  determine  if  abstinence  is  consistent  but 
requires more frequent contact and the smoker-clinician contact may be seen 
as  part  of  the  intervention.  There  is  currently  no  technique  available  for 
continuous monitoring of smoking status to give a reliable measure of sustained 
abstinence.  
 
The  need  for  biochemical  validation  is  controversial  but  often  necessary  to 
convince  peers  and  journal  editors  as  well  as  funding  institutions.  Indeed 
satisfying  the  funding  agency  that  smoking  cessation  rates  would  be 
biochemically confirmed was essential to the success of the application for a 
research grant. The accuracy of self-reported abstinence is controversial. Some 
studies  claim  that  self-reporting  is  reliable  and  accurate  in  most  cases  and 
some insist that biochemical validation is unnecessary.
235 Several other studies 
have demonstrated that deception rates may be as high as one in four. In other 
words 25% of people who claimed to have stopped smoking will have significant 
levels  of  continine  indicating  continued  cigarette  consumption.
153  The  large 
discrepancy between self-reporting and biochemical verification in the lung age 
study results supports the notion that validation is necessary in research and is 
discussed elsewhere in this thesis (see Table 6, p. 196)  
 
Smoking  or  smoking  cessation  can  be  measured  by  two  main  biochemical   145 
methods; measurement of breakdown products of nicotine (in blood, urine or 
saliva) and measurement of carbon monoxide (in blood or exhaled air).  
5.1.1 Biochemical measures of smoking 
Among  biochemical  methods  of  confirmation  the  use  of  a  biochemical 
breakdown product of nicotine called cotinine is the most accurate but the tests 
are intrusive and expensive. Cotinine is a metabolite of nicotine, and it or the 
hydroxyl  metabolites  of  cotinine  can  be  measured  in  urine,  blood  or  saliva. 
Although cotinine levels can be an accurate way of determining smoking status 
the use of nicotine gum or patches will also result in raised levels of cotinine 
and therefore smoking status can only be verified through simultaneous use of 
a carbon monoxide monitor. Although some vegetables and other foods contain 
nicotine, huge amounts would need to be eaten to invalidate a cotinine test for 
active smoking, but passive smoking may create false positives.
236-238 
 
The optimum cotinine cut off point to distinguish smokers from non-smokers is 
14.2  ng/ml,  which  correctly  classifies 99% percent  of  non-smokers  and  96% 
percent  of  smokers.  The  half-life  of  cotinine  is  approximately  20  hours  and 
therefore the test can detect most people who have smoked a cigarette within 
the past 48 hours. As already mentioned the disadvantage of this technique is 
that continued use of nicotine replacement therapy also gives positive results. 
Therefore simultaneous recording of current use of NRT is vital for interpretation 
of  the  results  (combined  with  concurrent  measurement  of  exhaled  carbon 
monoxide). 
 
Among the tests for cotinine, I chose to use the saliva cotinine test for my study.   146 
This  seemed  to  have  a  number  of  clear  advantages.    Collecting  saliva  for 
analysis is the least invasive and intrusive, easy to collect and despatch, and 
the instructions for use were easy to learn and teach. An independent nurse 
was instructed to personally witness the collection process without having the 
need for special skills (of phlebotomy). 
 
To  ensure  the  independence,  validity  and  reliability  of  the  results  I  chose  a 
registered  independent  laboratory  offering  a  postal  service.  Specimens  were 
processed  by  ABS  Laboratories,  Medical  Toxicology  Unit,  Wardalls  Grove, 
Avonley Rd, London, SE14 5ER. I also chose two independent highly qualified 
registered  nurses  to  collect  the  samples  by  home  visits  where  feasible  to 
maximise the collection of samples. One was a district nurse and the other had 
trained as a respiratory nurse whose job involved home assessment of patients 
with chronic respiratory disease. Neither of the nurses was involved with other 
aspects of the research project. 
 
Although  nicotine  breakdown  products  are  not  routinely  measured  in  clinical 
practice (as the tests are expensive and results are not rapidly available) carbon 
monoxide measurements are quick and easy to make after a modest capital 
outlay for the measuring device and are routinely used in smoking cessation 
clinics to confirm smoking status. Carbon monoxide can also be measured in 
blood  but  this  is  more  invasive,  needs  phlebotomy  skills  and  does  not  give 
immediate results. The potential advantages of blood measurement would be 
that it does not rely on the breathing and coordination skills of the participant 
and  that  results  are  independently  confirmed.  The  advantage  of  measuring   147 
carbon monoxide in exhaled air is that it can give immediate information to the 
examiner and feedback to the patient.  
 
Controversially  the  NHS  continues  to  use  the  four  week  smoking  cessation 
figures as the measure of success with point prevalence either self reported or 
validated with the measurement of exhaled carbon monoxide.
239 There have 
been calls for clearer standards for reporting within the health service which 
would enable meaningful comparisons between services and research.
240  
 
There are two main reasons to measure smoking levels in this study. The first is 
to  confirm  the  veracity  of  the  claim  of  a  participant  that  they  have  stopped 
smoking so that independent confirmation of systemic nicotine can be tested 
and  secondly  to  use both  the  levels  of  carbon  monoxide  in  exhaled air  and 
systemic nicotine in combination to determine if raised cotinine levels are due to 
nicotine  replacement  therapy.  I  used  carbon  monoxide  monitors  for  initial 
confirmation  of  cessation  at  the  twelve-month  examination  and  during  saliva 
collection  for  cotinine  testing.  I  chose  the  model  in  current  use  by  our  local 
primary care trust and issued for regular use in the smoking cessation clinics. 
The  device  is  simple  to  use  and  made  by  a  reputable  medical  instrument 
company  (Smoke  Check  –  catalogue  number  SC01).
241      This  model  has  a 
carbon monoxide range of zero to 500 per million and a sensitivity of one part 
per million.  
 
Using  this  model  had  three  clear  advantages.  Firstly,  they  were  already   148 
accepted within the NHS as complying with quality standards. Second, it made 
economic  sense  to use  equipment  already  available  and  in  use.  Finally,  the 
clinical staff were already familiar with the equipment and did not require  
additional training.  149 
 
5.2  Should nicotine dependence be measured and if so how? 
Quitting  success  has  been  associated  with  levels  of  nicotine  dependence. 
Therefore it can be a useful measure when comparing groups within a study 
and when comparing studies with one another. Furthermore, it is assumed that 
identifying those with greater nicotine dependence will help target treatment.  
 
The  Fagestrőm  tolerance  questionnaire  (FTQ),  Fagerström  Test  for  Nicotine 
Dependence (FTND), and the Heaviness of Smoking Index (HSI) are all widely 
used measures of nicotine dependence in smoking research. FTND and HSI 
are similar in their ability to predict smoking cessation to a small degree. Both 
the FTQ and FTND have strong internal validity (high retest reliability). 
 
The three measures of nicotine dependence are inter-related.  The FTQ was 
the first of the three and is longer than the other two. Many reviewers believe 
that it should make way to the others.
242 
5.2.1 FTQ (Fagerström tolerance questionnaire) 
The  development  of  the  tolerance  questionnaire  relied  on  the  correlation 
between  physiological  measures  of  tolerance  of  nicotine  with  physical 
dependence during smoking and withdrawal. The aim was to develop a way of 
measuring physical dependence. 
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Box 4 Fagerström tolerance questionnaire (FTQ) 
  
1. How many cigarettes per day (cpd) do you smoke?  
          Score: 0= 15 or less cpd, 1= 16 to 25 cpd, 2= 26+ cpd 
 
2. What brand do you smoke?  
          Nicotine yield – score: 0= 0.9mg or less, 1= 1-1.2 mg, 2=1.3mg + 
 
3. Do you inhale?  
          Score: 0=Never, 1= Sometimes, 2= Always 
 
4. Do you smoke more during the morning than during the rest of the day?  
          Score: 0=No, 1=Yes 
 
5. How soon after you wake up do you smoke your first cigarette? 
          Score: 1= within 30 minutes. 
  
6. Which cigarette would you hate to give up‘?  
          Score: 1 for ‘First one in the morning’. 
 
7. Do you find it difficult to refrain from smoking in places where it is forbidden, 
e.g. in church, at the library, cinema? 
          Score: 1 for yes 
  
8. Do you smoke if you are so ill that you are in bed most of the day?  
          Score: 1 for yes 
 
       Scoring range is 0-11 points. Eleven indicates maximum dependence 
 
 
With regard to the FTQ presented above there are a number of key points as 
follows:
243  
•  They assumed that brands which contain a higher dose of’ nicotine are 
consumed by those smokers with more physical dependence.   151 
•  Inhalation makes absorption of nicotine more efficient and is likely to be 
linked with dependence (Question 3). 
•  Dependent  individuals  will  need  nicotine  when  levels  are  low  in  the 
morning (Question 4, 5 and 6). 
•  The  urge  to  smoke  in  inappropriate  places  or  when  ill  points  to  less 
control and more dependence (Questions 7 and 8). 
The questions have face validity on the basis of widespread views, assumptions 
and observations about smoking and dependence at that time. 
 
Separating  the  physiological  and  psychological  dependence  using  heart  rate 
and body temperature requires good quality scientific methods such as using 
randomised double blind, placebo controlled trials. Most of the trials have been 
small scale non-blinded and not randomised.
244 Although the tolerance scale 
had initial face validity the correlation between scores and withdrawal symptoms 
is weak.
244 However the FTQ does correlate well with other biomarkers of the 
effects of smoking such as cotinine levels and carbon monoxide levels.
244 Other 
investigators  have  found  no  correlation  between  the  FTQ  and  most  of  the 
withdrawal  symptoms  including  irritability,  anxiety,  restlessness,  hunger, 
impatience, somatic complaints and insomnia. There was significant correlation 
between FTQ score and craving and also with difficulty concentrating.
245 
 
A stated function of the FTQ is to predict the success of smoking cessation and 
to target those smokers with high dependency who cannot quit without help. 
There  is  some  evidence  to  support  the  idea  that  high  nicotine  dependent 
smokers  do  better  with  nicotine  replacement  than  less  dependent  people.
246   152 
However low dependent people will do better with nicotine replacement than 
with placebo alone. 
5.2.2  Fagerström Test for Nicotine Dependence (FTND) 
The Fagerström Test for Nicotine Dependence (FTND) (see Box 5, p. 153) was 
developed  from  and  has  largely  replaced  the  FTQ.  Because  most  smokers 
inhale and nicotine rating of cigarettes is an unreliable indicator of absorption of 
nicotine (as measured by biochemical means), several questions contained in 
the  FTQ  were  discarded.  Revision  of  the  scoring  system  for  time  to  first 
cigarette and the number smoked per day improved the scale.
247 The FTND is 
shorter than the FTQ (six versus eight questions) and simpler in application and 
has  a  growing  body  of  literature  to  support  its  use  although  the  association 
between  nicotine  dependence  level  measured  by  the  scale  and  withdrawal 
symptoms remains small.
248 
 
Higher test scores are associated with carbon monoxide levels but high-scoring 
smokers are not clearly differentiated from those with mid-range scores.
242   153 
Box 5 Fagerström Test for Nicotine Dependence 
FTND  
The score for each answer is in brackets ( ). Add up the scores and compare 
with the limits at the foot of the page. 
1. How soon after you wake up do you have your first cigarette? 
A. Within 5 minutes (3) 
B. 6-30 minutes (2) 
C. 31-60 minutes (1) 
D. After 60 minutes (0) 
 2. Do you find it difficult to refrain from smoking in places where it is 
forbidden, e.g., in church, the library, the cinema, etc? 
A. Yes (1) 
B. No (0) 
 3. Which cigarette would you hate most to give up? 
A. The first one in the morning (1) 
B. All others (0) 
 4. How many cigarettes do you smoke per day? 
A. 10 or fewer (0) 
B. 11-20 (1) 
C. 21-30 (2) 
D. 31 or more (3) 
 5. Do you smoke more often during the first hours after waking than during 
the rest of the day? 
A. Yes (1) 
B. No (0) 
6. Do you smoke even if you are so ill that you are in bed most of the day? 
A. Yes (1) 
B. No (0) 
Score: 7 to 10 points = highly dependent on nicotine 
           4 to 6 points = moderately dependent on nicotine 
           less than 4 points = less dependent. 
   154 
Unfortunately  there  is  poor  correlation  between  this  and  other  widely  used 
measures  of  dependence  on  nicotine  such  as  the  Diagnostic  and  Statistical 
Manual  of  Mental  Disorders  (DSM  III-R  criteria).  The  implications  of  these 
differences will be discussed in the next section.
249 
5.2.3 Heaviness of Smoking Index (HSI) 
The  HIS  was  developed  from  the  FTQ  and  the  FTND  in  1989  after  the 
realisation that most of the difference in scores comes from just two of the items 
in the other two scoring systems.
247 
 
The  heaviness  of  smoking  index  is  created  as  the  sum  of  the  number  of 
cigarettes smoker per day and the time to first cigarette. HSI scores range from 
0–6 and are calculated by summing
 the points for time to first cigarette (TTF) 
after waking and number
 of cigarettes smoked per day (CPD).  
Box 6 Heaviness of Smoking Index (HSI) 
1. Time to first cigarette (ttf) 
   Score:
 < 5 mins ttf = 3 points 
    6–30 mins ttf = 2 points 
    31–60
 mins ttf= 1 point 
    > 60 mins ttf = 0 points 
 
2. Cigarettes smoked per day  (cpd) 
On  average,  how  many  cigarettes  do  you  smoke  each  day, 
including
 both factory-made and roll-your own cigarettes?’  
Score: 1–10 cpd = 0 points 
    11–20 cpd = 1 point 
    21–30 cpd = 2 points 
       > 31 cpd = 3 points
 
Higher HSI scores indicate more dependence on nicotine.   155 
 
The HSI is positively associated with nicotine dependence, and functions as 
well as the FTND. A prospective study, of nearly 1000 smokers, of the ability of 
the  three  self-reported  tests  (FTQ,  FTND  and  the  HSI)  to  predict  levels  of 
carbon  monoxide  at  the  outset  and  the  likelihood  of  cessation  after  group 
cessation were statistically significant.
242 The HSI has gained in popularity and 
use in the field of smoking research and has been applied in some recent large 
multi-centre cross-sectional studies.
20 However, in the mid range of HSI values 
in  a  large  survey  conducted  in  the  U.K.  (2006),  there  was  a  lack  of  an 
association between nicotine dependence and quit success compared to that 
found in other countries (e.g. Canada).
80 
5.2.4 Craving  
The subject of cravings is controversial as it refers to subjective feelings, which 
are thought to relate to nicotine dependency. There is little consensus about 
how best to define or assess cravings.
250  
Box 7 Questionnaire of smoking urges  
Smoking urges
250 
1.  I have a strong desire for a cigarette right now. 
2.  If it were possible I would smoke right now. 
3.  All I want now is a cigarette. 
4.  I have an urge for a cigarette. 
5.  I crave a cigarette right now. 
 
Despite the controversies, withdrawal and craving may be important as potential   156 
predictors of relapse, or as markers of treatment effects. Multiple questions with 
scales for different responses have been developed. Non of them have come 
into  regular  and  widely  accepted  use.
216;250  However,    the  assessment  of 
cravings may be operationalized by using a single question : 
On a scale of 1- 10 how strong are your cravings right now?  
Some investigators have found this form as reliable and valid as longer scales 
and  demonstrate  ability  to  predict  smoking  behaviour.
250  There  are  several 
longer scales used in research including the questionnaire of smoking urges, 
which asks respondents to indicate on a line (from strongly agree to strongly 
disagree) the strength of their agreement with the five items in Box 7 (p. 155) 
and a ten point craving scale which is similar.
216 
5.2.5 Critique of measures of nicotine dependence 
The development of reliable scales of nicotine dependence has potential use in 
both clinical practice and research. In theory the measurement of dependence 
should help practitioners to target those who need pharmacological help and 
then  to  titrate  doses  of  nicotine  replacement  in  accordance  with  degree  of 
addiction.  Nicotine  replacement  treatment  (NRT)  manufacturers  only 
recommend  the  use  of  their  products  when  smokers  are  consuming  ten 
cigarettes or  more  per  day.  However  the  evidence  for  use  of  titration  is  not 
strong and NICE technical guidelines on NRT do not set any lower limits of 
smoking dependence for the use of NRT.
137 Therefore currently, the main use 
of measures of dependence is in research. 
 
The implications of the differences in scoring with different systems are that 
estimates of the prevalence of nicotine dependence in the general population   157 
may vary depending on which instrument is used.
249 Some research studies 
enroll participants using criteria based on the level of dependence.  If different 
studies use different tools the results cannot be directly compared or used in 
meta-analysis.  Any  of  the  individual  tools  for  measurement  can  be  and  are 
commonly  used  for  interventional  studies  to  confirm  similarity  of  control  and 
intervention groups and successful randomisation. 
5.2.6 Rationale for non-inclusion 
A measure of nicotine dependence was not included in the lung age RCT. Even 
though measures of nicotine dependence are much more strongly associated 
with  cessation  than  measures  of  motivation,  and  nicotine  dependence  is 
regarded  as  a  major  factor  predicting  long-term  cessation  in  smokers,
27  this 
study  was  not  designed  to  identify  associations  between  cessation  and 
dependence.  
 
Furthermore, due to the poor correlation of nicotine dependence scores with 
each  other  or  with  particular  interventions  it  is  not  yet  reasonable  to  target 
particular  groups  of  smokers  or  individuals.  Our  research  study  was  not 
designed  to  target  a  particular  group,  indeed  the  recruitment  process  was 
deliberately aimed at being as inclusive of all smokers over the age of 35 and 
reducing the exclusions to a minimum to reflect the primary care population of 
smokers and not simply those seeking help with cessation. 
 
In hindsight there would have been some merit in collecting data on nicotine 
and this will also be discussed in Section 8.2 (see p. 207). The extra data would 
have  added  another  tier  of  information  to  strengthen  the  evidence  that   158 
randomisation had been successful. It may also have given some data about 
any correlation of lung damage and nicotine dependence but this was not the 
aim of the study, which was neither powered nor designed to test that theory. 
Also it would have been a distraction from the main purpose and taken extra 
time during recruitment and collection of the important core data. 
 
5.3  Should psychological variables be measured and if so 
how? 
Psychological  factors  influencing  behaviour  change  have  been  extensively 
discussed in the chapter on behaviour change theories (see Section 4, p. 89). In 
order to avoid repetition, here I will discuss three important areas of psychology 
that I believe are most relevant to this study and refer back to previous sections 
where necessary. The three factors I will discuss in this section on measuring 
psychological factors are: 
•  Motivation related to intention 
•  Self-efficacy 
•  Perceptions of risk to health 
 
Psychological factors are thought to have an important influence at every stage 
of smoking behaviour from initiation through to decisions to quit and factors in 
relapse. Therefore, investigators should consider their impact at every stage of 
the research process from designing interventions through to interpretation of 
results. 
   159 
The detail of the development, testing and validation of psychological tools is 
beyond the scope of this thesis. However it is of interest to outline some of the 
psychological factors that are most likely to be active and influential in smoking 
behaviour change in the context of this study of lung age. 
5.3.1 Measuring motivation related to intention to quit. 
In national surveys the majority (~70%) of smokers say they want to quit,
79 but 
there may be barriers from turning this intention or motivation into reality. One 
simple schema to assess this in a qualitative way is the grid below indicating the 
relationship between motivation and dependence. 
 
Table 4 Motivation, dependence and intervention goals 
Motivation  Dependence  Characterised by  Primary intervention goal 
Low  Low  Unlikely  to  stop  but 
could do without help 
 
Increase motivation  
Low  High  Unlikely to stop  Initially to increase 
motivation to make 
receptive to treatment 
for dependence 
High  Low  Likely  to  stop  with 
minimal help 
To trigger a quit attempt 
High  High  Unlikely  to  stop  without 
help  but  would  benefit 
from treatment 
Engage smoker in  
treatment 
(Table adapted from West
79) 
 
When considering measurement of motivation about smoking and cessation the   160 
different meanings of the term need to be considered. In terms of the study of 
motivation it may be regarded as the study of movement or action.
251 This may 
be  passive  in the  sense  of being  pulled  along by  a desire or  actively  being 
pushed along by a drive e.g. the desire for better health.  Different models of 
motivation by necessity are assessed and measured in different ways  
5.3.2 Maslow’s hierarchy 
According  to  Maslow’s  hierarchy  of  needs,  people  have  a  desire  or  are 
motivated to move from one level in the hierarchy to another.
252 This starts with 
the fulfilment of basic needs of life including warmth, food, clothing and shelter. 
Once each level is attained and satisfied then an innate need to reach the next 
level becomes the motivator. 
 
In the words of Maslow: ‘Man is a perpetually wanting animal. Also, no need or 
drive can be treated as if it were isolated or discrete; every drive is related to the 
state of satisfaction or dissatisfaction of other drives’.
253 Therefore once a lower 
level is attained then theory states that there is a motivation to move to higher 
levels  through  those  of  safety  and  love  and  esteem  to  self-actualisation. 
Paradoxically,  despite  self-actualisation  being  the  pinnacle  of  the  hierarchy, 
apparently  this  does  not  bring  about  satisfaction  or  eliminate  the  drive  for 
change. 
 
Motivation theory is not the same as behaviour theory. The motivations that 
Maslow  describes  are  only  one  class  of  determinant  of  behaviour.  Although 
behaviour is motivated it is also determined by other forces of biology, culture 
and circumstance.
253 Although the hierarchy of needs has been widely adopted   161 
in the processes of change in books and popular culture, and also in the realms 
of personal and professional development, it has not found a strong niche in 
research  into  smoking.  The  framework  may  fit  into  the  field  of  smoking  and 
cessation in a number of different ways. First, a person who seeks satiation of 
hunger may really be seeking more for comfort, or dependence. In contrast, a 
person may satisfy hunger or believe they are reducing stress by smoking a 
cigarette. Secondly, when a person is seeking to quit smoking they may be 
motivated by a desire to reduce threat to health thereby improving security in 
the  Maslow  hierarchy.  Discovering  how  people  view  their  smoking  and  their 
need to continue may give insights into how they can approach quitting and 
what factors may lead to relapse. 
 
A problem arises when conflicting cognitions come into play. A message that  
‘smoking  is  bad  for  you  long  term’  may  be  come  up  against  the  desire  for 
immediate  short  term  pleasure  from  a  cigarette.  The  conflict  or  dissonance 
between the two cognitions leads to stress and anxiety which can be expelled 
by rejecting one of the messages or changing behaviour.
251;254   
 
Although  the  theoretical  framework  is  of  use  in  qualitative  understanding  of 
some  behaviour  and  may  be  used  as  part  of  the  underpinning  rationale  for 
some forms of therapy such as motivational interviewing (see p. 70), I have 
been unable to find any smoking cessation research studies which have used 
scales of motivation based on Maslow’s hierarchy and cannot conceive of a way 
that this could be adapted for use in this purpose.  
   162 
5.3.3 Readiness and stage 
Changes  in  motivation  may  be  conceptualized  as  a  readiness  to  change  as 
described  in  motivational  interviewing.
142;255  Proponents  of  motivational 
interviewing  describe  motivation  as  simply  the  probability  that  a  person  will 
enter into and adhere to a specific change strategy. The role of the therapist is 
to  facilitate  and  support.  This  approach  assumes  a  phenomenological, 
humanistic  approach  of  self–actualisation.
256  This  is  in  contrast  to  traditional 
cognitive  theories  of  motivation  and  any  confrontational  approach  by  the 
interviewer.
256 The phenomenological approach to change is based on a view 
that  man  has  choice  and  that  change  is  intentional.  Accordingly  there  is 
potential for growth and change as a process of self–actualisation.  
 
The  readiness  to  change  ladder,  has  face  validity  and  consists  of  eleven 
response options on a continuum ranging from ‘not at all considering quitting 
smoking  in  the near  future’  to  ‘already  have  quit  smoking’.
257 Ladder  scores 
have been found to predict subsequent participation in programs designed to 
educate smokers about their smoking habit and its risks. However, the ladder 
scores do not predict abstinence confirmed by biochemical testing. 
 
The ladder has been associated with intention to quit, nicotine dependence and 
numbers of previous quit attempts.
216 As discussed in the chapter on behaviour 
change  this  adds  weight  to  the  conclusion  that  intention  to  quit  is  a  poor 
predictor of successful quitting.  
 
Although  the  popularity  and  standing  of  the  transtheoretical  model  and  the   163 
concept of stages is waning, many studies continue to use the idea of linking 
intention and motivation. For example a recent study in older smokers used the 
following question
258: 
‘Are you planning to quit smoking within the next month, next 6 months, 
sometime in the future (beyond 6 months) or not planning to quit?’ 
Responses were dichotomized into planning to quit versus not planning to quit, 
without overtly using TTM as a theoretical framework or presenting evidence 
that the question is a valid and reliable way of testing motivation. This seems to 
me a clumsy way of using what in essence is the same system. 
 
Changes in motivation may be conceptualized as a movement through stages 
as described in the trans-theoretical model (TTM).
211 With regard to stages of 
change it is believed that most people presenting for treatment are by definition 
in the preparation stage.  However there is no consistent evidence that these 
stages predict movement nor are they stable.
259 As many as 30% of smokers 
will alter their stated intention within a 30 day period.
259 The trans-theoretical 
model and stages of change is discussed in detail in Section 4.4 (p. 116). 
5.3.4 Rationale for choice of measuring tool  
The decision to use the trans-theoretical stages of change in this study was 
based on the pragmatic need for a simple and quick, staging and readiness to 
change, measure. The format used by the trans-theoretical model undoubtedly 
fulfils these two criteria.  
 
At the time of the start of this project the trans-theoretical model of stages was 
commonly used in quit research. In particular, many previous studies exploring   164 
the  use  of  spirometry  or  biomarkers  to  promote  quitting,  have  used  a  self 
reported  ‘intention  to  quit’  measure  based  on  the  trans-theoretical  stages 
questions or similar brief questioning.
36;155;217;260 Even very recent large multi-
centre international studies of predictive factors of smoking have used intention 
to quit based on almost identical questions used in this model.
27 In contrast, 
some key studies make no mention of a motivation or intention to quit measure 
in their methods or results.
35 A minority, however, use a surrogate measure of 
past motivation called ‘previous quit attempts’, but no detail is given about the 
period of time this refers to, and how it is measured or validated.
148;151;157;217 
 
The  main  criticisms  of  the  widespread  use  of  the  trans-theoretical  stages  of 
change classification have become evident since the research protocol for this 
study was developed (see Section 4.4.3, p. 123).
231 Even new studies of the 
psychological mechanisms of confrontational smoking cessation interventions 
using spirometry are not using sophisticated or widely established measures of 
motivation e.g. a study by Kotz (in press) used the question ‘how important do 
you find it to stop smoking on a scale of 0 (not important at all) through 10 (very 
important)?’
261 
 
Despite the  criticisms  of the  trans-theoretical  model  no  clear  consensus  has 
emerged to support an alternative scoring system of motivation to quit smoking, 
for research or clinical practice or for targeting interventions. Even though this 
model  is  not  ideal,  is  neither  stable  nor  reliable  method  of  establishing 
readiness to receive treatment, at least some comparisons can be made with 
previous research on using spirometry to promote smoking cessation. All else   165 
being equal the use of stages of change in this trial supports the conclusion that 
randomisation  was  successful  and  similar  rates  of  responses  were  obtained 
from both the control and intervention groups. It also supported the notion that 
the participants were not exclusively from a group of smokers on the verge of 
quitting. It is logical to assume that smokers who voluntarily attend smoking 
cessation programmes are motivated and in a state of readiness to change their 
behaviour. Some research programmes’ recruitment methods result in a high 
proportion  of  participants  who  are  already  ‘planning  to  quit’,  or  even  overtly 
exclude  those  who  are  not  planning  to  quit
159  and  therefore  any  results  of 
successful  cessation  are  biased  by  recruitment  or  selection  method.  For 
example, among the over 400 participants, in a randomised trial of biofeedback 
on lung cancer risk, only 3%
j of the participants were not considering stopping 
smoking within the next six months.
218  
 
In conclusion, despite its flaws, one clear benefit of using the blunt instrument of 
stage of change (TTM) is that the information may help determine whether or 
not comparisons can be made between studies using the same measures of 
motivation whereas if no measure is available there will be greater doubts about 
usefulness of making comparisons.  
                                            
j Pre-contemplative 3%, contemplation stage 57%, preparation stage 40%
218           166 
 
5.4  Other measures of cognition 
The  concept  of  self-efficacy  is  included  in  most  of  the  cognition  and  social 
cognition models of behaviour change (see Section 4.1.3, p. 92). Self-efficacy 
conceptualises an individual’s belief in their ability to perform a particular task or 
behaviour
262 and is probably important in determining the success of smoking 
cessation
263;264  and  relapse  is  consistently  predicted  by  measures  of  self-
efficacy.
265 Those who have been smoking a long time are more likely to be less 
confident about stopping.
258 Differences in self-efficacy have been implicated as 
part of the reason that cessation rates are lower among lower socio-economic 
groups.
20 
 
Measurement  of  self-efficacy  is  usually  through  questions  about  confidence. 
There  is  a  wide  range  of  tools  available  to  researchers,  which  attempt  to 
measure  self-efficacy.  In  some  studies  measurement  is  brief  and 
operationalized with a single question e.g.  
1.  ‘If you decided to give up smoking
 completely in the next 6 months, how 
sure are you that you would
 succeed?’ (Options of -Not at all sure/slightly 
sure/ moderately sure/ very
 sure/ extremely sure)
20;80;258 
2.  ‘How confident are you that you could quit smoking for good? (Options 
0= not at all, 2= a little, 3= very much, 4= extremely)
217;266 
 
The  most  recent  large  prospective  cross-sectional  study,  in  four  developed 
countries,  suggests  that  most  of  the  variables  tested  predicted  intention  or 
attempts to change rather than to the success of attempts.
80 Self-efficacy is the   167 
possible exception but the correlation is not strong. This is in keeping with the 
evidence presented under the chapter on health belief models (see Section 4.3) 
where  there  is  a  serious  gap  between  intention  to  change  and  successful 
changes  in  behaviour.  Measures  of  nicotine  dependence  were  the  only 
measures in that study which predicted both quit attempts and quitting, which 
suggests  that  interventions  that  focus  on  dependence  are  preferable  to 
interventions that only focus on expectancy-based variables. 
 
Alternatively more complex instruments can be used such as the confidence 
questionnaire.  The  original  questionnaire  is  far  too  lengthy  and  even  the 
fourteen item shortened form (form S), later introduced is too long for clinical 
contexts and most research studies.
216;267 Efficacy means more than the initial 
confidence  about  quitting;  it  also  encapsulates  the  confidence  and  ability  to 
remain abstinent.  
 
The  relapse  situation  efficacy  questionnaire  (RSEQ)  aims  to  measure 
vulnerability depending on context and situation.
216;268 The questionnaire asks 
the  respondent  to  rate  their  confidence  at  not  smoking  under  a  variety  of 
conditions on a scale of ‘not at all confident’ to ‘extremely confident’ (1 to 4). 
Excerpts from the RSEQ can be seen below. 
1.  ‘How confident are you that you can resist the temptation   to smoke 
when  you  are:  restless,  tired,  happy,  irritable,  sleepy,  tense, 
hungry etc’? 
Each of these categories are answered separately. 
2.  ‘How confident are you that you can resist the temptation to smoke   168 
when you are feeling very bad, bad…to   very good’? 
3.  ‘How confident are you that you can resist the temptation to smoke 
when your arousal or energy level is very low/ low/ to /very high?’ 
4.  ‘How confident are you that you can resist the temptation to smoke 
when you are eating and drinking?’  
A number of different scenarios are outlined concerning type and 
timing of consumption of food and alcohol to help the informant to 
understand and answer the questions.  
 
A  measure  of  confidence  was  not  measured  in  the  lung  age  study  and  the 
implications of that decision are discussed further in Section 5.5.1 (p. 169) and 
under the discussion of the weaknesses of the study (Section 8.2.2, p. 207).   169 
 
5.5  Should attitudes and beliefs about smoking be measured? 
5.5.1 What is an attitude? 
In terms of measurement, the consensus amongst most researchers is that an 
attitude is a state of readiness and a tendency to respond in a certain way when 
faced with certain stimuli. Most are dormant and become apparent in speech or 
behaviour  when  the  object  of  the  attitude  is  perceived.
233  Attitudes  are 
reinforced by beliefs (the cognitive component) and may be accompanied by 
strong  emotion,  which  may  lead  to  particular  intention  or  action.  They  are 
abstract and may not fit into any logical or recognisable pattern or mixture.
233 
Attitudes are said to be part of a mix of values, beliefs and feelings. 
 
Attitude scaling is a common method of measurement used in surveys. They 
are  not  designed  to  yield  insights  into  individual  cases  and  according  to 
Oppenheim  they  should  not  be  use  as  a  clinical  instrument.
233  Their  main 
function is to place people on a continuum in relation to one another but cannot 
measure them in absolute terms.
233 In terms of research they may be used to 
explore  associations  between  attitudes  and  differences  in  behaviour.  For 
example,  research  has  found  associations  between  concern  on  the  part  of 
smokers about their susceptibility to serious illness and their attempts to quit 
smoking and reduction of cigarettes smoked.
208 
 
Any  behaviour  may  be  graded  on  an  arbitrary  scale  by  asking  a  series  of 
questions about attitude e.g. as conceptualised by TPB (see p. 98). This may   170 
include-  
•  a person’s evaluation of the behaviour,  
•  their perceived risk of diseases associated with that behaviour and  
•  measures of changed perceptions of risk depending on the message or 
intervention under investigation. 
5.5.2 How can attitudes be measured? 
One important example of the use of scales in exploring the attitude variables 
active in smokers is as follows (see Box 8, p. 170 and Section 4.2, p 98): 
 
 
‘My not smoking (continuing to smoke) over the  
next six months would be’: 
Harmful          -3, -2, -1, 0, +1, +2, +3        Beneficial 
Unpleasant    -3, -2, -1, 0, +1, +2, +3        Pleasant 
Un-enjoyable -3, -2, -1, 0, +1, +2, +3        Pleasant 
Bad                -3, -2, -1, 0, +1, +2, +3        Good 
Foolish           -3, -2, -1, 0, +1, +2, +3        Wise 
(Adapted from Norman et al)
269 
Box 8 Measure of attitude towards not smoking  
‘Respondents attitude towards not smoking over the next six months was 
measured  using  three  semantic  differential  scales  (i.e.  bad-good, 
harmful-beneficial, foolish-wise) scored -3 to +3. The questionnaire also 
included  a  measure  of  perceived  susceptibility.  Respondents  were 
presented with a list of seven smoking related health problems (e.g. lung   171 
cancer, bronchitis) and asked to answer the question’: 
 ‘How  likely  do  you  think  it  might  be  that  you  will  develop  any  of  the 
following problems in the future if you continue to smoke?’ on a seven 
point scale, scored -3 to +3.
269 
 
One example of how concern about health may be operationalized is as follows 
in the study by Lipkus 2007
56:  
Participants were asked a question with four parts. 
‘To what extent do you feel worried that smoking is currently ‘ 
1.  harming your lungs?  
2.  harming  heart  and  circulatory  system  (e.g.  increasing  blood 
pressure)? 
3.  causing breathing problems (e.g. coughing, shortness of breath, 
wheezing or asthma)?  
4.  causing more colds? 
Response options ranged from 1 (not at all) to 7 (extremely).  
 
A  similar  but  not  identical  set  of  questions  were  used  in  a  large  population 
survey in four continents as folllows.
80 They called this ‘worries about health and 
quality of life’: This variable was created based on smokers’ responses to two 
questions at baseline:  
(1) ‘How worried are you, if at all, that smoking will lower your quality of 
life in the future?’  
(2) ‘How worried are you, if at all, that smoking will damage your health in 
the future?’    172 
Categories of the answers include: 
not at all worried, a little worried, moderately worried, very worried.  
Each variable was coded as a continuous measure from 1 (weak) to 4 
(strong) and the average of the two measures was used in analyses.  
The same study also tested the outcome expectancy of quitting:  
At baseline survey, smokers were asked,  
‘‘How much do you think you would benefit from health and other gains if 
you were to quit smoking permanently in the next 6 months?’’ Categories 
of the answer include:  
not at all, slightly, moderately, very much, and extremely.  
The variable was coded as a continuous measure from 1 (weak) to 5 
(strong).
80 
 
There  is  some  recent  support  for  the  notion  that  confronting  smokers  with 
previously  undiagnosed  airways  obstruction  with  the  results  of  spirometry 
increase  risk  perceptions  and  self-efficacy,  and  decreases  risk  denial  (self-
exempting  beliefs)  in  already  motivated  participants.
261  These  changes  in 
mediators are associated with a higher likelihood of smoking cessation. Risk 
perception was measured using two simple questions: 
1.  ‘How high do you estimate your risk of getting a serious disease at a later 
age when you do not stop smoking?’  (1=very low to 5 very high) 
2.  ‘How high do you estimate your risk of getting a serious disease within 
the next ten years when you do not stop smoking?’ (1=very low to 5 very 
high) 
   173 
 
Self-exempting beliefs are commonly found among smokers.
270;271 According to 
this idea if a smoker believes he is susceptible to the ill effects of smoking but 
continues to smoke this creates cognitive dissonance which creates anxiety. 
The concept of self-exemption implies that the individual reduces the anxiety by 
believing something else to create risk denial e.g. that smoking is not really as 
harmful as reported. Therefore, self-exempting beliefs are thought to have the 
potential  to  interfere  with  smoking  cessation.  Researchers  have  tried  to 
measure these self-exempting beliefs by using questions in a number of ways. 
There is some overlap in the selection of questions used in different studies to 
test exempting beliefs as follows:  
Respondents were asked to rate the following statements- 
Study 1. ‘Smoking is no more dangerous than breathing polluted air in 
urban areas’,  
Study 2.‘Some people can smoke their whole life and never get sick,’ 
Both  used  a  four  point  Likert  scale  (strongly  agree,  agree,  disagree, 
strongly disagree).  
 
When quoted in the literature these tools are often adapted from use in other 
contexts (e.g. attitudes to increased exercise, health screening, or eating more 
fruit).  The  examples  given  above  are  important  in  that  they  highlight  two 
problems  with  testing  attitude  in  smoking  research.  First,  among  the  large 
numbers of studies of attitudes, there is a lack of standardisation of questions 
and secondly there is a lack of evidence of validation available in the literature.   174 
5.5.3 Rationale for not using attitude or cognitive factors 
A  pragmatic  decision  was  made  not  to  include  a  measure  of  psychological 
factors  (including  self-efficacy  or  perceived  risk  or  perceived  benefit  from 
quitting) in this research project. In the context of primary care research the 
data collection tools have to be valid and concise to be acceptable to both the 
participating  practices  and  individuals.  Evidence  available  at  the  time  of  the 
development of the study did not suggest that the concept of self-efficacy was 
implicated  in  determining  smoking  behaviour  in  the  context  of  knowledge  of 
spirometry  results  or  lung  age.  The  main  aim  of  initial  data  collection  was 
confirmation  that  the  two  randomised  groups  were  similar  at  baseline. 
Extending the baseline tests on the basis of an unfounded speculation that self-
efficacy would be a major factor influencing the reaction to lung age was not 
part of the theory. Furthermore, during the initial literature review (even prior to 
the Cochrane review of biomarkers and smoking cessation)
115 I did not identify 
any  randomised  or  cross-sectional  studies  which  had  used  psychological 
measures of self-efficacy as part of the baseline data collection and therefore 
no precedent had been set and no comparisons with previous studies could be 
made even if such a measure had been included. 
 
However,  in  the  light  of  the  results  it  would  have  been  interesting  to  have 
recorded some measures of risk perception both before spirometry and after 
explanation of the results. Reactions to the information given and how this had 
change perceptions and intentions would have been interesting. There is only 
one published research paper on the effects of lung age on perceived health 
risk and desire to quit. This was a small pilot project among American college   175 
students.
56 They used a number of tools to measure health behaviour risk and 
emotional reaction to lung age information based on the health belief model. 
There are too many problems with the Lipkus et al. (2007)
56 study to make any 
meaningful comments about the ‘results’ or make generalisations. For example, 
based on population surveys, it is highly improbable that students of this age 
would show any abnormality on spirometry after an average of only four pack-
years  of  smoking  but  remarkably  75%  of  those  tested had  abnormal  results 
(average lung age 35 versus average age 20), numbers were too small and no 
power  calculation  was  done  prior  to  recruitment  to  come  to  any  meaningful 
conclusions. However they have made inroads into how to test a hypothesis 
about the mechanism of action of giving lung age as the intervention.  
 
I had some expectation that poorer lung age would lead to bigger likelihood of 
changed behaviour and some fears that good results might lead to indifference 
to change. However, to have immediately measured the psychological effects of 
the information may itself have been regarded as part of the intervention and 
influenced perception and intentions (see Section 4.6, p. 134).
165 Moreover, this 
would have been rather impractical as the intervention included written postal 
individual  feedback  and  therefore  any  questionnaire  about  changes  in  self-
exempting belief would have to be administered after the participant had read 
the letter. Any extra contact for data collection would have added complexity to 
the study and was therefore not considered. 
 
In  summary,  although  psychological  data  would  have  been  interesting,  the 
randomised controlled trial was not designed with a behavioural theory in mind   176 
and was not intended to analyse the intricacies of psychological forces related 
to lung age. Further research is required to explore the mechanism of action of 
the success of lung age as a smoking cessation tool. Further discussion about 
psychological measures will be included in the section on the weaknesses of 
the study (p. 205) and ideas for further research (see Section 8.3, p. 210).  
 
5.6  How to measure impact of smoking  
For the purposes of this study I was primarily interested in selecting a widely 
used, validated questionnaire that could measure the impact of smoking on the 
respiratory  health  of  participants  so  that  the  control  and  intervention  groups 
could be compared at baseline. I anticipated that this would have two important 
functions  necessary  for  this  study.  First  it  would  be  supportive  evidence  of 
successful  randomisation.  Secondly,  it  would  be  another  measure  of  the 
similarity of the two randomised groups, in addition to the objective measures of 
lung function and demographic data collected.  
 
Objective  measures  of  lung  function  (e.g.FEV1)  do  not  necessarily  correlate 
with the impact of lung function on daily life, as patients tend to adapt gradually 
to their limitations. Significant airways obstruction may be present before the 
individual is aware of any problem.
32 Treatment of airways disease is directed 
towards  improving  patients'  health  and  wellbeing.  Measurements  of  airways 
function do not reflect all the disease activity present in the airways that may 
affect the patient and spirometry results correlate poorly with other measures of 
health (see Section 3.1.1, p. 39).  
   177 
Physicians appear to estimate their patients' health using criteria different from 
the  patients  themselves.  Quality  of  life  questionnaires  provide  a  method  of 
quantifying  the  effect  of  disease  on  patients'  lives.  They  can  summarize  a 
number of aspects of the disease and provide an overall estimate of the effect 
of disease and benefits due to therapy. They have the potential to identify a 
threshold response to treatment that may be considered ‘worthwhile’, and allow 
comparison  between  therapies  with  respect  to  the  health  gain  that  each 
provides.
272  Therefore,  for  the  purposes  of  balancing  measurement  of  lung 
function with functional assessment a tool was required for this study, which can 
be used in research. 
 
There are a number of questionnaires that are widely used in clinical research 
and  attempts  have  been  made  to  validate  them  and  to  compare  one  with 
another. Validation aims to assess whether a questionnaire measures what its 
authors  claim  but  no  single  step  or  test  will  be  sufficient  to  allow  overall 
judgement.
238 
 
In general, questionnaires for respiratory health have two main properties. They 
can be used to compare and distinguish between the health status of different 
individuals  (discriminative)  or  they  may  be used to detect  changes  in  health 
over time or after treatment (evaluative).
238 
 
Essentially the SGRQ was a pragmatic choice for this research project. The 
instrument used needed to be able to discriminate between different levels of 
health between patients and to ensure that the distribution of respiratory health 
was more or less the same overall in both the control and intervention groups.   178 
Changes (evaluative) in respiratory health after intervention were not measured 
and were not a primary or secondary outcome measure in this research project.  
 
This tool has been used extensively in high profile studies such as the ISOLDE 
trial
273  and  continues  to  be  used  in  new  randomised  controlled  trials.
236;238 
Moreover it has been validated in many different settings and compared to other 
quality  of  life  tools.
274  The  SGRQ  has  become  a  standard  by  which  new 
questionnaires  are  judged
275  and  used  extensively  to  assess  the  impact  of 
treatments  for  asthma  and  COPD  where  the  measurements  such  as  FEV1 
(Forced Expiratory Volume in 1 second) or PEFR (peak expiratory flow rate) 
may not be significantly altered.
276;277 
 
Other widely respected and used instruments such as the chronic respiratory 
disease questionnaire (CRQ)
278, could have served the purpose equally well but 
the CRQ was designed specifically as an evaluative instrument and therefore 
would  have  been  more  useful  if  the  study  had  been  measuring  changes  in 
respiratory health as an outcome measure.  
 
The SGRQ and the CRQ are too long to be used by most doctors in routine 
clinical practice. Symptom scoring tools such as the Medical Research Council 
dyspnoea score (see Box 1, p. 43) are brief and are useful in the clinical context 
because of their focus and ease of use but measure only one aspect of the 
impact of respiratory disease and they fail to capture the broader picture of a 
person’s lung health on their quality of life. The Airways Questionnaire (AQ20) 
is  a  shortened  version  of  the  SGRQ  and  takes  two  or  three  minutes  to   179 
administer and was originally developed to assess asthma
279 (Appendix 3, p. 
292). The scores correlate moderately well with the SGRQ but there is poor 
correlation of scores with FEV1.
279;280 Therefore the shortened forms could have 
been used in this study but are not as good as the full form SGRQ which may 
be regarded as the gold standard life impact measure. 
 
In  summary  the  SGRQ  was  chosen  because  it  has  both  discriminative  and 
evaluative properties
238 and continues to be used in large randomised trials in 
intervention research in respiratory disease. Therefore, I describe the content 
and practical use of the SGRQ in detail in the next section. 
5.6.1 Saint George’s Respiratory Questionnaire (SGRQ). 
The  St  George's  respiratory  questionnaire  is  a  standardized  self-completed 
questionnaire for measuring impaired health and perceived wellbeing ('quality of 
life')  in  airways  disease.  It  has  been  designed  to  allow  comparative 
measurements of health between patient populations and quantify changes in 
health following therapy.
281 
 
The full questionnaire (see Appendix 3, p. 294) is a six page self-completed, 
supervised questionnaire. The participant is asked to make observations about 
their own health and in particular how their chest, cough and breathlessness 
influence  their  daily  life.  Three  component scores  are  calculated:  symptoms, 
activity, and impacts (on daily life), and a total score.
282 Guidelines are also 
available regarding completion and interpretation. The three component scores 
are explained in the guidance as follows: 
   180 
Symptoms- this component is concerned with the effect of respiratory 
symptoms, their frequency and severity. 
Activity-  concerned  with  activities  that  cause  or  are  limited  by 
breathlessness 
Impacts- covers a range of aspects concerned with social functioning 
and psychological disturbances resulting from airways disease. 
 
A total score is also calculated which summarizes the impact of the disease on 
overall  health  status.  Scores  are  expressed  as  a  percentage  of  overall 
impairment where 100 represents worst possible health status and 0 indicates 
best possible health status. Normal values for normal subjects (FEV1 91-99% of 
expected value) have been calculated (total score 6 [95% Confidence Interval 
5-7]) and the calculator will function with as much as 24% of data missing.  
 
Studies have been done to correlate SGRQ scores and FEV1 in COPD and 
asthma (see       Figure 7, p. 181). This plot was produced in 1999 and included 
in the manual for the SGRQ. Since then many studies have been published for 
asthma and COPD. In them, the mean values for FEV1 and the associated 
SGRQ scores lie on or close to this regression line. The authors state that a 
difference of four units between scores is clinically significant. This difference 
applies  to  a  change within  an  individual  over  a  period  of  time  and  between 
groups of patients.   181 
      Figure 7 FEV1  correlation with SGRQ scores 
 
 
In the pilot study for this research project I found that most literate participants 
could  complete  the  questionnaire  with  a  small  degree  of  supervision  and 
clarification.  Those  with  reading  difficulties  were  able  to  respond  to  the 
questions when read out loud. Invariably before the participant departed it was 
necessary to ensure that they had not missed any sections but otherwise they 
had a high rate of successful completion and took no more than 20 minutes to 
complete.
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6  Methods 
6.1  Management and governance 
6.1.1 Ethical approval and management 
The  study  was  approved  by  Hertfordshire Local  Research  Ethics  Committee 
(application  number  EC03718)  and  West  Essex  Local  Research  Ethics 
Committee (1608-0104) and registered prospectively on the National Research 
Register (ID no. N0096173751).  
 
I had established a practice based core management group to assist me with 
the day-to-day running of the project, which included he practice manager, two 
practice  nurses,  health  care  assistant,  and  a  patient  representative.    The 
academic and clinical research advisory group was set up and consisted of a 
local consultant respiratory physician (RD), academic general practitioner (TG) 
and the statistician (MG) as well as myself as principal investigator (GP). 
6.1.2 Sampling and recruitment 
A randomised controlled trial was chosen as the best study design to determine 
the  effect  of  the  intervention  whilst  avoiding  bias  and  reducing  influence  of 
confounding factors. We considered the possibility of contamination between 
participants. In practice this was not likely to be a problem as the intervention 
was given on an individual basis. Unless the participant (in the control group) 
went elsewhere to ‘get their lung age measured’ then there was minimal risk.
283  
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Cluster  randomisation  was  considered at the development  stage  as  it  would 
have simplified individual practice protocols but it would have required a larger 
numbers  of  participant  (GP)  practices  than  for  individual  randomisation.  For 
example we would need to recruit a total number of 16 clusters (practices) and 
total  sample  size  of  318  participants,  assuming  an  intra-class  correlation  of 
0.007  and  a  cluster  size  of  20  participants,  inflated  to  take  account  of 
attrition.
284-286  
 
Therefore, individual randomisation was the design of choice with the sample 
size  chosen  to  have  80%  power  to  detect  a  10%  difference  in  smoking 
cessation rate (e.g. 5% in one group versus 15% in the other group). A power 
calculation indicated the need for approximately 300 participants (137 in each 
group). We chose a ten percent difference from the intervention as a useful 
clinical  improvement,  which  would  compare  well  with  other  interventions 
described in the literature. Assuming an attrition rate of up to 50% we aimed to 
recruit 600 participants. 
 
With the cooperation and assistance of each of the five practice managers, I 
organised a search of computerized patient records from five general practices 
in Hertfordshire, and West Essex, to identify people aged 35 and over who had 
been  recorded  as  a  smoker  during  the  previous  12  months.    A  full  list  of 
exclusions and exclusions can be seen in Box 9 on page 184. Those on oxygen 
therapy  and  those  with  a  history  of  lung  cancer,  tuberculosis,  asbestosis, 
silicosis, bronchiectasis or pneumonectomy were excluded.  The rationale for 
excluding those with the diseases listed is that the lung age measurements from   184 
those individuals cannot be a true reflection of lung damage due to smoking and 
therefore  can  not  be  a  legitimate  educational  or  motivational  tool  when 
explaining results to smokers. Those on oxygen or housebound were excluded 
due to the practical logistics of conducting the research and the likelihood that 
the severity of lung disease or co-morbidity would preclude spirometric testing 
or meaningful lung age assessment. 
Box 9 READ codes for computer search   
 
 1.  Currently registered                           SHARED   
 2.  Current smoker. 137R Date range 9.11.02-todays date    SHARED 
 3.  Malignant Neoplasm bronchus B22z       EXCLUDED 
 4.  Bronchiectasis H34            EXCLUDED 
 5.  Asbestosis H41             EXCLUDED 
 6.  Pulmonary Tuberculosis A11          EXCLUDED 
 7.  Lobectomy of lung 74512          EXCLUDED 
 8.  Age between 0Y and 34Y          EXCLUDED 
 9.  Achondoplasia PG41            EXCLUDED 
10. Silicosis H421 H422.            EXCLUDED 
11. House-bound. 3CA            EXCLUDED 
12. Oxygen concentrator. Anytime. 5061 EMIS.     EXCLUDED 
13. Current Drugs, Oxygen cylinder in last 2 years    EXCLUDED   
Also exclude: 
14.  Unable  to  give  consent  e.g.  severe  senile  dementia,  severe  psychiatric 
illness etc. (no EMIS code available) 
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The ethics committees had approved the format of the invitation letters and the 
information sheet about the research. With the help and cooperation of each of 
the practices the invitations and information was sent to each of the people 
identified  as  current  smokers  on  the  registers.  These  were  sent  out  on  the 
practice headed notepaper in batches in order to spread the responses and 
follow  up.  Two  weeks  later,  we  telephoned  all  those  who  had  not  already 
responded,  offering  an  invitation  to  participate  and  to  answer  any  queries. 
Those  who  could  not  be  contacted  by  telephone  were  sent  a  second  letter. 
Posters were put up in the waiting rooms of each of the practices and clinicians 
in each of the primary care centres were asked to promote the study on an 
opportunistic basis and to encourage smokers to respond to the invitation to 
participate. Recruitment started in February 2004 and follow up was completed 
in March 2007. 
 
6.2  The assessment interview 
All potential participants were asked to confirm that they were current smokers, 
had  understood  the  information  provided,  and  would  be  available  for  re-
assessment in 12 months time.  Baseline data included age, smoking history in 
pack-years (average daily cigarettes divided by 20 and multiplied by the number 
of years smoking), medical history for exclusion criteria (see Box 9, p. 184), 
medication (especially use of steroids or antibiotics for chest infections in the 
preceding  12  months),  and  co-morbidity  including  chronic  bronchitis  or 
emphysema,  asthma,  other  lung  disease,  diabetes,  treatment  for  blood 
pressure, stroke, coronary heart disease (angina or heart attack) or other heart 
disease.    These  co-morbidities  were  not  used  as  exclusion  criteria  but  to   186 
confirm baseline comparability of groups and to make the study as inclusive as 
possible  and  representative  of  real  life  primary  care  populations  of  smokers 
(see Section 8.2.1, p. 205).   
 
All  participants  had  standard  lung  function  measurements  (FEV1,  FVC, 
FEV1/FVC)  using  a  Micromedical®  spirometer.  Reversibility  of  airways 
obstruction  was  measured  according  to  standard  British  Thoracic  Society 
guidelines.
47 Both groups were told that their lung function would be measured 
again after twelve months to see whether it had deteriorated.  At this stage they 
were  not  told  whether  they  were  in  the  intervention  or  control  group.    All 
participants were strongly encouraged to give up smoking and advised how to 
access local NHS smoking cessation clinics. 
 
Two instruments were used to confirm baseline comparability of groups: the St 
George’s Respiratory Questionnaire (SGRQ) (see Section 5.6.1, p. 179) and 
Prochaska’s stages of change questions in relation to smoking.  The SGRQ is a 
validated questionnaire designed to be self-administered under supervision and 
to measure the impact of respiratory diseases (in particular asthma and COPD) 
on an individual’s life.
281 Like other quality of life instruments, it has the potential 
to  identify  a  threshold  response  to  therapy  and/or  compare  the  response  to 
different therapies.
272 According to the authors scores of 7 or below are found in 
those with normal lung function. For full discussion of the choice of the SGRQ 
see Section 5.6.1 (p. 179).  
 
Stage  of  Change  questions  were  adapted  with  authors’  permission  from   187 
Prochaska  and  DiClemente’s  model  in  which  smokers  are  asked  three 
questions  and  classified  on  the  basis  of  their  response  as  in  the  ‘pre-
contemplative’, ‘contemplative’, ‘preparation’ or ‘action’ phase (see Figure 6, p. 
120 and Box 3, p. 117) (see Appendix 4, p. 301). 
 
6.3  Randomisation procedure 
A  clerk  (who  then  took  no  further  part  in  the  study)  had  prepared  600 
sequentially numbered opaque sealed envelopes.  Each envelope contained a 
card with allocation group determined by computer generated random number 
(odd  =  intervention).  Each  card  had  the  group  (intervention  or  control)  and 
written instructions for what information should be given to the participant. This 
was not opened until after the lung testing had been completed.  
 
If the participant met the inclusion criteria and gave written, informed consent, 
he or she was entered into the study and baseline spirometry completed. After 
lung testing had been competed, the next numbered envelope in the series was 
then opened to determine allocation group.  The written instructions about what 
group and what information to given was then followed. 
 
6.4  Instruments and tests 
I  organised  the  training  for  all  data  collectors  in  the  use  of  MicroLab  3500 
(micromedical Spirometers
241) which were newly purchased at the start of the 
study. They were instructed to check the readings for internal reliability on three 
criteria: (a) at least two FEV1 readings within 5% of each other; (b) the time   188 
volume curve of good quality; and (c) the internal spirometer computer display 
had to register ‘good blow’. They then measured carbon monoxide levels using 
Micromedical CO monitor.  
 
All the results were sent to the central address for the research project. On a 
weekly  basis  I  checked  the  new  data  for  completeness  and  quality  and 
completed the letters to participants and their general practitioner. 
 
For  the  follow  up  testing,  I  recruited  two  independent  nurses  who  were 
employed to contact each person who had made a self declaration that they 
had  quit  smoking  at  follow  up  examination.  One  of  these  two  nurses  then 
performed saliva sample collection from each participant in their homes. They 
were blinded to allocation group. They also recorded those who continued to 
take nicotine replacement therapy (NRT).  
6.4.1 Lung age estimation  
The concept of lung age estimation can be demonstrated graphically using a 
picture (Figure 8, p. 189), adapted from the work of Fletcher et al, which was 
used to show diagrammatically how smoking effectively ‘ages’ the lungs.
6;6 The 
example in Figure 8 (not to scale) shows how a man of 57 with a FEV1 around 
75%  of  the  average  value  for  his  age  has  a  ‘lung  age’  of  77.  The  graph 
illustrates a much more complex calculation based on estimates developed by 
Morris et al using reference linear regression equations to establish the best 
method (see Section 3.1.1, p. 44).
72;72 These authors showed that FEV1 was 
the  best  test  for  calculating  lung  age  using  a  mathematical  calculation  (see 
Equation  1,  p.  45).    In  practice,  adjusting  the  settings  of  the  spirometer   189 
automatically generates the individual’s lung age. 
 
Figure 8 Lung age illustration adapted from Fletcher and Peto 1977 
 
 
 
 
 
 
 
 
 
 
 
 
6.5  What participants were told about their lung function 
Within four weeks of recruitment, data collection and testing, I sent each of the 
participants their results by post, in a personalised letter (see Appendix 5, p. 
306). I first checked the quality of the spirometry tracing and considered the 
result in the light of clinical data. Where there was doubt, I sent the results to a 
chest physician (RD- clinical supervisor) for interpretation and advice (specialist 
interpretation was only required on six occasions). Written results were given to 
the control group as simple FEV1 (litres per second) with no further explanation. 
The  intervention  group  were  sent  their  results  as  ‘lung  age’  with  a  graphic 
display.    190 
 
All  participants  were  sent  a  standardised  explanation  of  how  smoking  can 
damage their lungs. In the intervention group, if the lung age was equal to or 
less than the individual’s chronological age, he or she was informed that their 
test result was normal, but smoking cessation was still recommended due to the 
risks of lung cancer, heart disease and stroke.  If their lung age was greater 
than their chronological age, the ‘lung age’ was given in years. 
 
In both the control and intervention group, when reversibility testing indicated 
asthma (over 15% and at least 400 ml improvement in FEV1 after 400 mcg 
salbutamol via a spacer device), I sent a letter to the participant advising them 
to attend their general practitioner for further management, and a copy to their 
doctor.  When spirometry findings suggested restrictive lung disease, I sent a 
letter to the participant advising them to attend their general practitioner and a 
letter  to  the  general  practitioner  to  alert  them  to  the  advisability  of  further 
investigation  and  guidelines  on  diagnosis,  investigation  and  referral  to 
secondary care (see Appendix 5, p. 308).  
 
6.6  Outcome measures  
The  primary  outcome  measure  was  verified  cessation  of  smoking  twelve 
months  after  the  initial  recruitment  interview  and  examination.  Secondary 
outcomes were changes in daily consumption of cigarettes and the identification 
of new diagnoses. 
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6.7  Follow up and confirmation of cessation 
Follow  up  examination  with  repeat  spirometry  was  performed  after  twelve 
months. Self-reported quitters had carbon monoxide breath testing immediately 
for  confirmation  of  smoking  cessation.  Within  four  weeks  of  attendance  for 
follow up I reviewed the results of the spirometry and compared them with the 
initial test results. I sent each participant a letter, which compared their two tests 
and  any  change  detected.  For  those  who had  reported that  they  had  quit,  I 
informed them in writing that they would be contacted by an independent nurse 
for a confirmatory test with a brief outline of what the salivary cotinine test would 
involve. 
6.8   Data analysis  
Data  were  analysed  on  an  intention  to  treat  basis.  Statistical  analysis  was 
performed using SPSS version 11.0.  Continuous data were analysed using the 
unpaired  t-test.  Categorical  data  were  analysed  using  the  chi-squared  test, 
except  where  expected  cells  were  found  to  be  less  than  5,  in  which  case 
Fisher’s Exact test was used. 
 
To test the hypothesis that severity of lung damage predicts quit success, the t-
test was used to compare the mean ‘lung age deficit’ (difference of lung age 
minus  chronological  age)  between  quitters  and  non-  quitters,  within  the 
intervention group only. 
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6.9   Assessment of costs 
This study was not designed to include a full economic evaluation. However, I 
had approximate data on the time taken for the spirometry tests to be carried 
out  and  for  results  to  be  communicated  to  patients  by  letter.  Costs  were 
calculated  in  terms  of  the  professional  and  administrative  time  required  per 
patient processed and also per successful quitter. The capital expenditure for 
equipment (spirometers and carbon monoxide monitors), start up, training costs  
and continine testing were not included in the estimates.
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7  Results 
7.1   Baseline characteristics 
We  recruited  561  participants,  whose  baseline  characteristics  are  shown  in 
Table 5 (p. 194). There were few statistically significant differences between the 
two groups at baseline; in particular, groups did not differ in their quality of life 
score  (SGRQ)  or  stage  of  change.    However,  there  were  significantly  more 
people  with  a  history  of  stroke  in  the  control  group.    The  incidence  of  co-
morbidity  was  high  (around  20%  of  all  participants),  reflecting  the  deliberate 
intention  of  the  study  not  to  exclude  high-risk  individuals  (and,  perhaps,  the 
inability  or  unwillingness  of  many  smokers  to  quit  despite  the  presence  of 
significant medical morbidity).   
 
 
Despite an average of 33 pack-years years of smoking, most participants in this 
study had ‘normal’ spirometry at baseline, which accords with previous studies 
on  comparable  populations.
5  Using  BTS  cut-off  values,  only  23.5%  of  the 
control group and 26.8% of the intervention group had baseline lung function in 
the ‘abnormal’ range.   194 
 
Table 5 Baseline characteristics of participants 
  Control (n = 281)  Intervention (n = 280) 
Age- mean (SD)  53 (11.9)  52.9 (11.9) 
% male (n)  47% (132)  45%(127) 
Pack-years -mean (SD)  30.3 (19.3)  31.1 (17.7) 
Daily cigarette consumption -mean(SD)  17.4 (8.2)  16.5 (9) 
Spirometry result     
FEV1 % predicted-mean(SD)  90 (19.8)  89 (19.8) 
% FEV1/FVC- mean ( SD)  75 (11.8)  73 (11.7) 
% with Abnormal FEV1      (n) 
(i.e. < 80% of predicted) 
23.5 (66)  26.8 (75) 
SGRQ score -mean  (SD)  28.9 ( 22.4)  26.7 ( 22.0) 
Past medical history % (n)     
COPD  7.2% (19)  7.7% (20) 
Asthma  11% (29)  9.3% (24) 
Other lung disease  2.7% (7)  2.3% (6) 
CVA or stroke  4.2% (11)  0.8% (2) 
Coronary heart disease 
        (angina or heart attack) 
5.3% (14)  2.3% (6) 
Other heart disease  2.3% (6)  1.2% (3) 
Diabetes  5.7% (15)  3.5% (9) 
Treatment for hypertension  21.3% (56)  19.1% (49) 
Precontemplative  29.3% (77)  29.2% (76) 
Contemplative  32.3% (85)  31.9% (83) 
Preparation  16% (42)  18.1% (47) 
Action  22.4% (59)  20.8% (54) 
New diagnosis of COPD  17.4% (49)  14.3% (40) 
 
FEV1=forced expiratory volume in one second; FVC=forced vital capacity; SGRQ-St George’s respiratory 
questionnaire;  CVA=cerebrovascular  accident;  CHD=coronary  heart  disease;  COPD=chronic  obstructive 
pulmonary disease.  
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7.2  Progress and outcome 
Progress and losses to follow up are shown in the flow diagram below.  
 
Figure 9 Progress and outcomes 
 
1390 letters to smokers on practice  
registers 
 
 
 
Recruited 561 current smokers aged  
35 year or above 
 
 
Randomization 
 
 
 
Control 
(n=281) 
 
Intervention (n=280) 
 
Not followed up  
(n=32, 11.38%) 
2 died 
2 cancer/asbestosis 
28  moved/failed  to 
respond 
 
 
 
Not followed up  
(n=31,11.07%) 
1 died 
1 cancer/asbestosis 
29 moved/failed to respond 
 
 
 
12 months follow up  12 months follow up 
18/281 quit in 
control group 
= 6.4% 
 
38/280 quit in  
intervention group 
 =13.6% 
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Follow  up  data  at  12  months  are  shown  in  Table  6  (p.  196).  All  recruited 
participants  were  included  in  the  final  data  analysis.  Those not returning  for 
follow up (32 and 31 people respectively in the control and intervention group) 
were analysed as if they continued to smoke.  
Table 6 Results at 12 months 
  Control  
(n = 281) 
Intervention  
(n = 280) 
P value 
Lost to follow up  11.4% (32)  11.0% (31)  0.9 
Smoking status       
     Confirmed cessation (cotinine CO)  6.4% (18)  13.6% (38)   0.01 
     Smoker at 12 months  90.4% (254)  84.6% (237)    
     Unknown  3.2% (9)  1.8% (5)    
Self-reported cessation  15.2% (37)  20.2% (44)   
Average daily cigarettes  13.7 (SD 10.5)  11.7 (SD 9.7)  0.03 
Attended NHS smoking clinics  1.4% (4)   1.7% (5)    
Used smoking cessation help 
(Clinic, NRT, bupropion , acupuncture) 
7.8% (22)   10.7% (30) 
0.2 (chi  
square test) 
Quit rates in different stages of 
changek 
     
           precontemplative  3.9% (3/77)  6.7% (5/75)   
           contemplative  5.9% (5/85)  14.5% (12/83)   
           preparation stage  11.9% (5/37)  14.9% (7/47)   
           action stage  8.5% (5/59)  18.9% (10/53)   
           not classifiedl  0% (0/18)  18.2% ( 4/22)   
 
All  recruited  participants  were  included  in  the  final  data  analysis.  Those  not 
returning  for  follow  up  (32  and  31  people  respectively  in  the  control  and 
                                            
k Exploratory data (not published in BMJ). Study not powered to give statistical significance  
l Pilot study of 40  participants did not include stage of change measurement   197 
intervention group) were analysed as if they continued to smoke. Verified quit 
rates  were  6.4%  in  the  control  group  and  13.6%  in  the  intervention  group 
(difference = 7.2%, p=0.005, 95% CI: 2.2% to 12.1%). Telling participants their 
lung age was thus associated with an absolute reduction of 7.2% in the smoking 
rate compared to giving them their lung function tests results as raw FEV1 data.  
The number needed to treat (NNT) for the intervention to achieve one additional 
sustained  quitter  is  14.    Both  the  control  group  and  the  intervention  groups 
reduced  their  average  self-reported  cigarette  consumption;  average 
consumption of cigarettes at follow up was significantly lower in the intervention 
group (11.7 per day, SD 9.7) compared to the control group (13.7 per day, SD 
10.5) (p=0.027).  
 
The average lung age deficit in quitters was 8.0 and in non-quitters was 8.8. 
The difference was not statistically significant. Thus there was no evidence to 
suggest that success at quitting is related to severity of lung damage. 
 
Data  for  quit  rates  in  the  different  stages  of  change  in  the  control  and 
intervention groups are included in Table 6. Statistics are not included for their 
significance as the study was not powered to detect differences between these 
subgroups.  These figures reveal a trend to relatively better quit rates in the 
intervention group for all stages of change and in those in the stages which are 
said to measure ‘readiness to change’. 
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7.3   Costs  
The time taken for the health care assistant to undertake a spirometry test was 
approximately 30 minutes; GP spent a further 15 minutes per patient reviewing 
results  and  preparing  a  personalized  feedback  letter,  and  this  required 
approximately ten minutes of secretarial and receptionist support.  Using 2007 
salary costs for the relevant staff, we estimate the cost of this intervention at 
£20 per patient processed and £280 [previous figure x 14] per successful quitter 
(given a NNT of 14).  The economic burden of disease of COPD in the UK is 
estimated  to  be  an  average  of  £  820  per  annum.(£150  per  annum  for  mild 
COPD)(2004)
67. 
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8  Discussion  
8.1   Summary of findings  
This  study  is  the  first  published  large  RCT  with  adequate  follow-up  and 
independent  proof  of  cessation  to  demonstrate  that  personalized  ‘lung  age’ 
feedback  is  effective  in  promoting  smoking  cessation.
84    This  study  strongly 
supports the policy of giving patients their spirometry results expressed as ‘lung 
age’ along with advice about the dangers of continuing to smoke and methods 
of quitting. 
 
In  2001  a  non-systematic  overview  analysed  twelve  studies  that  provided 
feedback  on  personal  biomarkers  as  part  of  behaviour  change  strategies  in 
smokers.
147 The authors concluded that success was likely to depend on how 
the information was conveyed and understood, and how it related to behaviour. 
They also suggested that success may depend on graphic displays or written 
personalized information as well as the prospect of gain rather than negative 
messages about costs or disadvantage. 
 
A  Cochrane  review  of  the  evidence  for  the  effectiveness  of  biomarkers  in 
smoking cessation was published in October 2005. Observational studies were 
included  in  the  background  discussion  but  only  RCTs  were  included  in  the 
analysis, which concluded that due to limited evidence no definitive statements 
could be made about the effectiveness of biomarker assessment as an aid for 
smoking  cessation.
115  None  of  the primary  studies  included  in  the  Cochrane 
review had used ‘lung age’ in the intervention. The negative conclusions of that   200 
review should be updated in the light of this new study. 
 
The  debate  about  the  usefulness  of  screening  with  spirometry  was  recently 
rekindled by a large non-randomised observational study of 4494 smokers from 
Poland.
157  Their  results  indicated  that  spirometry  promoted  cessation.  Those 
with airways obstruction were more likely to quit, but even the group with normal 
lungs  on  spirometry  had  a  higher  quit  rate  (12.0%)  than  would  normally  be 
expected after simple physician advice (4-6%).
124 In this study, ‘lung age’ was 
not  used  to  explain  results  to  participants,  but  the  authors  did  use  a  visual 
display  of  Fletcher  and  Peto’s  diagram
6  (Figure  1,  p.  44)  to  compare  the 
participant’s result with average-for-age and project the likely deterioration with 
continued smoking. These authors did not have a control group but attributed 
the high quit rates in those with normal lung function to a ‘healthy volunteer’ 
effect (those who had opted for the programme were seen as more motivated to 
quit).  
 
The results of our study are broadly consistent with the findings of the Polish 
study, with one important difference. Contrary to the conclusions of the latter 
(and  to  clinical  speculation),  we  demonstrated  that  successful  quitting  is  not 
dependent on the severity of lung damage as demonstrated by spirometry. A 
45-year-old smoker who is told that their ‘lung age’ is normal is as likely to quit 
as one who is told that his or her ‘lung age’ is 65. Giving information in an 
understandable  and  visual  way,  whether  the  news  is  positive  or  negative, 
seems to encourage higher levels of successful smoking cessation than those 
who are given feedback that is not easily understandable.   201 
 
This begs the question of what triggers the decision to quit, and the mechanism 
by which successful and sustained quitting occurs. Clinical experience suggests 
that  deterioration  in  health  does  not  necessarily  lead  to  altered  behaviour 
whether that is smoking, drugs, or dietary. The high rate of co-morbidity (20%) 
in our sample population confirms that many who are likely to exacerbate a 
chronic  health  problem  by  smoking  continue  to  do  so.    Anecdotally,  some 
participants in our trial were relieved when the results were found to be normal 
and therefore felt it was ‘not too late’ to be trying to quit.  
 
This apparent win-win situation may explain the apparently paradoxical finding 
that knowing one’s ‘lung age’ helps a smoker to quit whatever the result. If ‘lung 
age’ is ‘normal’ there is an incentive to stop before it is too late. If ‘lung age’ is 
abnormal  then  this  is  a  clear  message  that  the  lungs  are  undergoing 
accelerated deterioration, which would be slowed if the smoker quit (Figure 1, p. 
44  and  Figure  8,  p.  189).  Further  research  is  needed  to  elucidate  the 
psychological  forces  that  are  active  in  successful  quitting  in  different 
circumstances.  
 
Some addiction experts have proposed that the transtheoretical model should 
be rejected in favour of a new integrated model.
92;231 Any new psychological 
theory of smoking cessation will need to explain the unexpected finding that 
normal results within personal biomarkers are as likely to promote cessation as 
abnormal ones.  
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In  this  study,  we  measured  stage  of  change  (using  Prochaska  and  di 
Clemente’s transtheoretical model) to ensure that the intervention and control 
groups  were  comparable  for  this  variable  at  baseline,  but  the  study  was 
underpowered  to  test  the  hypothesis  that  a  smoker  in  the  ‘active’  phase  of 
quitting would find lung age feedback more useful than someone in the ‘pre-
contemplative’  phase.  Nevertheless,  the  quit  rates  (Table  6)  at  the  different 
stages reveal a trend which is supportive of the ‘stages of change model’. The 
intervention, of using lung age as the motivating trigger, appears to work better 
at every ‘stage’. Even quit rates for those in the precontemplative stage (6.7%) 
are  better  than  the  overall  quit  rate  in  the  control  group  (6.4%).  This  data 
supports  the  notion  that  the  intervention  should  be  used  in  a  non-targeted 
fashion  towards  the whole  population  of  smokers  rather than  restricting  it  to 
those who declare themselves intending to change. This is in stark contrast to 
many other interventions including the NHS stop smoking clinics which target 
those in the preparation and action stage. 
 
 
Current  NICE  guidelines  include  one  on  brief  interventions  and  referral  for 
smoking  cessation
29;287(which  do  not  mention  spirometry  testing  at  all)  and 
another on the management of chronic obstructive pulmonary disease.
67 The 
implication is that spirometry testing is useful only when the patient has (or is 
suspected  of  having)  established  lung  damage.    The  findings  of  this  study 
suggest  that  both  these  guidelines  should  be  reviewed  and  that  ‘lung  age’ 
testing (which is a quick, office based test that can be undertaken by a health 
care assistant) should be considered as part of a brief intervention package –   203 
either in all smokers over 35 (the lower age limit for this study) or all smokers. 
Although this is a relatively brief intervention compared to NRT or motivational 
interviewing, it is a complex intervention as defined by the Medical Research 
Council guidance.
288  The essence of a complex intervention is that it contains a 
number of interacting components and it is not certain which of the components 
is essential to the success of the intervention. The lung age intervention is at 
the simpler end of the scale of interventions to which the term applies. Caution 
is  required  about  applying  the  lung  age  intervention  to  other  groups  or 
subgroups  of  smokers  and  in  other  contexts.  This  has  importance  when  it 
comes to implementing the findings of the lung age study.  
 
Currently  the  New  Contract  for  General  Practitioners  in  the  UK  (new  GMS, 
Quality and Outcomes Framework) includes incentives to confirm the diagnosis 
of COPD using spirometry and to record smoking status in those with a record 
of  significant  co-morbidity  (Coronary  heart  disease,  hypertension,  diabetes, 
CVA and asthma) and to give cessation advice. However there is no incentive 
to actively case find COPD among smokers (or ex-smokers) in these high-risk 
groups or in the general population.  We therefore recommend that the new 
NHS GP contract (Quality and Outcomes Framework) should include incentives 
for  spirometric  assessment  accompanied  by  personalized  communication  of 
‘lung  age’  in  smokers.  However  great  care  needs  to  be  exercised  before 
suggesting that doing spirometry and giving the result as lung age will be as 
effective as the whole of the (complex) intervention including explanation of the 
graphic display and written personalised results. Preserving the fidelity of the 
intervention  may  require  a  more  robust  vehicle  for  implementation  such  as   204 
through Primary Care Trust funding (e.g. local enhanced services).  
 
Our cost estimates, which assume that spirometry is carried out in UK general 
practice,  suggest  that  ‘lung  age’  estimation  and  communication  is  of 
comparable  effectiveness  to,  and  potentially  cheaper  than,  other  currently 
available  treatments  on  the  NHS  including  nicotine  replacement  therapy 
(NRT)
122,  bupropion
114,  face-to-face  counseling
121,  and  telephone 
counselling.
289 Given the heavy health and economic burden of smoking, we 
believe  that  formal  economic  evaluation  of  this  new  and  simple  intervention 
should be a research priority. 
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8.2   Strengths and weaknesses of the study 
With the benefit of hindsight I have considered that a number of changes would 
have improved the design and conduct of this study. The following observations 
and comments are based on the benefit of ideas about things which I believe 
could have been done differently. Where there are good reasons that I did not 
do them I discuss these. Where there were areas of omission I will try to explain 
why they would have been beneficial. 
8.2.1 Strengths of the study population  
In this section I will show how the study gains credibility from being as inclusive 
as possible of those from the general primary care population and reducing the 
exclusions  to  a  minimum  as  described  in  the  methods  section  (see  Section 
6.1.2, p. 182).  
Inclusion and exclusion criteria  
Many studies exclude those with any significant co-morbidity, including known 
COPD or even those who had had spirometry in the previous twelve months. As 
this is the first study to use the concept of lung age I believed it was important 
and reasonable to include those people as they would have a 50:50 chance (by 
randomisation) of receiving their results in the new format (in terms of lung age). 
Furthermore,  I  wanted  the  population  of  smokers  to  be  representative  as 
possible of those encountered in real-life general practice. Those smokers with 
co-morbidities of diabetes, coronary heart disease, and hypertension etc. have 
usually been told many times of the increased risks with continued smoking. 
Therefore, despite the fact that this group includes those who are very resistant 
to advice and change, it is important to test any new intervention on those who   206 
could benefit most from quitting. 
 
Many other studies of smoking cessation interventions exclude those who have 
poor motivation to change their behaviour as judged by one of several different 
possible questions (e.g. the stages of change algorithm placing them in the pre-
contemplative  and  contemplative  stages).
159  The  usual  reason  given  for 
excluding those not intending to quit is that they will not be helped as much as 
those  who  are  ready  for  change  and  that  interventions  should  be  targeted 
towards  those  who  will  benefit  most.  I  had  no  reason  to  believe  that  the 
intervention would be better for those who were ready to change and therefore 
did not exclude those who are self-declared not contemplating quitting and are 
therefore thought to be resistant to change.  
 
The study was not promoted as a programme for quitting smoking per se. I 
deliberately wanted to explore whether those resistant to change would respond 
to new information about their health. Although lung age might be regarded as a 
frightening tool or a scare tactic I prefer to think of it as giving personal-health 
information  in  an  understandable  and  meaningful  way.  I  hoped  that 
communication  of  the  information  would  allow  people  to  make  informed 
decisions.  Because  of  the  inclusive  nature  of  the  recruitment  policy  it  is 
anticipated that the results are more likely to be transferable and generalizable 
to other general practice or primary care populations. 
 
 
   207 
8.2.2 Weaknesses in data collection 
Depression score 
On a similar theme, I did not exclude those with mental health disorders except 
under the general exclusion of those unable to understand the information sheet 
or give informed consent. This would not exclude most people with depression. 
Participants were not asked to complete any type of depression questionnaire. 
In hindsight there are several good reasons that it would have been good to 
have a baseline measure of depression.  For example this would have been a 
useful co-morbidity to list as those with depression are at risk of being neglected 
by smoking cessation campaigns and interventions and they are a vulnerable 
group with high rates of relapse after cessation.
290 Furthermore it could have 
been useful to gather data about any association of knowledge of lung age and 
changes  in  depression  scores.  This  would  have  been  extra  evidence  of  the 
ethics and safety of this intervention in different subgroups. Conversely this had 
not  been  considered  as  a  primary  or  secondary  outcome  and  therefore 
including an additional depression questionnaire would have added extra time 
and complexity to the study. Other issues about the meaning and impact of 
giving bad news (poor lung age) to depressed or anxious people or those with a 
history  of  depression  is  an  area  of  concern  as  the  information  has  the 
theoretical potential to cause relapse.
291 This will be discussed in more detail in 
the section on ideas for further research. 
Measure of Nicotine dependence 
On reflection I could have included a score of nicotine dependence in the initial 
data collection. This would have strengthened the evidence that the control and 
intervention groups were alike and also been a valuable additional dimension   208 
and  add  integrity  to  the  study.  However,  because  this  was  a  randomised 
controlled trial the findings remain valid even if the degree to which nicotine 
dependence played a role is not known. The fact that very few people in either 
group  admitted  to  using  smoking  cessation  clinics  or  nicotine  replacement 
therapy highlight the possibility that this study is complementary to use of NRT 
rather than in direct competition with that intervention. 
Social and economic status 
Some of the feedback has cast doubt on the generalisability of the results to 
other populations. It would have been useful to collect socio- economic data on 
these patients. 
Smoking history of the family 
There  is  clear  evidence  from  other  studies  that  living  and  socialising  with 
smokers is a barrier to continued abstinence. Secondly, there is also evidence 
that false positive exhaled carbon monoxide can occur with passive smoking. 
Data  about  the  smoking  habits  of  the  household  would  have  helped  in 
interpreting some of the results but overall would have had little effect as the 
primary  outcome  measure  was  cotinine  levels  in  saliva  which  is  unlikely  to 
produce false positive results with passive smoking. 
Body mass index 
Some of the normal scales for respiratory function include the patients weight 
as this is know in some circumstances to effect the results of lung function tests. 
The reference tables for FEV1 that I used in this study do not require entry of 
this data but weight was probably relevant in a couple of cases where extreme 
obesity affected the FEV1. It could have been useful and very little extra work 
and time would have been necessary to collect the extra data.    209 
Self- efficacy 
Various  psychological  theories  have  been  discussed  with  reference  to 
behaviour change. It is important to emphasise that this research study was not 
testing a particular behaviour theory. There were no preconceived ideas about 
how the intervention would work. Rather, the study was designed to test if the 
intervention worked rather than how it might work. In hindsight the concepts of 
self-efficacy  in  particular  are  very  interesting  and  possibly  have  a  role  in 
mediating the changes that were seen in this study. Although it would have 
been  interesting  this  was  not  the  main  aim  of  the  study  and  data  collection 
would  have  become  too  complex  and  time-consuming  if  all  these  different 
aspects had been covered. It is also possible that the process of collecting that 
sort of data, in a sense, becomes part of the intervention – as the types of 
questions trigger a series of thoughts attributing change to ideas that might not 
otherwise be present.
162 In conclusion I believe that it was correct not to divert 
the research into chasing a theory prior to demonstrating the efficacy of the 
intervention. However this has already acted as a stimulus to new research
56;270 
and comment  and I include a few ideas for further  research (see Section 8.3, 
p. 210).  
Definitions of abstinence 
The  nature  of  this  research  was  that  the  intervention  was  a  one-off 
measurement and information-giving exercise with written personalised advice 
but  without  lengthy  counselling  or  other  measures  to  promote  smoking 
cessation. Point prevalence with biochemical validation was the logical choice 
of measuring smoking status and twelve months was chosen as the best period 
in keeping with other research and the period for which the study was funded. In   210 
hindsight I could have measured three month or six-month progress rates, as I 
did at the pilot stage, but in reality the final end-point of interest was the status 
after twelve months.  I could also have measured quit attempts but these are 
surrogate  end-points,  which  do  not  necessarily  lead  to  lasting  change.  An 
important next step is to do long term follow up and retrospective analysis of the 
reasons that the smokers quit in this study. 
 
8.3   Further research 
A  number  of  researchers  have  tried  to  use  biomedical  markers  to  motivate 
change in behaviour. The most recent studies have advanced knowledge about 
what might work with regard to giving information to smokers about the health of 
their lungs.
84;157 Many authorities will neither fully accept nor incorporate the 
results into clinical practice or policy until they have been replicated. Therefore it 
is  assumed  that  publication  of  further  studies  of  lung  age  and  its  effect  on 
smokers would add value to this study. In particular it would be useful to know 
how well the intervention works in different subgroups of smokers depending on 
age, ethinic group or socio-economic status. 
 
This research and thesis has uncovered some surprising results. In particular 
the results have produced some broad questions about the use of lung age and 
the mechanisms of action of the intervention. For example: 
•  What do smokers and non-smokers understand by the term lung age? 
•  What  are  the  different  psychological  forces  involved  in  quitting  when 
smokers are presented with their lung age? 
•  Are these forces influenced by mental illness especially depression?   211 
•  What is the effect of receiving bad news about lung age on psychological 
health (e.g. anxiety, depression)? 
•  What is the value in early diagnosis of COPD? 
•  Does screening for early COPD result in better outcomes e.g. reduced 
progression, earlier smoking cessation, less mortality? 
•  Is  there  value  in  targeting  lung  age  assessment  according  to  other 
criteria such as stage of change or nicotine dependence? 
8.3.1 Qualitative research questions 
The original concept developed by Morris and Temple
72 and this lung age study 
have provoked some interesting questions about the meaning of lung age. Of 
particular interest is the meaning that smokers may attribute to the information 
given. Intuitively, it would have been easier to understand or attribute meaning 
to the concept of lung age, if those with the worse results (highest lung age to 
real  age  deficit)  were  the  most  likely  to  be  motivated  to  quit  smoking.  That 
concept was certainly considered in previous papers about the improved quit 
rates in those with lung damage in non-randomised trials.
157 However, the fact 
that the lung age intervention was associated with better quit-rates irrespective 
of the result begs many new questions. 
 
In  the  discussion  of  the  results  in  this  thesis  (see  Section  8.1,  p.  199)  I 
considered why good results might lead to better quitting and why bad results 
might not, and vice versa. I suggested a win-win situation where those with 
good results are more motivated to quit because ‘it is not too late to change’ 
and those with poor lung age are motivated by the idea of halting progression of 
damage.   212 
 
Using complex models from cognitive theories I might be able to theorise about 
what cognitions are active in different types of people and this will be discussed 
in the next section. However from a qualitative point of view I think there would 
be great value in studying what smokers understand by the concept of lung age 
and  furthermore  studying  different  ‘new  typologies’  of  smoker  that  have 
emerged from the lung age study as follows: 
 
1.  Normal lung age and failure to quit smoking 
2.  Normal lung age and successful quitting 
3.  Abnormal lung age and failure to quit 
4.  Abnormal lung age and successful quitting 
 
It could be of great value to gain an understanding of the range of meaning that 
is attributed to their results by these different groups. Within each group it may 
be that there is also a range of meaning, which triggers a variety of responses, 
including continued smoking, attempts at cessation or successful cessation. 
Possible methods 
Focus groups 
Initially  it  would  be  valuable  to  arrange  some  focus  groups  of  smokers  (not 
previously involved in the research) to establish what range of understanding 
there can be with the concept of lung age. They could be presented with a 
number of scenarios of smokers with different results and an explanation similar 
to  that  given  in  the  lung  age  study  using  a  graphic  of  lungs  aging  and  the 
possible effects of smoking.   213 
 
Sample questions: 
1.  If your lungs cannot return to normal how much value do 
         you see in stopping smoking? 
2.  If you found out that your lungs were functioning as if  
         they are 10 years older than your age, how would you react? 
3.  If you found out that your lungs were functioning as if they are    
         20/30/40 years older than your age, how would you react? 
4.  How would you understand a lung age of 110? 
 
Structured interviews 
Having  established  a  range  of  responses  it  would  be  possible  to  conduct 
structured  interviews  with  people  who  had  been  in  the  lung  age  study  to 
establish how they actually stopped smoking and whether the intervention had 
influenced them at all. The study would have to start from the neutral position of 
not assuming any one influence had been greater than another. 
 
Possible open questions for ex-smokers from the lung age study: 
I understand that you used to be a smoker and have now quit. 
5.  What were the main things that kept you smoking for xx years?  
6.  What did you like about smoking? 
7.  What did you not like about smoking? 
8.  What do you think were the factors that helped you to quit? 
9.  How did you finally quit? 
   214 
If the lung age study has not featured during the above open questions then 
proceed as follows: 
10.  What do you remember about taking part in the research 
         study on smoking? 
11.  What happened at your first interview and examination? 
12.  What was your result and what did you think of the results? 
13.  What if any effect did that have on your desire to stop smoking? 
Possible questions for continuing smokers from the lung age study: 
14.  What were the main things that have kept you smoking for  
          xx    years? 
15.  What do you not like about smoking? 
16.  What do you like about smoking? 
17.  Have you tried to quit smoking? 
18.  What do you think are the things that might help you to quit? 
19.  If you have never considered or tried to quit smoking can you  
         think of any situation which might make you change? 
If the lung age study has not featured during the above open questions then 
proceed as follows: 
20.  What do you remember about taking part in the research study 
         on smoking? 
21.  What happened at your first interview and examination? 
22.  What was your result and what did you think of the results? 
23.  What, if any, effect did that have on your desire to stop 
        smoking? 
   215 
The above questions and the focus groups could be used in two ways. First the 
transcribed  data  would  analysed  and  coded  for  emerging  themes.
292 
Subsequent interviews should be coded with the earlier interviews in mind in 
order to compare data. A theme or variable may emerge allowing categories to 
be  discovered.  The  process  continues  until  no  new  themes  are  apparent 
(saturation). From this process it is hoped that a theoretical framework would 
arise.  Secondly, once the range of possible answers has been explored, this 
data can be used to inform the development of a questionnaire. In this way by 
triangulation one might be able to understand more fully the possible effects of 
lung age in different circumstances. A questionnaire could then be piloted and 
then used on all the people who took part in the original study. Furthermore, as 
the  qualitative  data  produces  a  better  understanding  it  may  be  possible  to 
develop more specific questions to be used in the prospective trials described 
below.  
8.3.2 Follow up data on original study 
Given adequate funding and time the first priority in the quantitative area of 
research would be to follow up those involved in the original study to discover 
the continuous abstinence and point prevalence smoking cessation rates two 
and three years after the intervention. This would be briefer than the one year 
follow  up  because  spirometry  assessment  would  be  unnecessary.  Ethical 
permission and new consent would be required. I would propose that all those 
who gave consent to be contacted in the future be contacted via the persons 
own GP after they check the personal details and state of health in order to 
avoid distressing mistakes or breaches of confidentiality. 
   216 
8.3.3 Asymptomatic airways obstruction 
There  has  been  considerable  debate  about  the  group  of  people  with 
asymptomatic  lung  damage  that  are  emerging  from  opportunistic  spirometry 
and  that  would  arise  from  screening  if  this  was  implemented.  As  discussed 
elsewhere it is unknown whether there are differences between them and their 
counterparts  who  present  with  symptoms.  Most  of  those  with  so-called 
asymptomatic airways obstruction have been detected in primary care and are 
not  then  retested  or  confirmed  by  ‘experts’  in  respiratory  laboratories  or 
secondary care. There is continuing controversy about the accuracy of those 
results  and  value  of  detecting  these  individuals.  Likewise  there  will  be  even 
more controversy when new technology allows individuals to test themselves. 
This  begs  lots  of  questions  about  accuracy  and  safety  issues  and  the 
development of devices for self-diagnosis and self-monitoring. 
  
Every clinician will recognise the situation where a patient denies symptoms but 
on  simple  clinical  observation  they  are  clearly  breathless  or  wheezing  after 
slight exertion. This denial is often couched in terms of ‘I thought I was just 
unfit’, or ‘I have put on weight ‘. We do need innovative and objective ways of 
assessing primary care patients, which are quick and accurate and do not just 
rely on spirometry or symptom scores. 
 
Studies  should  also  assess  what  proportion  of  patients  with  previously 
undiagnosed airflow obstruction who present with a first COPD exacerbation 
does not receive a clinical diagnosis of COPD.
293  
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There  were  nine  cases  of  moderate  or  severe  COPD  discovered  during  the 
period  of  the  lung  age  trial.  It  seems  remarkable  that  these  people  had  not 
noticed  symptoms or consulted  with  a health  professional.  In  our  initial  data 
collection  we  relied  on  self-reporting  of  pre-existing  diseases  used  in  the 
morbidity  data.  It  may  be  that  communication  failed  or  there  was  lack  of 
understanding of terminology and their disease was on their medical record. 
Unconnected with this research, I have personal experience of visiting a patient 
at their home while they breathed oxygen though a mask, and simultaneously 
denied  knowledge  of  her  COPD  to  a  specialist  respiratory  nurse.  Therefore 
there may be various reasons that they denied a pre-existing condition that was 
already on redord and therefore this aspect of the research may have been an 
overestimate of new diagnoses. 
8.3.4 Psychological and cognitive factors 
The  lung  age  study  was  designed  to  test  the  hypothesis  that  this  complex 
intervention would have an effect on smoking behaviour but was not specifically 
designed  to  test  mechanisms  or  to  test  a  particular  psychological  theory  of 
behaviour change. Nor was the study designed to target any one theoretical 
determinant of behaviour change. 
 
The best way to test the theory, that the effect of using lung age is associated 
with  or  mediated  through  specific  cognitive  factors  to  produce  changes  in 
behaviour, is to do a prospective trial and include an initial assessment of those 
variables of cognition. The most practical method would be to ask questions 
designed  to  test  variables  thought  to  be  active  such  as  self-efficacy,  threat 
aversion or perceived susceptibility depending on the theory being investigated   218 
(see  Section  4.1.4,  p.  96  and  also  Section  5.3.1,  p.  159).  Alongside  those 
measures the study would also test factors that might interfere or modify the 
response for example nicotine dependency, culture, education and depression. 
 
8.4    Practice based research 
In  this  brief  section  I  reflect  on  the  process  of  primary  care  practice  based 
research. This is not intended to be a comprehensive assessment of the past 
and future of research in primary care but some thoughts on how this fits in the 
context  of  caring  for  patients  and  dealing  with  other  demands  made  on  the 
primary health care team. I will also ponder the benefits to individuals, the team 
and the local community of primary care providers. 
 
The Government is keen that research capacity should develop within primary 
care. The most recent statement in the new national health research strategy 
document declares the intention to ‘create a National School for Primary Care 
Research’.
294 Historically, research has been less well supported and funded in 
primary care compared to secondary care. The demise of primary care research 
was  even  contemplated  by  an  editorial  in  The  Lancet  in  2004.
295  A  large 
proportion  of  health  care  activity  goes  on  in  primary  care  and  good  quality 
evidence for many activities is seriously lacking.
296 It makes logical sense that 
interventions should be tested where they are used rather than extrapolating 
from highly selected secondary care populations.  
 
There is probably no fundamental difference in the make up of practices which 
are involved in research and those which are not.
297 Practice based research is   219 
a  process,  which  has  been  shown  to  develop  in  a  non-linear  way  usually 
starting by the initial interest and enthusiasm of a single professional.
298 Initially, 
any research activity may be seen by other members of the primary care team 
as a distraction from patient care and the business of general practice and an 
unnecessary  use  of  time  and  resources.  It  may  also  cause  conflict  due  to 
different priorities. However, if these barriers are overcome and the right funding 
and  infrastructure  and  training  are  available  the  practice  may  move  forward 
through  a  series  of  phases,  which  have  been  called  transformation, 
consolidation, and moving on to collaboration.
298 This transformed organisation 
will have a new culture and infrastructure to support research. 
 
I believe that, as a practice, we have reached a critical moment where we could 
build on the success of the research venture and seek to become a ‘research 
ready  practice’  with  enthusiasm  and  infrastructure  to  support  innovation  and 
collaboration. We have applied to be included in the Primary Care Research 
Network  (East  of  England)  strategy  for  establishing  a  network  of  research 
practices.   220 
 
8.5   How should practice and policy change? 
How much change to practice and policy should come from the results of one 
study  is  a difficult  question  to  answer.  As the  results  are  disseminated, and 
policy makers either accept or reject the findings, the amount of impact and 
what sort of change will happen as a result of this research will gradually unfold. 
Whether change should come about through gradual dissemination from the 
grass roots or whether change is better coordinated and managed from a top 
down process is a debate that is beyond the scope of this thesis. However, it is 
feasible that both may happen to some degree. The grass roots change can 
happen locally and in a small-scale way that is more manageable and can act 
as a beacon for others to follow when the practicalities have been ironed out.  
 
After  finding  that  the  lung  age  concept  influenced  decisions  by  individual 
smokers we decided to use the information to try a practical demonstration of 
what  a  lung  screening  service  might  look  like.  We  managed  to  secure  six 
months funding from a pharmaceutical company to employ a respiratory nurse 
to  invite  and  test  all  those  on  our  practice  register  who  were  recorded  as 
smokers or ex-smokers. 
 
The aims of the programme were two-fold. First we were trying to detect more 
cases of COPD in our practice population as prevalence figures suggested that 
we continued to have a large number of undetected cases. Secondly, we were 
committed to use the research findings in a practical way to encourage more of 
the continuing smokers to quit. The first aim required that we test both current   221 
and  ex  smokers  and  the  second  aim  concentrated  on  those  continuing  to 
smoke. 
 
A  computer  search  of  our  practice  database  of  10300  registered  patients 
showed  our  practice  prevalence  of  COPD  patients  to  be  1.62%.  A  further 
search  revealed  2578  smokers  or  ex-smokers.  We  excluded  those  who  are 
already  on  the  COPD  and  asthma  registers,  those  with  lung  cancer  and 
asbestosis and those who had been in the intervention group of the lung age 
study. We included those over 35 year of age who had a computer record of 
being a smoker or ex-smoker. 
 
During the 6 months of nurse funding, 305 smokers or ex-smokers attended for 
testing by spirometry. The nurse filled out a computer template of data for each 
of them, which included current daily consumption of cigarettes, smoking history 
to  calculate  pack-years,  and  symptoms  (cough,  wheeze  and  shortness  of 
breath). Spirometry was done with the same equipment as in the lung age study 
with post-bronchodilator measurement where indicated. 
 
Ex-smokers  who  attended  had  all  data  collected  and  were  told  about  their 
results in a usual traditional way of having ‘normal results’ or a diagnosis of 
mild, moderate or severe COPD, according to BTS guidance. Those who had 
normal lung function were reassured. All those with any degree of COPD were 
offered annual flu immunisation and pneumonia vaccination and asked to attend 
early if they developed respiratory symptoms. Those with moderate or severe 
COPD were offered an appointment with a doctor to discuss the diagnosis and   222 
treatment options.  
 
Current  smokers  were  given  their  results  as  lung  age  and  all  of  them  were 
offered help with smoking cessation through local clinics. If the FEV1 was under 
80% and their FEV1/FVC ration was under 70 % then they were placed on the 
COPD register and given the same options as above for the ex-smokers for 
follow up. 
 
From  a  practice  perspective  the  programme  was  easy  to  run  but  the 
communication and relationship with the pharmaceutical company lead us to 
decide that we would not involve them again for a similar programme. Their 
decision-making  was  slow  and  cumbersome,  they  changed  the  point  of 
communication three times during the run up to and during the programme and 
they were late paying us for the work done (the last payment came 4 months 
after  the  end  of  the  pilot  programme  despite  repeated  promises  of  earlier 
payment).  They  also  started  requiring  unprecedented  access  to  our  practice 
nurses and gave her false promises about courses and funding.  
 
The preliminary data is encouraging. Just over 300 patients came for testing. Of 
those  tested  17%  (53/305)  had  previously  unrecorded  abnormalities.  The 
majority had mild COPD (44), eight had moderate COPD and one was severe 
by BTS criteria.  
 
It would be wrong to extrapolate the figures from this small pilot programme to 
justify a nationwide study but the costs are roughly 110 pounds for each new   223 
case of COPD and 650 pounds to discover a new case of moderate or severe 
COPD, which would warrant medical therapy and preventative measures.  
 
It is too early to say whether a twelve-month audit of the screening programme 
will  show  any  improvement  in  follow  up,  influenza  immunisation  uptake  or 
smoking cessation among those with smoking related lung disease. However, 
we  have  shown  that  a  mini-screening  programme  is  both  practical  and 
acceptable to our practice population although there is still work to be done to 
attract those eligible individuals who could not or chose not to attend the clinics. 
 
8.6   Commercial impact  
8.6.1 Health Enterprise East  
Health  Enterprise  East  is  an  NHS  funded
m  regional  operation established to 
encourage  new  ideas  to  gain  a  commercial  foundation  and  to  enable 
innovations to be developed to maximise benefits for patients, NHS staff and 
the  wider  health  community.  Health  Enterprise  East  (HEE)  is  the  NHS 
Innovations Hub for the East of England, set up to help NHS staff across the six 
counties  (Bedfordshire,  Cambridgeshire,  Essex,  Hertfordshire,  Norfolk  & 
Suffolk) develop and take forward new innovative ideas – both products and 
services – to enhance healthcare delivery.  
 
I  have  had  some  discussion  with  Health  Enterprise  East  about  the  possible 
                                            
m HEE is funded by the Department of Health, Department of Innovation, Universities & Skills 
and the East of England Development Agency (EEDA).   224 
expansion of availability of lung age testing by developing an information and 
instruction pack to implement a programme by Primary Care Trusts or other 
smoking cessation providers. A commercial organisation has been developing 
the technology to test flow through a small disposable tube using blue tooth 
technology for transmitting the results to a mobile phone. This has the potential 
to make lung age testing widely available to individuals without reference to a 
health  professional.  Although  this  is  an  exiting  development and a  tribute  to 
modern technology it is a dangerous precedent to isolate one aspect of the 
research  results  and  extrapolate  that  the  same  benefit  would  apply  in  other 
circumstances. It is not clear which parts of the intervention are indispensable to 
achieve the same quit rates as the lung age study. A hand held disposable 
measuring device could give a lung age but in isolation from advice to quit and 
without verbal and written advice as follow up. Quality control would be more 
difficult. How would the manufacturers ensure that those with odd results or 
deteriorating results were reliably informed of the need to consult a qualified 
clinician?  These discussions are at an early stage but they offer the potential 
for disseminating the methods and techniques used in the lung age trial.   225 
 
8.7   Government policy 
8.7.1 Changes to Quality and outcome framework (QOF) 
There  have  been  two  revisions  of  the  indicators  used  in  the  Quality  and 
outcome  framework  (QOF)  since  it  was  initially  negotiated  in  2003  and 
implemented in 2004. With any dynamic process it can be difficult to match the 
research evidence with practical application and inclusion in a framework like 
the QOF. Within the QOF, the emphasis on COPD and smoking remains high 
despite so many other competing areas of clinical need.  
 
I welcome the most recent revision of QOF, which permitted inclusion of those 
with  early  changes  of  COPD  into  the  diagnostic  criteria.  The  initial  inclusion 
criteria  of  COPD  in  the  QOF  were  different  from  all  other  well-established 
guidance. The official rationale was that those with a percent predicted FEV1 
greater than 70% of normal were unlikely to have symptoms and that emphasis 
should be on those with more severe disease and therefore there was no need 
to include these in prevalence figures or follow up or smoking intervention. In 
my opinion, there are several good reasons why this was misguided. It is clear 
that the best way to prevent disabling, symptomatic COPD is through smoking 
cessation.  By  excluding  those  with  minor  changes  on  spirometry  they  were 
reducing the potential contact with professionals during the period that the most 
good could be done. Admittedly at that time there was no good evidence that 
early detection of mild COPD would lead to improvements in rates of smoking 
cessation  but  there  already  was  well  established  evidence  that  simple  brief   226 
advice  from  a  health  professional  can  be  effective  in  reducing  smoking. 
Dismissing asymptomatic or early obstructive changes as trivial could reduce 
the  impact  of  any  advice  to  quit.    Furthermore,  to  initially  choose  inclusion 
criteria, which were different to every other national and international guideline, 
seemed to defy any type of logic. Not only was it illogical and unhelpful but it 
was  not  compatible  with  diagnostic  criteria  embedded  in  clinical  computer 
systems or evidence based clinical guidelines.
39  
 
Although  important  interventions  such  as  long  term  oxygen  therapy  and 
pulmonary  rehabilitation  are  not  included  as  distinct  entities  in  the  QOF  the 
rationale given by the contract guidance for the requirement for documentary 
evidence  of  annual  monitoring,  of  the  FEV1  of  patients  with  COPD,  is  that 
deterioration  can  be  detected  so  that  treatment  can  be  changed  or  referral 
made.  The  regular  recording  of  FEV1  is  therefore  used  as  a  surrogate  for 
quality of care in these patients. Further discussion of this aspect of the QOF is 
beyond the scope of this thesis.  
 
The results of this thesis should be a valuable contribution to the knowledge 
base for decisions about inclusion of indicators for the QOF. The new finding 
that knowledge of lung age helps improve smoking cessation rates does not 
necessarily  support  the  notion  that  those  with  early  asymptomatic  airways 
obstruction should be included in the disease register as it is not known whether 
regular  or  repeated  lung  age  testing  has  any  further  significant  effect  on 
smoking cessation rates. However the key to systematic lung age testing of 
smokers is to have good data collection and an accurate register of smokers.    227 
 
It  is  well  recognised  that  COPD  is  under-diagnosed  and  will  progress  with 
continued smoking.
5;59;60;299 It therefore makes sense for those who smoke to 
have regular spirometry so that they may have ongoing advice and treatment 
for  symptoms.  Some  of  the  counter  arguments  will  be  included  in  the  next 
section about screening.  
8.7.2 UK National Screening Committee (NSC) criteria 
The National Institute of Health and Clinical Excellence (NICE) guidelines do 
not  recommend  spirometric  screening  of  all  smokers  or  ex-  smokers  for 
obstructive  changes.  Recently  the  U.S.  Preventive  Services  Task  Force 
(USPSTF)  confirmed  their  previous  advice  that  screening  for  COPD  is  not 
recommended.
300;301 
302 
 
In this section I review some of the criteria necessary for a test to be included in 
national  screening  programme  and  to  what  extent  the  current  state  of 
knowledge about COPD is consistent with those criteria. 
 
The  UK  National  Screening  Committee  (NSC)  has  published  criteria  for 
considering a test to be valid effective and appropriate as a screening test.
303 
The criteria are divided into four sections:  
• The condition,  
• The test,  
• The treatment and  
• The screening programme.  
   228 
Ideally all the criteria should be met before screening for a condition is initiated. 
 
The condition
303  
According to NSC 
1.  ‘The condition should be an important health problem.’ 
2.  ‘The  epidemiology  and  natural  history  of  the  condition,  including 
development  from  latent  to  declared  disease,  should  be  adequately 
understood and there should be a detectable risk factor, disease marker, 
latent period or early symptomatic stage.’ 
3.  ‘All the cost-effective primary prevention interventions should have been 
implemented as far as practicable.’ 
 
There  is  overwhelming  evidence  that  COPD  is  a  very  serious  and  growing 
health problem and there is a period in early disease where it is detectable 
before it has seriously damaged health. There is also clear evidence that there 
are a large number of cases that remain undiagnosed (see Section 3.1, p. 36). 
The  main  cause  of  COPD  (in  90%  of  cases)  is  smoking  and  the  only 
intervention,  which  will  prevent  progress  of  the  condition,  is  cessation  of 
smoking. There are now lots of cost effective interventions for helping people to 
stop smoking if they are willing to engage with cessation programmes.  
 
As far as cost effective primary prevention interventions (criterion 3) the most 
effective  methods  to  prevent  damage  are  to  reduce  the  numbers  of  young 
people starting to smoke. However, that discussion is beyond the scope of this 
thesis.    229 
 
The test
303 
According to NSC 
1.  ‘There should be a simple, safe, precise and validated screening test.’ 
2.  ‘The distribution of test values in the target population should be known 
and a suitable cut-off level defined and agreed.’ 
3.  ‘The test should be acceptable to the population.’ 
4.  ‘There should be an agreed policy on the further diagnostic investigation 
of individuals with a positive test result and on the choices available to 
those individuals.’ 
 
As already explained in detail the main test for COPD is spirometry, which is 
simple,  safe,  available  in  primary  care  and  most  patients  are  able  to 
successfully perform the manoeuvres necessary. On the negative side there 
has  been  considerable  disagreement  between  researchers,  specialists  and 
primary  care  workers  about  the  quality,  reliability  and  interpretation  of 
spirometry done in primary care.
304 Some studies have shown very high quality 
testing and interpretation of results and others have seriously failed to deliver 
quality.
304;305  The  USPSTF  has  called  for  more  studies  on  the  diagnostic 
accuracy  of  spirometry  in  primary  care  compared  with  the  secondary  care 
setting.
300 There are two separate issues at stake in the argument. The first is 
about training the clinical or technical staff to perform the test with a sufficient 
skill and good quality control. The second is about knowledge of interpreting the 
graphs and figures.
304 Any screening programme would need good training in 
both these areas and sufficient continuous monitoring to maintain quality. Any   230 
problems could be explored during a pilot project for the screening   programme 
before this is rolled out to the whole country.  
 
In  addition  there  is  plenty  of  discussion  about  the  differences  between  the 
diagnostic criteria and reference tables used by different countries. There have 
been attempts to get consensus and standardisation for testing.
306 It would be 
vital to reach a national consensus before a screening programme could gain 
widespread acceptance.  
 
The treatment
303 
According to NSC 
1.  ‘There  should  be  an  effective  treatment  or  intervention  for  patients 
identified  through  early  detection,  with  evidence  of  early  treatment 
leading to better outcomes than late treatment.’ 
2.  ‘There  should  be  agreed  evidence  based  policies  covering  which 
individuals should be offered treatment and the appropriate treatment to 
be offered.’ 
3.  ‘Clinical management of the condition and patient outcomes should be 
optimised in all health care providers prior to participation in a screening 
programme.’ 
 
This is probably the most controversial of all the areas and the biggest barrier to 
the  implementation  of  a  screening programme  for  COPD.    Some  authorities 
maintain that the research base of treatments for clinically detected COPD are 
unlikely to be applicable to those detected by a screening programme.
300 There   231 
is  general  agreement  that  treatment  has  some  value  in  those  with  COPD 
detected after presentation with symptoms.
307 The logic is that most patients 
detected by prevalence studies have mild or moderate disease.
53 In the lung 
age study there were no newly diagnosed cases of severe COPD. A quarter of 
new diagnoses were in the moderate category. Therapeutic interventions with 
medication, oxygen and pulmonary rehabilitation are mostly effective in those 
with moderate and severe disease. Furthermore, there is no evidence that drug 
treatment of COPD slows down decline in lung function.
308 These two factors 
have lead to the conclusion that early detection and intervention is not useful.
309 
It is also argued that early detection in the mild or asymptomatic phase could 
lead  to  the  excessive  and  unnecessary  use  of  monitoring,  medication,  and 
medicalisation of mild disease and a diversion of resources better used to treat 
those with more serious conditions.
61 
 
In my opinion these arguments are flawed. If the medical profession do not take 
seriously the early signs of COPD it is likely that the patient will also trivialise 
their situation. If they have already stopped smoking then there is nothing more 
to be gained in detecting mild airflow obstruction but for those who are smoking 
or frequently relapse this sends the wrong messages as we know that their 
disease will almost certainly progress with continue smoking. An important part 
of  primary  care  is  about  primary  and  secondary  prevention  and  the  early 
detection of disease as well as monitoring chronic illness. We already have a 
professional  duty  to  diagnose  early  and  monitor  various  conditions  without 
actively  treating  them  except  with  lifestyle  advice.  For  example  we  monitor 
those  with  raised  thyroid  stimulating  hormone  (TSH)  levels,  borderline   232 
hypertension,  chronic  kidney  disease  or  obese  people  with  impaired  fasting 
glucose.  Increased  contact  (annual  or  less)  promotes  the  opportunity  to 
reinforce  brief  health  messages,  prevent  deterioration  (with  weight  loss, 
exercise, diet or smoking advice) and detect the changes, which indicate the 
need for more active medical intervention. In the case of early COPD, once 
detected  by  screening,  these  individuals  can  be  offered  smoking  cessation 
advice  repeatedly  and  may  benefit  from  other  measures  like  influenza 
immunisation. Repeated testing will also allow earlier recognition of progression 
to a more serious level of disease requiring medication. 
 
With good clinical guidelines and training it is unlikely that medication will be 
introduced prematurely and unnecessarily especially as it is well established 
that  the  course  of  the  disease  is  not  influenced  by  medication.  At  present 
medication  is  mainly  used  for  relief  of  symptoms  or  long-term  reduction  in 
exacerbations. The first will be a relief to some patients who think they are just 
getting older or are unfit and the latter is only relevant under well-established 
criteria of disease severity and occurrence of recurrent infections. Therefore in 
my view it is unlikely that medication would be overused with earlier diagnosis. 
 
The concerns over wasting resources may assume that highly paid doctors are 
doing the testing. There is plenty of evidence to suggest that other members of 
the  primary  health  care  team  can  be  trained  to  perform  spirometry  even  if 
interpretation has to be done by others.
5 Moreover it is already assumed in the 
NHS that primary care personnel are using spirometry to diagnose and monitor 
those with COPD.  Even in the absence of the new evidence described in this   233 
thesis  it  is  well  known  that  simple  brief  advice  from  a  health  professional 
increases the chance of smoking cessation. Those with early lung damage are 
revealed  as  the  group  at  risk  of  accelerated  deterioration  of  lung  function 
compared  to  non-susceptible  smokers  or  non-smokers.
6  Admittedly,  once 
sustained abstinence from smoking has been achieved there is less indication 
for  repeated  screening  or  monitoring.  It  is  not  known  if  those  with  mild  or 
asymptomatic  COPD  would  benefit  from  other  preventative  care  like  annual 
influenza vaccination. 
 
The second argument is that early detection of COPD with spirometry alone or 
as  part  of  a  multi-component  intervention  has  not  been  shown  to  improve 
smoking cessation rates.
151;159 These arguments have some merit but in my 
opinion are short sighted. Newer studies are pointing towards greater smoking 
cessation rates in those with lung damage as discussed previously (see Section 
3.4.3, p. 84).
157 
 
The screening programme
303 
According to NSC 
1.  There  should  be  evidence  from  high  quality  Randomised  Controlled 
Trials that the screening programme is effective in reducing mortality or 
morbidity. The information that is provided about the test and its outcome 
must  be  of  value  and  readily  understood  by  the  individual  being 
screened. 
2.  There should be evidence that the complete screening programme (test, 
diagnostic procedures, treatment/ intervention) is clinically, socially and   234 
ethically acceptable to health professionals and the public 
3.  The benefit from the screening programme should outweigh the physical 
and psychological harm (caused by the test, diagnostic procedures and 
treatment)  
4.  The cost of the screening programme (including testing, diagnosis and 
treatment,  administration,  training  and  quality  assurance)  should  be 
economically balanced in relation to expenditure on medical care as a 
whole (ie. value for money). 
 
There may be some barriers to introduction of a screening programme from the 
public. The programme has to be acceptable to the public if uptake is to be 
sufficient to warrant the administrative effort involved. Identifying the population 
to be screened would rely on having access to a database of smokers and ex- 
smokers. Initial screening could be done through questionnaire about previous 
smoking and early symptoms which would increase the yield from spirometry.
5 
Inevitably, the screening will produce false positives.  The psychological effects 
of this are unknown and need further research as outlined in Section 8.3.2 (p. 
215).
300 
 
Economic analysis has been done to some extent with evidence presented in 
the NICE guidelines for COPD.
37 The model used showed that opportunistic 
case finding in primary care is a relatively cost-effective strategy but this has not 
been extended to screening per se. 
 
If the anticipated benefits for those with COPD are viewed only in terms of long   235 
term outcomes from drug therapy then I agree that screening is an inefficient 
method of detection and a waste of limited resources because the numbers 
needed to screen are estimated to be about 800 if smokers over 40 years of 
age are screened to defer the first exacerbation, which is a fairly innocuous 
positive  outcome.
300  However,  if  the  results  of  this  thesis  are  accepted  and 
duplicated then the improvement in smoking cessation could be a major step 
forward in helping to improve long term morbidity from smoking. 
 
In  conclusion,  I  echo  the  British  Lung  Foundation’s  disappointment  that 
screening  was  not  introduced  in  2008.  They  call  the  undiagnosed  COPD 
patients  ‘the  missing  millions’  which  could  have  been  detected  if  the  British 
Government  had  included  COPD  when  it  announced  new  screening 
programmes  in  2008.
310  However  there  is  still  the  possibility  that  the  new 
National Service Framework for COPD due late in 2008 will include changes in 
favour of earlier detection of COPD (see Section 8.7.3, p. 235). 
8.7.3 National Service Framework 
The background to National Service Frameworks (NSF) for COPD has already 
been outlined in Section 2.3.2 (p. 30). I submitted evidence from this research 
to  the  NSF  External  Reference  Group  (NSF-ERG)  to  support  my 
recommendations to development of the NSF for COPD (Appendix 6 p. 311). 
 
The NSF is due to be published and is likely to include a two-stage approach to 
screening for the disease. The first step would be a screening questionnaire 
and the second step would be spirometry for high-risk individuals. In my opinion 
it  is  imperative  that  the  screening  questionnaire  does  not  rely  purely  on   236 
subjective assessment of symptoms as many people attribute their reduction in 
exercise tolerance to poor general fitness or age and some will deny symptoms, 
which  are  observably  present.  There  is  strong  evidence  that  questionnaire 
screening for smoking history and cough are strong predictors of abnormality on 
spirometry.
5  The  NICE  guidelines  for  COPD  already  support  opportunistic 
testing of those smokers and ex smoker who have symptoms and I hope the 
NSF takes this a step further towards a more organised strategy.
32 The main 
pros and cons of screening for COPD have been discussed in the previous 
section (see p. 227).   237 
 
9  Reflective section 
9.1   Relationships with practices 
The initial approach to practices was on the basis of e-mail and letter contact to 
a named doctor to ask whether their practice computer data included a list of 
current  smokers  and  if  they  could  easily  give  an  indication  of  numbers  of 
smokers recorded within the preceding twelve months over the age of 35 years. 
The response to this informal enquiry was encouraging. The pilot study had also 
given information about recruitment rates and strategy (see Section 9.2, p. 239). 
 
I liased with the director of public health at the Primary Care Trust to see what 
interest  could  be  generated  and  what  assistance  could  be  available.  The 
response was that they could not help with funding but they had an interest in 
improving knowledge, skills and training for primary care spirometry. Therefore 
they agreed to fund the purchase of ten spirometers of the type used in the 
research.  They  invited  local  practices  to  apply  for  the  PCT  spirometers  with 
several provisos. The main condition was that a member of the practice would 
receive  compulsory  training  in  the  theory  and  use  of  the  equipment.  Priority 
would be given to those practices who agreed to help recruit participants for the 
research project but involvement was not deemed mandatory. 
 
The  second  wave  of  training  and  recruitment  of  practices  to  help  in  finding 
participants  occurred  through  a  primary  care  training  day.  At  that  time  the 
Primary Care Trust was holding occasional half-day training sessions in topics   238 
relevant  to  all  primary  care  staff  members.  Each  person  elected  to  rotate 
through  an  optional  series  of  45-minute  sessions  about  diagnosis  and 
management of COPD including an opportunity to learn about the advantages 
of  involvement  with  the  research  project.  Dr  Richard  Dent,  local  respiratory 
consultant and clinical supervisor for this project, gave the preliminary plenary 
introductory talk and held a further optional question and answer session on 
COPD management at that training day. I gave a talk about the new general 
practice contract and COPD and how the participation in the research project 
could benefit diagnosis and data collection for the practice and their patients. 
Another one of the sessions on the rotation on that training day was practical 
hands-on spirometry by an experienced respiratory nurse. 
 
Several practices were keen to participate and some were adamant that they 
wanted no involvement. Selected members of the research management team 
and I made formal visits to several practices which had shown some interest in 
the project, but were either undecided or wanted more detailed information. On 
three occasions I gave a detailed presentation to a group of practice personnel, 
including management, doctors, nurses and health assistants.  
 
Each of the practices signed a contract with us to say that they had read and 
understood  the  information  and  would  comply  with  the  terms  of  the  ethics 
committee.  As  with  individual  participants,  it  was  made  clear  that  a  practice 
could drop out at any time should they change their mind. No practice dropped 
out and we did not have any problems or disputes with the practices involved. In 
fact relationships have been enhanced and communication is very good.    239 
 
I  produced  an  information  pack  for  each  of  the  five  practices  with  details 
including ethics, procedures and resources such as templates for letters to send 
out to potential participants. Further training in searching computer databases 
and  sending  out  invitation  letters  was  given  in-house  at  each  of  the  five 
participating  practices.  Support  and  advice  was  available  throughout  and 
relationships  remained  good  throughout  the  study  period. 
 
9.2   Problems with recruitment 
Issues over recruitment are inevitable. The pilot study gave us a clear indication 
of how we could achieve the numbers necessary and the preliminary work on 
practice smoking registers indicated the number of practices, which would need 
to be involved to reach the targets.  
 
Personal  letters  to  individual  smokers  followed  by  a  telephone  call  from  the 
practice staff, supported by clinicians on an opportunistic basis, improved the 
numbers of willing participants from 4% to 18%. 
 
I had very little adverse feedback from this process. One person phoned the 
research desk number to complain about privacy. All the letters were sent to 
smokers in the name of their own registered doctor on headed practice paper of 
that particular practice. The address for their response was the central research 
practice  address.  Once  the  person  realised  that  we  had  no  access  to  their 
personal records and the letter had been sent out from their own doctor they 
were satisfied that there had been no breech of confidentiality.   240 
 
The funding body (The Health Foundation) for the project had given us a time 
limit for the award of 24 months from start to finish. This concentrated the efforts 
for recruitment but also created a bit of a problem as we reached the twelve-
month  mid-point  without  managing  to  recruit  the  600  participants  originally 
planned.  I  renegotiated  the  time  frame  with  the  Health  Foundation  and  they 
were happy for a three-month extension on the basis that I was not asking for 
extra  funds  and  that  the  statistical  power  of  the  study  relied  on  sufficient 
participants. With the extension we were able to reach a modified target above 
560 participants. As the original power calculation indicated the need for a total 
of  approximately  300 participants  with  an overly  pessimistic  estimate  for  the 
attrition  rate  (see  Section  6.1.2,  p.  182),  the  actual  recruitment  level  of  560 
current smokers represented a generous margin of safety to achieve adequate 
follow up for statistical analysis. 
 
9.3   Changes to protocol and ethical permission 
The pilot study had exposed a number of issues that required modification for 
the full research study.  
9.3.1 Abnormal results  
It was important that the protocol made provision for results that necessitated 
review by the person’s own doctor where the results of spirometry indicated an 
important  abnormality  other  than  smoking  related  airways  obstruction.  In 
consultation  with  R  D  (RD=  consultant  respiratory  physician  and  clinical 
supervisor),  I  introduced  new  safety  measures  after  the  initial  pilot  study   241 
highlighted the need. The safety net for these included a number of steps as 
follows. I reviewed all results of spirometry personally within two weeks of the 
initial data collection. If the spirometry was indicative of a restrictive disorder I 
sent  the  tracing  and  background  clinical  data  to  RD.  If  he  confirmed  my 
diagnosis  I  sent  a  letter  directly  to  the  participant  asking  them  to  make  an 
appointment with their doctor. I also sent a letter to their doctor with a copy of 
the spirometry and a standard guideline of what conditions in their past medical 
history might be responsible (see Appendix 5, p. 308). The general practitioner 
was advised that their patient would be making an appointment and requested 
that  the  doctor  should  review  the  records  to  decide  if  this  abnormality  was 
already  on  record  and  also  advised  on  what  investigations  or  referral  was 
necessary.  We  had no  complaints  from  either  the  study  participants or  from 
their doctors about the way that this was conducted. 
 
The original protocol was based on the British Thoracic Society guidelines for 
diagnosis of COPD. Under those guidelines it is necessary for the FEV1 to be 
under 80% of the predicted level (for age height and gender) and for the ratio of 
FEV1/FVC to be 70% or less. At that time the new General Medical Services 
contract  also  included  the  need  to  perform  reversibility  testing  on  those 
suspected of having COPD. Several issues arose to make this unsatisfactory. 
The National Institute for Health and Clinical Excellence (NICE) produced a new 
set of guidelines in February 2004 dismissing the requirement for reversibility 
testing. In many ways this change to national guidelines was irrelevant to this 
study. The main objective of the study was to see the effects of communicating 
lung damage through using the lung age concept and therefore the pros and   242 
cons of using reversibility had limited relevance.  However, part of the overt 
benefits  of  this  study  to  participants  and  their  doctors  was  to  enhance  and 
improve  the  records  and  registers  of  those  with  smoking  related  damage. 
Therefore our data had to be consistent with the new contract requirements 
(see QOF, p. 31) and indirectly and long term with NICE.  
 
While  inconsistencies  existed  between  NICE  and  QOF  we  had  to  make  a 
compromise in keeping with the aims of the study. In essence we wanted to get 
a ‘personal best’ result for individuals from spirometry. Dr RD suggested that to 
get a personal best for all participants regardless of initial raw testing we should 
give 400mcg of salbutamol to every participant. This could have also had the 
added benefit of streamlining the protocol. I had two objections to this idea.  
 
The first objection was that the average time for the data collection and testing 
would be extended by about 20 minutes as this is the lag time needed from 
administration of salbutamol until its effect. Under the original protocol only one 
in four participants needed this extended time for testing.  
 
The second problem with this approach is that we would have been giving an 
unnecessary  drug  to  people  who  had  normal  lung  function  (in  75%  of 
participants).  This  may  have  been  more  difficult  to  get  through  the  ethics 
committee  as  an  amendment  and  may  have  made  smokers  less  willing  to 
participate.  
 
Therefore,  because  of  the  ethics  of  giving  unnecessary  medication  and  the   243 
potential detriment to recruitment I took a pragmatic decision to make a minor 
change to the protocol. Any smoker who had an FEV1 under 80% (regardless 
of FVC result) would be given the dose of salbutamol recommended by BTS 
and retested after a 20 minute interval. A review of the cases where this would 
have been effective from the beginning was done to see if this had made any 
difference to the information given to participants. The conclusion was that the 
differences were subtle and of no relevance to the main aims of the study and 
primary outcome measure. 
 
The  protocol  for  spirometry,  reversibility  testing  and  referral  lead  to  some 
interesting situations and required discussion with RD.  
 
Example 1.  
A 67-year-old man had been smoking for 54 years (since the age of 13). First 
spirometry indicated mild obstruction. His last cigarette had been 30 minutes 
before testing.  After 400mcg of salbutamol his FEV1 had improved 10% and 
was subsequently in the normal range.  
Commentary on example 1. 
Under  BTS  guidance  and  by  the  modified  quality  framework  (2008/09  new 
general medical services contract) for primary care this is a normal result. It 
demonstrates the value of the ‘personal best’ policy of the research and the 
usefulness of the European Respiratory Society guidance for COPD that uses 
‘post-bronchodilator’  spirometry  (see  Section  3.1.1,  p  39).  Ironically  it  also 
illustrates the fact that despite 56 years of smoking and an estimated 68 pack 
years  his  lung function  was  normal.  However  he did have  hypertension  and   244 
heart disease and had not thus far been persuaded to stop smoking. 
 
Example 2.  
A 77 year old man admitted to having diabetes, asthma and angina during the 
data entry interview and denied having any of the exclusion criteria. His initial 
spirometry performed on 31.1.2005 suggested a restrictive disorder. His FEV1 
was 31% of the predicted value with a normal FEV1/FVC ratio. He was in the 
control group and therefore lung age was not given but as he had a restrictive 
pattern on spirometry his GP was alerted in keeping with the protocol.  
Commentary on example 2. 
Restrictive  disorders  or  impairments  are  characterised  by  reduced  lung 
expansion and lung volumes compared to predicted normal values. Typically 
because  both  the  forced  expiratory  volume  (in  the  first  second)  and  vital 
capacity are reduced the ratio of the two values is normal on spirometry. Any 
condition  reducing  diaphragm  movement  may  cause  a  restrictive  pattern 
including pregnancy, tight corsets or central obesity. Poor function of the other 
respiratory muscles due to injury or disease can also cause restriction. Disease 
of the lung tissue such as asbestosis, pulmonary fibrosis, sarcoid, or pleural 
effusion can also cause a restrictive pattern.  
 
Asbestosis was one of the exclusion criteria in the recruitment protocol but had 
not  been  recorded  so  far  in  this  man’s  history.  He  said  he  had  asthma  but 
review of his notes for this thesis (he is a registered patient at my practice) 
shows that his GP had thought he had COPD. The patient was subsequently 
investigated by the local physicians and in 10.7.2007 (2 years after recruitment   245 
to the research) finally had a high resolution Computerised Tomography scan 
which  showed  he  had  interstitial  lung  disease  and  a  history  and  findings 
consistent  with  asbestos  damage.  The  research  had  correctly  picked  up  an 
abnormality that previous contact with clinicians had not interpreted correctly 
and the safety net of referral mechanisms had worked successfully.  Despite 
having multiple medical problems made worse by smoking he is still alive and 
continues to smoke at the time of writing (October 2008). 
9.3.2 Outcome measures 
Change in lung function  
A change in FEV1 from recruitment compared to follow up was a secondary 
outcome  in  the  original  pilot  study.  This  was  used  as  an  incentive  to  draw 
participants  back  who  were  not  in  the  intervention  group.  The  control  group 
were told: 
‘Whether or not you have stopped smoking we will invite you back after 
12 months to see if there are any changes to your lung function’. (see 
Appendix 5. Information sheet for participants, p. 303) 
This information was then included in their personal letter after the follow-up 
examination. In reality this short-term data was not regarded as an important 
outcome  as  previous  research  had  established  that  FEV1  measurement  in 
COPD does not change significantly year on year but on the surface it seemed 
an acceptable reason for encouraging those who were in the control group to 
return for follow up.
61;63 However, the collection of this data resulted in a few 
interesting  clinical  situations.  Below,  I  will  outline  an  example  which 
demonstrates the real life general practice beneath the statistics. 
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Example  
Mr A was aged 49 at recruitment and was smoking 15 cigarettes per day with a 
history  of  23  pack  years.    He  had  no  exclusion  criteria  and  was  found  on 
spirometry to have a lung age of 113. The FEV1 was 1.65 litres which was only 
43 % of the predicted level for a man of his age and height. There was no 
improvement  20  minutes  after  giving  four  puffs  of  salbutamol  metered  dose 
inhaler  through  a  spacer  device.  Later,  further  interpretation  of  his  results 
showed him to have a restrictive pattern. He was referred to his GP for further 
evaluation where he was noted to be morbidly obese (weight 165kg and BMI 
51) he also had an abnormal glucose tolerance test consistent with diabetes 
mellitus. On follow up after twelve months he was still smoking but his lung age 
had  improved  dramatically  and  was now  64  years  (FEV1  3.63  litres  76% of 
predicted).  Therefore  his  forced  expiratory  volume  in  the  first  second  had 
improved by nearly two litres.   
Commentary on example  
There is a danger that the narrative of illness is lost in the facts and figures of 
quantitative research.  This example illustrates one of the detrimental effects of 
gross obesity. On review of his records after one year from recruitment his lung 
function was very much improved and his weight had dropped to 128 kg (BMI 
39). Although he remains grossly obese, he said he attributed his improved lung 
function to the loss of 40kg of weight and felt much better. It is not possible to 
attribute  the  loss  of  weight  to  the  intervention  in  this  research  but  it  is 
encouraging that this has been an unintended outcome. Moreover, his last set 
of  blood  test  results  indicates  that  his  fasting  blood  sugar  and  glycosylated 
haemoglobin (HbA1c) have returned to normal.    247 
 
This was an exceptional case but demonstrates that data collection and clinical 
context is important when considering the outliers in terms of odd results. In this 
case an unprecedented improvement in FEV1 needed an explanation and it 
was  fortunate  that  we  had  access  to  the  information.  The  pros  and  cons of 
recording weight and collecting other data and measuring other outcomes not 
included in this study will be discussed in the section on weakness of the study 
(see p. 207). 
 
Measuring cotinine 
The original protocol for the pilot study included the measurement of exhaled 
carbon  monoxide  as  the  only  objective  method  of  confirming  self-reported 
smoking cessation. It did not include an independent collection and analysis of 
objective  biochemical  confirmation  of  smoking  cessation  with  cotinine  levels. 
The  initial  proposal  submitted  to  the  funding  agency  also  did  not  contain 
cotinine  measurement.  As  part  of  the  conditions  for  funding  the  Health 
Foundation  insisted  that  independent  confirmation  should  be  included  and 
funding  was  supplied.  Ethics  approval  was  sought  and  easily  obtained  as  a 
modification of the original protocol. Self-reporting of abstinence from smoking 
is not necessarily reliable and the integrity of research results is greater when 
independent  biochemical  validation  is  conducted  and  is  discussed  in  detail 
elsewhere in this thesis (see p. 145).
141;153  
 
Drug interactions 
Interactions of salbutamol with other medication are extremely rare but there   248 
were  several  situations  where  there  was  a  theoretical  interaction  of  beta 
blockers with the beta agonist (salbutamol). RD maintained that the interaction 
would not be of clinical significance and we would not be compromising patient 
safety with simultaneous use. Also, in theory beta-blockers may make airways 
narrower  (by  bronchospasm  in  asthmatics)  and  therefore  make  lung  age  or 
FEV1  worse.  The  protocol  would  have  detected  and  briefly  countered  those 
effects without needing any changes.  
 
9.4    What is the meaning of lung age? 
During a conference presentation of the research at a fairly early stage at a 
primary care research conference on 3
rd March 2005, I was challenged by a 
member of the audience about the meaning of lung age. It is interesting that 
during the hundreds of times I had explained the lung age graph nobody else 
had made this challenge. The point was – ‘What does it mean to have the lungs 
of a 75 year old? Most fit 75 year old do not have breathing trouble and are not 
compromised or concerned about their lungs so why should we be?’ 
 
Estimates of lung age made by professionals have not been used before in 
research and personal estimates made by smokers about their own health are a 
new concept with research in its infancy.
56 No published qualitative research is 
available about the perceived meaning and impact of this information. Since the 
completion of the study one pilot study has been done on the psychological 
factors  which  included  a  preliminary  personal  estimate  of  lung  age  by  the 
participants.
56 Suffice it to say that further research is needed and this has been 
explored in Section 8.3.1 (p. 211).   249 
Some  concern  was  raised  when  we  discovered  that  some  participants  were 
related to each other. What would we do if they were randomly allocated to 
different groups? Would there be problems with contamination? In reality this 
did not happen often. There are a couple of examples of married couples who 
were allocated to different groups. Therefore one knew their lung age and the 
other did not. On another occasion both were allocated to the same group and a 
healthy competition arose. 
 
9.5   Reflections on BMJ rapid responses 
The original published British Medical Journal article is reproduced in Appendix 
7 (p. 312), the accompanying BMJ editorial in Appendix 8 (p. 319) and the full 
text of the rapid responses is reproduced in Appendix 9 (p. 320). 
 
Professor  Hiroshi  Kawane  from  Japan  expressed  concerns  that  lung  ages 
above 100 years made using lung age ‘impractical’ (see Rapid response on 7
th 
March 2008, p. 320). I think that he is suggesting that the patient cannot extract 
meaning or understand from this type of information. The assumption that he 
makes is that there is no point in giving results like this to smokers. However, I 
think that is a question that has not been answered by any published research 
and leads to some interesting questions that should be the subject of proposals 
for future research (see Section 8.3, p. 210). 
 
A second letter (see Rapid response on 8
th March 2008, p. 320) seemed to 
criticise the absence of a counselling arm of the research. It is completely true 
that the study did not attempt to compare more complex counselling. Those   250 
who volunteer for repeated and time-consuming counselling are probably, by 
selection  and  self-selection,  a  different  group  to  those  who  were  willing  to 
volunteer  for  this  study  and  by  definition  in  a  group  who  want  to  quit.  This 
research is indeed attempting to see the effect of a short ‘one-off’ intervention 
on twelve-month outcomes. This highlights the need for the inclusion of other 
data  about  the  research  population  in  different  studies  so  that  meaningful 
comparisons can be made. 
 
A lay correspondent requested a chart or scale to be made available with the 
idea that individual members of the public can do their own check in the same 
way as peak flow meters are used by asthmatics to monitor their own peak 
expiratory flow rate (PEFR) (Rapid response on 9
th March 2008, p. 320).  This 
opens  up  an  interesting  area  of  potential  discussion  about  how  results  are 
interpreted (in this case by a non medical person) and used. There are at least 
two  areas  of  misconception  encapsulated  in  this  response.  The  first 
misconception is that peak flow rates and other spirometry results are related. 
My answer was that some attempts have been made by other researchers to 
correlate FEV1 with PEFR but this has never become an established method. 
Therefore there is no reliable formula to make the conversion from PEFR into 
lung age. There are well-established diagnostic criteria for diagnosing COPD 
using spirometry measurements (FEV1 and FEV1/FVC ratio) but PEFR cannot 
be used for this purpose. PEFR is very valuable for diagnosis and monitoring of 
asthma.
32 I believe that I missed an opportunity to address a broader question, 
which  has  at  its  centre  a  second  misconception.  The  writer  of  the  letter  is 
assuming that the research results can be extrapolated to mean that there value   251 
in smokers self-testing their lung age. Although there has been a move towards 
asthmatic patients taking greater control of their condition by regular self-testing 
of  PEFR  there  is  no  published  research  to  support  self-testing  of  FEV1  in 
smokers  or  COPD.  Chronic  disease  management  is  well  ingrained  in  the 
primary care system in the NHS but there is a paucity of evidence to show the 
benefit of regular monitoring of lung function.
311 
61  
 
Drs M and S Saraswat made some good observations about the difficulties of 
generalising  the  results  to  other  populations  (Rapid  response  on  9
th  March 
2008, p.320). In particular they were concerned about the selected population 
and lack of inclusion of those with mental health problems. Certainly these were 
two of the weaknesses of the study. The protocol did not exclude those with 
mental disorders or other addictions. However the data collection did not collect 
information specific to mental health or socio-economic status. Anecdotally we 
were very aware that we recruited some people with depression. This will be 
discussed at greater length under a later section about weaknesses of the study 
(see p. 205). 
 
The  long  response  from  Jay  Schrand  (27
th  March  2008,  p.  320)  discusses 
among other things the possible effect of damage to the part of the brain called 
the insular and likelihood of smoking cessation. Among the number of points 
that he tries to make is that because the control group had a significantly larger 
number of stroke patients and because stroke in the insular region of the brain 
promotes disgust for previously enjoyable stimuli the effect of the intervention in 
the lung age study may have been diluted. It is indeed true that the intervention   252 
group  had  a  larger  number  of  participants  with  cerebro-vascular  accidents 
(CVA) than the control group. In a sub-analysis I have looked at whether those 
with a history of CVA are more likely to respond to the intervention. The results 
section does not portray the full clinical picture of what happened during the 
trial. The baseline characteristics are that 11 (4.2%) of the control group gave a 
self-reported past history of stroke or transient Ischaemic attack whereas the 
intervention group had a significantly lower number (2 or 0.8%) (see Table 5, p. 
194). These numbers changed at follow up. During the twelve-month follow up 
period, the control group acquired one more person to the CVA/TIA group and 
the intervention group more than doubled to five people with CVA/TIA. This in 
itself is an impressive demonstration of the risk of complications from smoking. 
Only one person from each group was among the successful quitters.  
 
There are several flaws to Mr Schrand’s arguments. First and foremost if stroke 
was instrumental in reducing smoking then this would have happened in the 
immediate aftermath of the event, not at some distant future date of another 
intervention. Therefore those people would have already stopped smoking and 
not even appear in this study of continuing smokers. Secondly the study was 
not designed to analyse the role of stroke in smoking cessation and therefore 
the changes observed within this subgroup cannot be regarded as significant 
even  though  the  fact  that  one  person  from  each  group  stopped  smoking  is 
interesting  from  an  illness  narrative  point  of  view.  In  fact  hidden  within  the 
quantitative data is the interesting observation that most of the people in this 
group had no intention of quitting or trying to quit at the time of recruitment to 
the study. This is no surprise as they are a group who must be very resistant to   253 
health  messages  from  professionals  especially  as  some  had  other  co-
morbidities such as coronary heart disease and diabetes. The 77 year old in the 
control group who quit was already at the action stage of change. The person in 
the intervention group also was in the action stage of change when recruited 
and had a poor lung age (93 years) for her actual age of 69. Unfortunately she 
was one of those who had a stroke during the study period. The datum does not 
reveal which of these factors stimulated her ultimate smoking cessation. This is 
an area that needs further research (see Section 8.3, p. 210). 
 
A public health trainee made some very useful observations about the precise 
nature  of  the  intervention  highlighting  the  fact  that  lung  age  is  not  given  in 
isolation to an interaction with a professional and more contact than the control 
participants which may have led to bias (see Rapid response on 28
th March 
2008,  p.  320).  My  response  was  to  agree  with  their  statement  that  the 
intervention is more than just giving lung age measurements. However, it is not 
correct to say that this is methodological bias. Bias is defined as ‘any systematic 
error in the design, conduct or analysis of a study that results in a mistaken 
estimate  of  an  exposure’s  effect’.
312  Although  the  abstract  summarized  the 
intervention as ‘giving results in terms of lung age’, they erroneously failed to 
look beyond the abstract to fully understand the methodology of the research. 
The full text version of the research intervention clearly and openly states that: 
‘Participants  in  the  intervention  group  were  given  their  results  verbally, 
immediately  after  randomisation,  in  the  form  of  ‘lung  age’  with  a  graphic 
display’. And ‘Written results were given to the intervention group as lung age’. 
This is not bias, this is the complex intervention. Anyone wanting to introduce   254 
the intervention in their own clinical practice must be careful not to shortcut the 
intervention to just a verbal delivery of ‘lung age’. The complex intervention that 
produced the effect on quit rate in this study has three important components: 
verbal  information,  graphic  information,  and  an  individualised  results  letter. 
Together, these interventions seem to help people think about their health in a 
personalised way. It is not possible to isolate the component of this study that 
had  the  greatest  influence.  The  misunderstanding  of  this  respondent 
emphasises the point that clinicians, managers and commercial interest groups 
will need to consider the ‘whole package’ if they wish to get similar favourable 
outcomes.  
 
Dr  Donzeli,  Director  of  Health  Education  Service  in  Milan,  objects  to  my 
recommendation that lung age testing in smokers could be included in the new 
General Practice Contract for the England (Rapid response on 8
th April 2008, p. 
320). I agree that incentives in the form of targets and financial inducements for 
activity can be a poor substitute for payment for results. From an economic 
perspective the controllers of the purse strings would probably be better off only 
paying clinicians for proof of sustained cessation. However, the current system 
in NHS smoking cessation clinics of declaring success rates at four weeks post 
treatment  are  at  best  naïve  and  at  worst  a  cynical  way  of  over-inflating  the 
achievements of the strategy. As Dr Donzeli works in a different health system 
his perspective is influenced by his own working environment. My suggested 
strategy to improve diagnosis of COPD and, as a potential spin-off, improve 
cessation  rates  was  made  in  the  context  of  an  existing  computerised  data 
collection system and payment structure.    255 
 
Philip H. Quanjer, who was the main author of some authoritative papers from 
the European Respiratory Society on standardisation of lung function testing,
306 
asks the question ‘Should we use lung age?’ (see Rapid response on 16
th April 
2008, p. 320). He uses the example of a 50 year old 1.78 metre tall man. His 
first  point  is  that  different  reference  tables  (ECCS/ERS
306,  Crapo  and 
Morris
64)
306 for assessment of spirometry results each have a different average 
result for  the predicted FEV1 of an individual, which vary by a factor of over ten 
percent (350mls). He makes the further observation that if this subject had the 
exact average FEV1 under each of these three different reference tables his 
lung age would be between 62 and 83 years. He therefore regards the concept 
of lung age as fictitious because it does not take into account the concept of a 
range of normal. He goes on to question the desirability of using this ‘fiction’ 
within the context of the doctor-patient relationship.  
 
I have to agree with Dr Quanjer that we have an interesting dilemma. It is true 
that the different tables of normal and abnormal test results given by different 
authorities lead to a wide range of normal.  It is also true that my research is 
using the concept of lung age to provoke change. It is open to debate whether 
this constitutes fiction, deception or legitimate use of the concept.  Even if a 
single set of reference tables is analysed in more depth it is apparent that there 
are some interesting observations. The BTS and NICE both regard an FEV1 
reading of more than 80% of predicted result as normal, using the ECCS tables 
as  its  reference  (see  Table  3,  p.  41).  Given  that  lung  age  is  calculated  as 
equivalent to 100% of predicted value, values for our subject of between 80%   256 
and  99%  will  give  a  lung  age  that  is  different  (worse)  compared  to  the 
chronological  age.  This  is  an  inevitable  consequence  of  using  this  concept, 
which  may  be  regarded  as  a  useful  strategy  or  deception  depending  on 
perspective. This is also discussed under the ethics section (see p. 257). 
 
The other issue highlighted here is the international differences in criteria for 
diagnosis of abnormal and the different reference tables. With reference to the 
example of a 50-year-old 1.83 metre tall male, according to ECCS his results 
will be regarded as 100% normal if his FEV1 is 3.86 litres. The same subject 
tested  by  ATS  guidelines  using  the  NHANE  3  reference  tables  would  have 
100%  normal  results  if  his  FEV1  is  3.29  litres.
65  There  has  been  a  call  for 
standardisation between countries (with the caution that different racial groups 
need  adjustments  to  the  calculations)  and  concerns  about  the  variable 
definitions of abnormal spirometry.
306;313 The potential confusion does not end 
there as other authors question the accuracy of using a percentage of predicted 
level or an absolute level for the ratio of FEV1/FVC to make a diagnosis of 
COPD. They regard a better measure using standard deviations from predicted 
normal. Further discussion of the complexities of different reference tables and 
accepted normal measurements in different countries is beyond the scope of 
this thesis.   257 
 
9.6   Ethical issues 
From  the  start  of  the  protocol  development  I  was  conscious  of  the  possible 
problems of giving bad news (about lung function) that might offend or upset 
and of giving good news, which might encourage the continuation of harmful 
behaviour. The ethics committee did not bring up any objections at all about this 
aspect of the research. The feedback to participants was very carefully worded 
in  an  attempt  to  avoid  harm.  The  immediate  feedback and  the personalised 
letters to individuals sent after testing made it clear that even in the context of 
‘normal results’ we still encourage smokers to give up smoking. The results do 
not give any information about the other effects of smoking such as the risk 
heart disease, lung cancer and stroke. In other words normal lung testing did 
not mean everything else was fine.  
 
The mental health of individuals was not measured. I did become aware that a 
number  of  smokers  attending  the  research  were  also  on  antidepressants. 
Depression and the use of antidepressants were not on the list of exclusions for 
the study. Subsequent further literature review of previous research reveals a 
mixture  of  literature  with  some  associations  of  smoking,  depression  and 
relapse
291 and some which show improvements in mental health with quitting.
314 
Therefore, in hindsight it may have been wiser to exclude those with moderate 
or severe depression in case the news of lung age was detrimental to the state 
of their mental health. However, this was not done and no negative feedback 
has been received through the local general practitioners.  
   258 
Many studies, of interventions designed to promote smoking cessation, include 
measures  of  depression  and  some  are  specifically  targeted  at  those  with 
depression. I acknowledge that some useful data could have been generated 
had this study included a depression score in the baseline and follow up data 
collection. This is discussed more under the section on weakness of the study 
(see Section 8.2.2, p. 207). 
 
The ethics of giving good news to those with normal lung function is possibly 
the reverse side of the same coin. In essence this is the negative side of the 
question ‘does bad lung age encourage people to stop smoking?’  
 
Research evidence published since the start of this project seemed to indicate 
that  poorer  lung  function  is  correlated  with  increased  quit  rates.
157  In  the 
absence of that evidence and without any data at all about the effects of giving 
data as lung age any outcome was possible and the only means of testing the 
theory  was  with  a  randomised  controlled  trial.  The  default  message  to 
participants was to encourage them all to quit regardless of the results and with 
the message that the lung function was not the only effect either way. Therefore 
I believe ethically our position was sound.    259 
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11 Appendices 
11.1  Appendix 1. Glossary 
 
Spirometry 
A subject is asked to blow into a tube connected to a machine (spirometer), 
which can measure the different patterns of airflow and the rate and amount of 
air that is expelled from the lungs. The information can help to decide if there is 
damage to the lungs, and assist in distinguishing between different types of lung 
disease. Standard measurements include FEV1, FVC and the ratio FEV1/FVC  
(see below). 
 
FEV1. Forced expiratory Volume 1. 
Forced expiratory Volume 1 is the amount of air expelled by the lungs in the first 
one  second  by  forcibly  breathing  out  measured  with  a  spirometer.  This  is 
compared to normal tables for height, age, gender and racial origin to allow 
expression as percentage of ‘normal’. 
 
FVC. 
This is the total amount of air that can be expelled from the lungs with one 
forced breath after a full breath in.   287 
 
11.2  Appendix 2. Summary of Cochrane review 2005 
 
Summary  of  studies  included  in  the  Cochrane  review  of  biomedical 
markers.
115 
 
Bize R, Burnand B, Mueller Y, Cornuz J. Biomedical risk assessment as an aid 
for smoking cessation. [Review] [61 refs]. Cochrane Database of Systematic 
Reviews 2005 
 
Three  studies  in  the  review  tested  the  effect  of  exhaled  carbon  monoxide 
measurements,
152;153;217  three  tested  the  combination  of  exhaled  carbon 
monoxide  measurement  and  spirometry,
36;148;155  and  one  tested  the  effect  of 
spirometry alone.
151 One study included in the review looked at the influence of 
showing pictures of arterial damage in individual smoker’s ultrasound tests.
154 
Another study investigated the effect of information about genetic susceptibility 
to lung cancer.
217  
 
The trials were conducted in three different settings: five trials took place either 
in  general  practice
151-153  or  in  outpatient  clinics,
154;155  two  in  a  'smoking 
clinic'
148;217, and one in a health promotion clinic for army veterans. 
36 Four trials 
took place in the United States,
36;148;155;217 two in the United Kingdom,
152;153 one 
in Italy
151 and one in the Seychelles Islands.
154 
 
The mean age of the participants, when given, varied between 35.5 years and 
53.7 years. The proportion of females in the trials varied between 4% and 63%. 
The mean number of cigarettes smoked per day varied between 11.9 and 29.2. 
The mean number of cigarettes smoked per day was highest in the trials set in 
a 'smoking clinic' (35.5 per day in Walker 1985 
148, 22.7 per day in Audrain 1997 
217) or among veterans.
36  
 
Levels  of  nicotine  addiction  as  assessed  by  the  Fagerström  score  and   288 
proportions of patients in the various stages of change according to Prochaska 
and  Di  Clemente  were  only  given  in  some  trials  and  could  not  be  used  to 
compare the study populations of the different trials. 
 
Three of the trials isolated the effect of exhaled CO on smoking cessation rates 
resulting in the following odds ratios and 95% confidence intervals (95% CI): 
0.73 (0.38 to 1.39), 0.93 (0.62 to 1.41), and 1.18 (0.84 to 1.64). Combining CO 
measurement with genetic susceptibility gave an OR of 0.58 (0.29 to 1.19).  
Exhaled CO measurement and spirometry were used together in three trials, 
resulting in the following ORs (95% CI): 0.6 (0.25 to 1.46), 2.45 (0.73 to 8.25), 
and 3.50 (0.88 to 13.92).  
Spirometry results alone were used in one other trial with an OR of 1.21 (0.60 to 
2.42). 
 
Methodological problems 
Only one of the eight trials reported an adequate randomisation procedure.
151 
Four studies did not report the method of randomisation, or did not give enough 
information  to  assume  that  allocation  was  adequately  concealed.
36;148;154;217 
Three reported inadequate concealment of allocation, with allocation by day or 
week of attendance,
152;153 or by odd/even numbered questionnaire at the time of 
check-in.
155  
 
Remarkably, only one study included a power calculation estimation of sample 
size prior to recruitment.
155 This estimate was based on a quit rate of 25% in the 
intervention group versus 10% in the control group. This is probably a rather 
optimistic estimate of the possible effect of intervention. 
 
All studies included male and female adults who were smokers at the time of 
inclusion. Only two studies gave a definition of being a smoker at the time of 
inclusion.
154;217 
   289 
Urinary cotinine level was used to validate smoking cessation at follow up in two 
trials.
151;153 One study used the same validation procedure but only on a sub-
sample  (41%)  of  self-reported  ex-smokers.
152  Two  studies  used  expired  air 
carbon monoxide.
36;148 Two studies did not use any biochemical validation.
154;155 
 
Methods of recruitment varied widely. Among the three studies conducted in 
general practice, one recruited patients at their first visit,
152 another screened 
outpatients on specific days
151 and the last screened all outpatients during the 
recruitment  period.
153  One  study  recruited  smokers  among  outpatients  in 
primary care clinics.
155 The two studies conducted in 'smoking cessation clinics' 
recruited  smokers  by  media  advertisement.
148;217  The  remaining  two  studies 
recruited  the  last  consecutive  155  smokers  who  participated  in  a  health 
survey,
154 and veterans that responded to mailed invitation to attend a health 
promotion clinic.
36 Participation rates (i.e. the proportion of those approached 
who agreed to take part in the trial) were seldom recorded. 
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11.3   Appendix 3. Questionnaires 
11.3.1  Beliefs about quitting 
Some of the questions used to measure beliefs about quitting in the study by 
Hyland  et  al  ‘Individual-level  predictors  of  cessation  behaviours  among 
participants in the International Tobacco Control (ITC) Four Country Survey’.
80 
(see Section 3.2.1, ‘Why do people start or stop smoking?’) 
 
Beliefs about quitting 
 
Intention to quit  
In next month, in next 6 months, beyond 6 months, not planning to quit:  
This variable comes from the question ‘Are you planning to quit 
smoking (in next month, in next 6 months, beyond 6 months, not planning to 
quit)?’ 
 
 
Self-efficacy of quitting 
Current smokers were asked, ‘If you decided to give up smoking completely in 
the next 6 months, how sure are you that you would succeed?’  
Categories of the answer include: not at all sure, slightly sure, moderately 
sure, very sure, and extremely sure.  
The variable was coded as a continuous measure from 1 (weak) to 5 (strong). 
 
Smokers were asked, ‘How much do you think you would benefit from health 
and  other  gains  if  you  were  to  quit  smoking  permanently  in  the  next  6 
months?’  
Categories of the answer include: not at all, slightly, moderately, very much, 
and extremely.  
The variable was coded as a continuous measure from 1 (weak) to 5 (strong) 
.   291 
Worries about health and quality of life 
This variable was created based on smokers’ responses to two questions at 
baseline:  
(1) ‘How worried are you, if at all, that smoking will lower your quality of life 
in the future?’  
(2) ‘How worried are you, if at all, that smoking will damage your health in 
the future?’  
Categories  of  the  answers  include:  not  at  all  worried,  a  little  worried, 
moderately worried, very worried.  
Each  variable  was  coded  as  a  continuous  measure  from  1  (weak)  to  4. 
(strong) and the average of the two measures was used in analyses 
 
 
Favourable attitudes about smoking 
This variable was created based on smokers’ response to the following two 
statements:  
(1) ‘You enjoy smoking too much to give it up’;  
(2) ‘Smoking is an important part of your life’.  
Each  variable  was  coded  as  a  continuous  measure  from  1  (weak)  to  5 
(strong) and the average of the two measures is used in analyses. 
 
 
Overall attitude about smoking 
At baseline, smokers were asked: ‘What is your overall opinion of smoking?’ 
The variable was coded into a three-category variable: positive, neutral or 
negative. 
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11.3.2  Airways Questionnaire 20/30 
(The AQ20 comprises the first 20 items. A ‘Yes’ response is scored ‘I’, ‘No’ and 
‘N/A’ responses are scored ‘O’.) 
The following - questions are concerned with the effect of your chest trouble on 
your everyday life. Please respond ‘Yes’, ‘No’ or ‘Not Applicable’ (N/A) to each 
item. 
 
(1) Do you suffer from coughing attacks during the day?  
(2) Because of your chest trouble do you often feel restless?  
(3)  Because  of  your  chest  trouble  do  you  feel  breathless  maintaining  the 
garden?  
(4) Do you worry when going to a friend’s house that there might be something 
there that will set off an attack of chest trouble? 
(5) Do you suffer from chest symptoms as a result of exposure to strong smells, 
cigarette smoke or perfume? 
(6) Is your partner bothered by your chest trouble? 
(7) Do you feel breathless while trying to sleep? 
(8) Do you worry about the long-term effects on your health of the drugs that 
you have to take because of your chest trouble? 
(9) Does getting emotionally upset make your chest trouble worse? 
(10) Because of your chest trouble are there times when you have difficulty 
getting around the house? 
(11) Because of your chest trouble do you suffer from breathlessness carrying 
out activities at work? 
(12) Do you feel breathless walking upstairs because of your chest trouble? 
(13) Because of your chest trouble do you suffer from breathlessness doing 
housework?   293 
(14) Because of your chest trouble do you go home sooner than others after a 
night out? 
(15) Because of your chest trouble do you suffer from breathlessness when you 
laugh? 
(16) Because of your chest trouble do you often feel impatient? 
(17) Because of your chest trouble do you feel that you cannot enjoy a full life? 
(18) Do you feel drained after a cold because of your chest trouble? 
(19) Do you have a feeling of chest heaviness? 
(20) Do you bother much about your chest trouble? 
(21) Do you have difficulty taking part in sports because of your chest trouble? 
(22) Do you worry about getting an attack of chest trouble even when you are 
well? 
(23) Are you embarrassed by heavy breathing? 
(24) Does your chest trouble affect you other than when you are having an 
attack? 
(25) Do you do all the things you want to regardless of the effects on your chest 
trouble? 
(26) Because of your chest trouble do you often feel helpless? 
(27) Do you work badly when your chest trouble is bad? 
(28) Because of your chest trouble do you have difficulty doing housework? 
(29) Is your sex life affected by your chest trouble? 
(30) Do you suffer from discomfort when you cough? 
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11.3.3  St. George’s Respiratory Questionnaire (SGRQ) 
This  questionnaire  is designed  to  help  us  learn  much  more  about  how  your 
breathing is troubling you and how it affects your life. We are using it to find out 
which aspects of your illness cause you most problems rather that what the 
doctors and nurses think your problems are. 
 
Pleas read the instructions carefully and as if you do not understand anything. 
Do not spend too long deciding about your answer 
 
 
Before completing the rest of the questionnaire: 
Please tick one box to show how you describe your current health: 
 
Very good   
Good    
Fair   
Poor   
Very poor   
 
 
 
 
 
 
 
 
 
Copyright reserved 
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Part 1. St. George’s Respiratory Questionnaire  
 
Questions about how much chest trouble you have had over the past 4 weeks. 
 
 
Please tick (√) one box for each question 
 
 
Over the past 4 weeks,  Most 
days  
a week 
Several  
Days a 
week 
A few  
days a  
month 
Only 
with 
Chest 
infection 
Not at  
All 
1. I have coughed: 
 
         
2.  I  have  brought  up 
phlegm (sputum) 
         
3. I have had shortness of 
breath 
         
4.  I  have  had  attacks  of 
wheezing 
         
 
5. During the past 4 weeks, how many severe or very 
unpleasant attacks of chest trouble you have had? 
More than 3 attacks   
3 attacks   
2 attacks   
1 attack   
 
No attacks   
 
6. During the past 4 weeks, how long did the worst 
attack of chest trouble last?  
More than 3 attacks   
A week or more   
3 or more days   
1 or 2 days   
 
Less than a day   
 
7. Over past 4 weeks, in an average week, how many  No good days     296 
good days (with little chest trouble) have you had? 
1 or 2 good days   
3 or 4 good days   
Nearly every day   
 
Every day is good   
 
 
8. If you have wheeze, is it worse in the morning?  No   
  Yes   
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Part 2. St. George’s Respiratory Questionnaire 
 
 
Section 1 
 
How would you describe your chest condition? Please tick (√) one: 
 
The most important problem I have   
Causes me quite a lot of problems   
Causes me a few problems   
Causes no problem   
 
 
If you have ever had paid employment. Please tick (√) one: 
 
My chest trouble made me stop work together   
My chest trouble interferes with my work or made me change my work   
My chest trouble does not affect my work   
 
 
Section 2 
Questions about what activities usually make you feel breathless these days. 
 
Please tick (√) in each box that applies to you these days: 
 
  True  False 
Sitting or lying still                        
Getting washed or dressed     
Walking around the home     
Walking outside on the level     
Walking up a flight of stairs     
Walking up hills     
Playing sports or games     
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Part 2. St. George’s Respiratory Questionnaire 
 
Section 3 
Some more questions about your cough and breathlessness these days 
Please tick (√) in each box that applies to you these days: 
  True  False 
My cough hurts     
My cough makes me tired     
I am breathless when I talk     
I am breathless when I bend over     
My cough or breathing disturbs my sleep………………..............…     
I get exhausted easily     
 
Section 4 
Questions about how your chest trouble may have on you these days. 
Please tick (√) in each box that applies to you these days: 
  True  False 
My cough or breathing is embarrassing in public     
My chest trouble is a nuisance to my family, friends or neighbours     
I get afraid or panic when I cannot get my breath     
I feel that I am not in control of my chest problem     
I do not expect my chest to get any better     
I have become frail or and invalid because of my chest     
Exercise is not safe for me     
Everything seems too much of an effort     
 
Section 5 
Questions about your medication, if you are receiving no medication tick here ( ) 
And go to Section 6. 
Please tick (√) in each box that applies to you these days: 
  True  False 
My medication does not help me very much     
I get embarrassed using my medication in public     
I have unpleasant side effects from my  medication…      ……..     
My medication interferes with my life a lot       299 
Part 2. St. George’s Respiratory Questionnaire 
 
Section 6 
 These  are  questions  about  how  your  activities  might  be  affected  by  your 
breathing. 
 
Please tick (√) in each box that applies to you because of your breathing: 
 
  True  False 
I take a long time to get washed or dressed     
I cannot take a bath or shower, or take a long time     
I walk slower than other people, or I stop for a rest     
Jobs such as homework take a long time, or have to stop for rests     
If I walk up one flight of stairs, I have to stop or slow down     
My breathing makes it difficult to do things such as walk up hills, 
Carry things up stairs, garden, dance, play bowls or golf 
   
My breathing makes it difficult to do things such as carry heavy 
Loads, dig the garden or shovel snow, jog or walk at 5 miles per 
Hour, play tennis or swim 
   
My breathing makes it difficult to do things such as very heavy 
manual work, run, cycle, swim fast or play competitive sports 
   
 
Section 7 
We would like to know your chest trouble usually affects your daily life. 
 
Please tick (√) in each box that applies to you these days: 
 
  True  False 
I cannot play sports or games     
I cannot go out for entertainment or recreation     
I cannot go out of the house to do the shopping……………………      
I cannot do housework     
I cannot move far from my bed or chair     
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Please now tick (√) in the box (only one) which you think best describes how 
your chest affects you. 
 
It does not stop me doing anything I would like to do   
It stops me doing one or two things I would like to do   
It stops me doing most of the things I would like to do   
It stops me doing everything I would like to do   
 
Thank you for filling in this questionnaire. Before you finish would you please 
check to see that you have answered all the questions. 
 
11.3.4  Permission to use SGRQ 
From: G P <parkesko@hotmail.co.uk> 
Date: Mon, 27 Oct 2008 10:08:05 +0000 
To: <pjones@sgul.ac.uk> 
Subject: FW: Copy of questionnaire. Permission and publication 
 
Dear Prof Jones 
thank you for arranging for a copy of the SGRQ to be sent.  
  
Sorry to be a nuisance for asking again.  
Please could you confirm that you give permission for me to reproduce  
the St George's Respiratory Questionnaire in my PhD thesis? 
 
Best wishes 
  
Gary ParkesTo: parkesko@hotmail.co.uk 
Subject: Re: Copy of questionnaire. Permission and publication 
From: pjones@sgul.ac.uk 
Date: Mon, 27 Oct 2008 12:11:17 +0000 
 
Of course. Permission granted.  
Paul J Sent from my BlackBerry® wireless device 
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11.4  Appendix 4. Stages of change correspondence 
 
From: diclemen@umbc.edu  
To: Gary Parkes 
Subject: Using the three questions as an outcome measure? 
 
These have been used extensively.  Preparation are those who say yes to 30 
days and to a quit attempt in the past year.  If you are going to assess every 6 
months, I would change the quit attempt time frame to 6 months rather than a 
year  so  the  time  frames  do not  overlap.   Sorry  for  the  delay.   I  have  been 
travelling. 
Carlo 
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11.5  Appendix 5. Letters to participants and GPs 
11.5.1  Letters to participants  
Practice Headed Paper 
Dear <insert patient name> 
Our practice is participating in a study of people over the age of 35 who smoke 
and we would like to invite you to take part. If you no longer smoke please let us 
know and we will amend your medical record. 
 Before you decide, it is important for you to understand why the research is 
being  done  and  what  it  will  involve.  Please  take  time  to  read  the  following 
information and ask if anything is not clear or you would like more information. 
Thank you for reading this. 
The purpose of the study 
The study is looking at ways that smoking affects your health and is attempting 
to find a new way of motivating people to stop smoking. 
Why you have been chosen 
People who are smokers over the age of 35 years are being invited to take part. 
If you receive this by post your doctor has sent it out to you because he/she has 
a record in his notes that you are a smoker. The researchers will only know 
about  you  if  you  respond  to  this  invitation  and  give  consent  to  participate. 
Otherwise no one except your usual doctor(s) will know or have any access to 
your records. 
We have enclosed a full information leaflet, which should answer most of your 
questions. 
If you would like to take part please contact the practice on 01920<………> or  
the research office on 01992 464900. 
Someone from your Doctors’ surgery will phone you in the next few weeks to 
offer you an appointment.  
Yours sincerely 
Dr………………… and partners 
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11.5.2   Information sheet for participants 
 
Information sheet about research study 
 
Before  you  decide  to  be  a  volunteer  for  the  test,  it  is  important  for  you  to 
understand why the research is being done and what it will involve. Please take 
time to read the following information and ask if anything is not clear or you 
would like more information. Thank you for reading this. 
 
Frequently Asked Question  
 
1. Who can volunteer for the test? 
Anyone who is 35 years old or over AND is currently a smoker may be eligible. 
There are some people who are unsuitable, such as those with lung cancer or 
who have had part of a lung removed. 
 
2. I have no intention of quitting smoking; can I still have the test?  
Yes. The testing is about informing people about their own health and even if 
you decide to continue smoking you will be able to see the change in your lungs 
over the study period. 
 
3. I am already thinking of (or trying to give up) giving up smoking can I still 
have the test? 
Yes. Even if you are thinking of quitting you are still able to have the test. As 
long as you are still a smoker at the first visit for testing you can be included in 
the study.  
 
4. Who cannot volunteer for the study? 
Most people over 35 are eligible for the study even if they have other conditions 
like diabetes, heart disease, asthma, or chronic bronchitis. However there are 
some diseases, which prevent the test being done or make it unreliable. There 
is a full list of things that exclude people from the study on the ‘questionnaire   304 
page’  If  you  are  still  unsure  please  discuss  with  the  research  assistant  or 
contact the research administrator.  
  
5. What is the purpose of the study? 
The study is looking at ways that smoking affects your health and is attempting 
to  find  a  new  way  of  giving  information  about  the  health  of  your  lungs  and 
empowering people to stop smoking. 
 
6. What happens if I change my mind? 
Refusal to take part will not affect your normal care from your own doctor. If you 
decide to take part you can withdraw your consent at any time without needing 
to give an explanation. 
 
7. What do I have to do?  
The  study  does  not  involve  any  experimental  drugs.  Your  medical  care  will 
continue to be in the control of you and your own doctor.  
The study will involve you attending a designated testing site (usually a local GP 
surgery) as near to your home as possible on  two occasions over a twelve 
month period. You will also be contacted about 3 to 6 months after the initial 
testing to check there are no questions or problems. 
The research doctor or nurse will ask you about your past medical history and 
to fill in a questionnaire about your quality of life related to breathing function. 
You will be asked to do a simple breathing test.  
A  random  half  of  the  participants  will  be  given  information  about  their  lung 
function in a new way. 
After repeating the test and a questionnaire in 12 months all participants will be 
told how their health and lungs have changed and a report will be given to their 
own doctor (with your written consent). 
Everyone will be given standard basic information about stopping smoking.  
 
8.  How much time does it take? 
The initial assessment takes between 30 and 40 minutes. The second visit will 
be shorter and take about 15 to 20 minutes.  
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9. What are the advantages of taking part? 
After the results are complete you will be able to find out how smoking has 
affected your health and how it has changed over a 12-month period. If you give 
your written consent, at the end of the study your own doctor will get a report 
containing information, which is not routinely available.  
 
10. Is it confidential? 
When  the  results  are  analysed  and/or  published  any  information  will  be 
anonymous  and  any  personal  details  will  be  strictly  confidential  to  the 
researchers. 
 
11. Do I get any payment for volunteering? 
The study is funded by a research charity called The Health Foundation. No 
financial incentive can be offered although we hope to offer either a token or 
travel  expenses  to  thank  you  for  your  time  and  participation.  We  are  also 
planning to have prize draw towards the end of the study, and your name will be 
included, unless you opt out.  
 
12. I live outside the area can I volunteer? 
Unfortunately, the rules governing research mean that at the moment we can 
only  test  people  in  Hertfordshire  and  West  Essex  where  ethical  committee 
approval has already been obtained.  
 
13. Any other questions please e-mail us on info@step2quit.co.uk 
or telephone 01992 <……..>  and speak to <……………> (9am-5pm or leave a 
message) or contact <………..name> at the <………surgery>.   306 
 
11.5.3  Post-test personalised letters to participants 
Letter to intervention group 
 
Address 
Participant Number.      
Date of examination: 
Dear M.    
We hope that you may benefit from knowing about the effect of smoking on your 
lung function. Your results are displayed below.   
Your ‘lung age’ was measured as <   > years compared with your actual age of 
<   >. 
LUNG AGE. There is a natural gradual decline in function of the lungs with age. 
Smoking can make your lungs decline more quickly as if the lungs are ageing 
more rapidly.  The good news is that if you stop smoking the ‘rate’ of decline will 
returns to normal.  
If you have access to the internet you can see more detailed explanation on 
www.step2quit.co.uk 
Reversibility testing was done/not done 
Result positive / negative 
FEV1  changed  <      >%  with  400mcg 
salbutamol 
 
 
 
This type of lung function test does not tell 
us anything about the risk of other serious diseases related to smoking such as 
Lung cancer or Heart disease or Stroke. Smoking cessation is therefore still 
important for all people regardless of their age or the results of these lung tests. 
The test will be repeated in 12 months to measure any change. 
Yours sincerely 
Dr. 
FEV1.  Amount 
of air blown in 1 
second 
<   >litres 
FVC.Total 
volume of lungs 
<   >litres 
Your  LUNG 
AGE 
<   >years   307 
 
Letter to control group 
 
Address 
Participant Number         
Date of examination:  
 
Dear M 
We hope that you and many others may benefit from more knowledge about the 
effect that smoking is having on your lung function. Your results are displayed 
below.  An explanation of the terms used is below.  
Reversibility testing was done/not done 
Result positive / negative 
 
FEV1 changed <   >  % with 400mcg salbutamol. 
They  will  be  repeated  after  12  months  for  comparison  whether  you  are  still 
smoking or not. 
FEV1. This is the amount of air expelled by the lungs in the first one second by 
forcibly breathing out into a machine called a spirometer. 
FVC. This is the total amount of air that can be expelled from the lungs with one 
forced breath after a full breath in. 
The lung function test (Spirometry) will be done again in 12 months to measure 
any change due to your smoking. 
This type of lung function test does not tell us anything about the risk of other 
serious diseases related to smoking such as Lung cancer or Heart disease or 
Stroke. Smoking cessation is therefore still important for all people regardless of 
their age or the results of these lung tests. 
Thank you for taking part 
Yours sincerely 
 
Dr G Parkes. 
For further help with smoking cessation contact your GP surgery or the local 
Hertfordshire Help line 0800 389 3998 or speak to your local pharmacist.  
 
FEV1  <   >litres 
FVC  <   >litres   308 
 
11.5.4  Letters for restrictive abnormality  
Date of examination:  
Re:     
Address:  
Dear M.       
We  hope  that  you  may  benefit  from  more  knowledge  about  the  effect  that 
smoking is having on your lung function. After your visit and examination on 
<date> I have reviewed your results and looked at the information you gave to 
the researcher about your past medical history. Although I cannot be certain 
from one set of tests, the results suggest you may have a condition called a 
restrictive disorder as well as any changes from the smoking. 
Because  of  this  I  am  sending  a  copy  of  this  letter  to  your  GP 
(Dr<…………>[code]). It may be that there is already some record in your notes 
about this condition. Please make an appointment to see your GP who will want 
to review your record and decide if it is necessary for you to have some more 
investigations.  
We will still invite you to return for a second examination in 12 months. 
Thank you for taking part 
Yours sincerely 
Dr G Parkes.  
For further help with smoking cessation contact your GP surgery or the local 
Hertfordshire Help line 0800 389 3998 or speak to your local pharmacist.  
Date.     Litres  %  of  predicted 
value 
Baseline results  FEV1     
  FVC     
Reversibility 
testing 
FEV1     
% change  FVC     
cc. Dr. <         > 
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Letter to general practitioner about restrictive abnormality 
Dr. 
Address 
Dear Dr. < name >                , 
Your  patient,  <name>  has  consented  to  take  part  in  this  research  study 
investigating the value of screening for lung damage in smokers above the age 
of 35 years. 
  
After their visit and examination on < date>, I have reviewed the results and 
looked at the information they gave to the research assistant about their past 
medical history. The results suggest they may have a restrictive disorder as well 
as any obstructive changes from the smoking. They have declared that they 
have a previous diagnosis of (deleted as per data) COPD/ asthma/other lung 
disease. 
 
However, It may be that there is already some record in their notes to account 
for the restrictive spirometry changes, (e.g. intrinsic causes such as TB, fibrosis, 
drug  induced  interstitial  disease,  sarcoid;  extrinsic  causes  such  as  musculo-
skeletal disorders of the chest or spine). 
 
If  the  past  medical  history  does  not  reveal  an  adequate  explanation  for  this 
finding, please arrange for any further clinical evaluation or investigation that 
may be necessary. 
 
Your patient has consented to return for a second research examination in 12 
months. 
Yours sincerely 
 
 
Dr G Parkes.  
P.T.O. for results 
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Date.     Litres  %  of  predicted 
value 
Comment 
Baseline results  FEV1      >80% =normal 
  FVC      >80% =normal 
Reversibility 
testing 
FEV1    % change  >15% =reversible 
FEV1/FVC ratio  %      >70% normal 
Assessment  and 
recommendation 
Normal/restrictive/Obstructive. 
Mixed restrictive and obstructive  
Stop smoking 
Check records 
Investigate cause 
Encl. spirometry   
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11.6  Appendix 6. Correspondence with NSF 
(see Section 2.3.2) 
From: parkesko@hotmail  
To: COPD NSF@DOH.co.uk> cc: 
Subject: New evidence for screening smokers 27/11/2007 18:26 
 
I would like to bring to your attention new evidence to support the spirometric 
lung testing of all smokers aged over 35 I attach a copy of the RCT which is 
currently  under  peer  review  for  publication  by  the  BMJ.  In  summary: 
 
1. Screening smokers (and ex- smokers) results in a large number of people 
with previously undiagnosed lung damage. 
2. Giving spirometry results in the form of 'lung age' promotes smoking 
cessation. In fact this research reveals a doubling of successful smoking 
cessation 
Yours faithfully 
Dr G Parkes  
 
From: COPD_NSF@dh.gsi.gov.uk 
 Subject: Re: New Evidence for Screening smokers 
 To: parkesko@hotmail.co.uk 
 Date: Tue, 18 Dec 2007 16:06:01 +0000 
 Dear Dr Parkes 
  
Thank you very much for sending this article for our attention. I have forwarded 
to our evidence review team in order to ensure that this i included within our 
evidence on which the National Service Framework wil be based. 
 
 Best wishes, 
 Fiona Phillips 
 COPD NSF Team 
 Department of Health  312 
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11.10    Appendix 10. Other feedback  
11.10.1  Centre for Evidence-Based Medicine, Oxford 
 
Dear Dr Parkes 
 
My GP practice journal club session today we looked at your recent trial in the 
BMJ on telling smokers their lung age. We were all enthused by the idea of 
integrating this into the overall practice, but had a few questions we wanted to 
ask. 
 
1. Could you let us have an example of the letter you sent at 4 weeks? Was it 
simply the lung age plus: 
‘This type of lung function test does not tell us anything about the risk of other 
serious diseases related to smoking such as lung cancer or heart disease or 
stroke. Smoking cessation is therefore still important for all people regardless of 
their age or the results of these lung tests.’ and the smoking cessation clinic 
number? 
 
2. You sent the letter to all current smokers, but we wondered how to make this 
part on an ongoing practice routine? We considered just doing it when smokers 
presented  (and  perhaps  repeating  every  5 years)  but  wondered  if  you other 
ideas? 
 
Also out of curiosity, can I ask if you have had others approach about details of 
the ‘how to’? 
Congratulations on a really useful study, 
Regards 
Paul Glasziou 
Director, Centre for Evidence-Based Medicine, 
Department of Primary Health Care, 
University of Oxford   333 
11.10.2  Islington PCT 
 
Subject: query re your research 
Date: Tue, 10 Jun 2008 12:07:01 +0100 
From: mary.price@islingtonpct.nhs.uk 
To: parkesko@hotmail.co.uk 
 
Dear Gary, 
I read with interest you work re effect on quit rate of telling patients their lung 
age.  Can you tell me how the cost per successful quitter of £280 is reached?  I 
am interested to know what the capital and revenue costs in equipment and 
additional personnel are in order to make a business case for doing something 
similar. 
 
Many thanks 
Mary Price 
Long Term Conditions and Access Coordinator 
Islington PCT 
 
11.10.3   Barnet PCT 
 
Dear Gary 
 
 I was very interested in the recent BMJ article (14
th April) – ‘Effect on smoking 
quit rate of telling patients their lung age’ and wish to prepare a business case 
for lung age testing/screening to be offered to all clients accessing our Stop 
Smoking Services. This will involve rolling out the scheme to a large number of 
GP practices, pharmacies and a small number of clinics.    
 I  would  be  very  grateful  for  your  advice  and  would  appreciate  if  you  could 
provide the following information detailed below. 
  
•  Cost  of  Spirometer  used  and  parameters  you  used  in  choosing  the   334 
Spirometer. Would you recommend it for our purposes? 
•  Whether you would advise one Spirometer per GP practice or one for 
each practitioner providing smoking cessation advice and treatment 
•  What is content/involved in the training, cost of training, how training was 
delivered e.g. number trained per session (we would need to train GP’s 
practice nurses, pharmacists and smoking cessation clinic advisors) and 
duration of training sessions   
•  Estimated time of screening test and explanation of result to client - in 
the  paper  it  states  30  minutes  to  perform  the  test  and  a  further  15 
minutes  per  patient  reviewing  results.  Please  can  you  give  me  some 
details of why it takes this length of time as this will be an issue for GP’s, 
practice nurses and pharmacists in terms of capacity to incorporate this 
test into their current practice  
•  What information is given to the clients about the test? 
 Many thanks  
  
Kind Regards 
  
 Susan Hearn 
Lifestyle Services Manager 
Health Improvement Directorate 
Barnet Primary Care Trust 
1st Floor, Deansbrook House 
Edgware Community Hospital 
London 
HA8 0AD 
 
11.10.4   ACP Journal Club 
 
Dear Dr. Parkes  
 
Below is the URL of the abstract and commentary for your recent research that 
was featured in ACP Journal Club. Thank you very much for your collaboration 
in the process of abstracting and commenting on your important work.   335 
http://www.acpjc.org/Content/149/1/issue/ACPJC-2008-149-1-005.htmhttp:/// 
http:///When  opening  your  abstract  you  will  be  asked  for  a  username  and 
password. the username is ******** and the password is ******* 
Below is the link to the commentator form for completion. 
http://plus.mcmaster.ca/commentators/form/acp.aspx 
Yours sincerely,   
 
R. Brian Haynes, MD, PhD                
Editor  
Evidence-Based Journals 
Health Information Research Unit 
McMaster University 
1200 Main Street West, HSC-3H7 
Hamilton, Ontario, CANADA L8N 3Z5 
Phone: 905-525-9140 Ext 22737 
Fax: 905-546-040 
 
11.10.5  Evidence Based Nursing 
 
Dear Dr. Parkes,  
The Limes Surgery, 
  
RE: Your article: Effect on smoking quit rate of telling patients their lung age: 
the Step2quit randomised controlled trial. BMJ. 2008;336:598-600.  
In  addition  to  your  captioned  article  being  chosen  for  abstraction  for  ACP 
Journal  Club,  it  was  also  chosen  for  Evidence-Based  Nursing 
(http://ebn.bmj.com/). Evidence-Based Nursing is a quarterly publication of the 
BMJ  Publishing  Group.  Its  purpose  is  to  help  nurses  keep  up  to  date  by 
abstracting  high  quality  articles  from  key  journals  of  relevance  to  nursing 
practice. Your article was chosen for abstraction because it met (at least) these 
criteria:  
i. random allocation of participants to comparison groups;  
ii. follow up (end point assessment) of at least 80% of those entering the 
investigation;    336 
iii. outcome measure of known or probable clinical importance;  
iv. analysis consistent with study design.  
Attached is a structured abstract plus expert commentary of your study. If you 
have  problems  opening  this  file,  please  let  us  know  right  away  and  we  will 
resend in another format.  
 
The purpose of this letter is to give you the opportunity to please verify the 
accuracy of our version of your work before we go to press. In the abstract we 
may have included some calculations based on the data in your article. The 
redline feature is turned on so that you can make any corrections directly in the 
abstract. Please do not turn off the feature so that your edits will clearly be 
noted.  
Our Glossary can be viewed at  
http://hiru.mcmaster.ca/EBJournals/EBN_AE-Glossary.pdf 
If you have any comments or corrections for the abstract that we have prepared 
or for the expert commentary, please contact Joanne Gunby. Joanne can be 
reached by telephone ((905) 525-9140 x22091), fax (905-546-0401), or e-mail 
(gunbyj@mcmaster.ca).  
Because we have a deadline to meet, we will need to assume our version is 
acceptable unless we hear from you within two working days of this message to 
you.  
 
Congratulations  on  your  fine  article  and  thank  you  in  advance  for  your 
cooperation.  
Yours sincerely,  
Editorial Office 
Evidence-Based Nursing  
 
11.10.6  Faculty of 1000 Medicine 
 
Dear G Parkes, 
 
Your article (citation below) has been evaluated and rated by a respected peer 
within 'Faculty of 1000 Medicine'. We welcome your response to the evaluation, 
especially if you would like to comment on any criticisms made or if you feel   337 
certain aspects of the article have been overlooked. Effect on smoking quit rate 
of telling patients their lung age: the Step2quit randomised controlled trial. BMJ, 
2008 Mar 15. 
 
Please click the following url link to be directed immediately to the published 
comments for free:  
http://www.f1000medicine.com/article/8kphldcjyfx71t2/id/1109230  
Feel free to involve your colleagues too and show them the feedback you have 
received  for  a  piece  of  your  work.  This  link  will  remain  accessible  when 
forwarded  by  email  and  your  colleagues  will  also  be  able  to  view  the 
commentary for free.  
 
'The  Faculty'  is  made  up  over  2000  of  the  world's  leading  researchers  and 
clinicians. Their aim is to highlight and rate those articles that they think add 
important  knowledge  to  the  literature.  Many  of  the  world's  leading  medical 
institutions  already  subscribe.  We  look  forward  to  your  response  to  the 
evaluation, if you believe one would be of value to our readers. We advise that 
your response should be no more than 400 words. Please contact the other 
authors when preparing your response and email your responding comments to 
editorial@f1000medicine.com.  
Please also note that, unless specified otherwise, it will be assumed that the 
response  was  sent  on  behalf  of  the  entire  author  group.  By  sending  your 
response or comment to editorial@f1000medicine.com you grant us the right to 
publish such response or comment.  If you would like further access to our other 
content you can register for a free 3-week trial. Please see the link at the foot of 
this email. 
 
 We look forward to hearing from you. 
 With all best wishes, 
 
Dr Pritpal S Tamber, MBChB 
Managing Director, Faculty of 1000 Medicine 
This study undertook a new direction for patients trying to quit smoking. The 
results demonstrated that supplying a patient with personal medical information   338 
produced  a  surprisingly  large  positive  effect,  bigger  than  what  might  be 
expected from the usual nicotine replacement therapy trial. This RCT found that 
smokers given comprehensible ‘lung age’ information following spirometry were 
more likely to have quit smoking 12 months later than those given raw FEV1 
(forced  expiratory  volume  at  one  second)  feedback  (13.6%  versus  6.4%, 
p=0.005,  95%  confidence  interval  2.2%-12.1%).  These  results  need  to  be 
replicated before any firm conclusions are drawn. The study was underpowered 
to  examine  the  extent  of  lung  age  deficit on  quitting  behaviour. This  lack  of 
power  and  the  lack  of  a  control arm  (receiving  non-personalised  information 
about the effect of smoking on lung age) means it is impossible to dissociate the 
effect  of  receiving  personalised  risk  information  from  the  effect  of  simply 
receiving  a  verbal  description  of  the  effect  of  smoking  on  lung  age.  While 
interesting,  further  work  is  necessary  before  changes  are  made  to  clinical 
practice.  
 
Robert West 
with Jennifer Fidler 
UCL, United Kingdom 
PSYCHIATRY 
Evaluated 19 May 2008
 
11.10.7  Wakefield District PCT 
 
Subject: Lung age and screening for COPD 
Date: Thu, 6 Nov 2008 16:49:59 +0000 
From: Lisa.Chandler@wdpct.nhs.uk 
To: Parkesko@hotmail.co.uk 
 
Dear Dr Parkes, 
I  hope  you don’t  mind  me  contacting  you,  I  am  sure  you  have  had  a  lot  of 
interest in the work you had published in the BMJ. 
My background is as a Practice Nurse and Secondary Care Respiratory Nurse 
Specialist and I am now working as Respiratory Programme Manager in Public 
Health at WDPCT. We are attempting to implement a pilot with our local stop 
smoking service to identify patients with undiagnosed COPD. To encourage the 
stop smoking service to take part we are using screening spirometers, which   339 
will  also  provide  lung  age,  and  quoting  your  research  and  increased  quit 
success. We have been trying to get this work off the ground for the past 18 
months and your work has opened a number of doors that had been closed to 
us previously, so thank you!I am writing to ask if any patient or professional 
information was produced as part of your study and if so whether we would be 
able to negotiate the use of the information for the pilot we are undertaking. We 
are particularly interested in any patient information issued at the time of the 
test. 
Thank you for your time. Regards 
Lisa Chandler 
 
Respiratory Programme Manager 
Wakefield District PCT 
West Yorkshire 
WF10 5LT 
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11.11   Appendix 11. Presentation Slide 
 
Slide 1 Introduction 
 
Slide 2 Step 2 quit   341 
 
Key facts -East of England
 Smoking Prevalence 23%  
 Over 200 deaths per 100 000 population 
due to smoking
 22 deaths per day
 Total 2004-5.
Smoking in the East of England Smoking in the East of England
March 2007: An update from the March 2007: An update from the
Eastern Region Public Health Observatory Eastern Region Public Health Observatory
Total population  5.5 million people Total population  5.5 million people
 
Slide 3 Prevalence of smoking 
 
  27% of smokers 1
 Aged over 35 
 have lung damage (COPD)
1.Van Schayck CP et al. BMJ 2002;  24(7350):1370 .
Smoking causes 
Lung Damage
 
Slide 4 Lung damage  
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Biomarkers -
Is Screening smokers worthwhile?
  Cochrane review 2005 -
  Due to limited evidence no definitive statement could be made 
about the effectiveness of biomarkers to promote successful 
smoking cessation1
Reference 
(1)  Bize R, Burnand B, Mueller Y,  Cornuz J. Biomedical 
risk assessment as an aid for smoking cessation. [Review] [61 
refs]. Cochrane Database of Systematic Reviews 
2005;(4):CD004705.
 
Slide 5 Biomarkers Cochrane review 2005 
 
 
  Some recent evidence that detection of lung 
damage improves smoking cessation(2)
(2)  Bednarek M, et al. Smokers with airway obstruction 
are more likely to quit smoking. Thorax 2006; 
61(10):869-873.
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Quotes from NICE
  Smoking damage is detectable after 20 pack 
years of smoking - e.g.35.
  the mean age of detection of COPD in the UK is 
55
  Use of spirometry can detect the presence of 
airflow obstruction earlier, even if no symptoms 
are present.
  that the biggest factor that can have an impact on 
disease progression is smoking cessation . 
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What is Spirometry?
 blowing into a tube connected to a 
machine (spirometer)
 Detects obstruction or restriction
 Standard measurements include 
FEV1, FVC
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What is lung age?
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What is lung age?
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Lung Age
  A simple and clear way of explaining lung 
damage to patients.
  FEV1 relates to aging of lungs. Smoking can give 
results equivalent to accelerated lung age
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Does
Spirometric lung age  Testing Enable 
Patients To Quit Smoking?
  STEP 2 Quit Smoking study screened current 
smokers aged 35+
  Randomised control study.
  Results of lung function  given to intervention 
group as ‘lung age’.
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Recruited 561 current smokers aged 
35 year or above
Randomisation
Control 
( n=281)
Intervention 
( n=280)
LUNG AGE
Baseline data and  
spirometry
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Baseline characteristics -(sample)
  Age            53 53
  %Male 47 45
  Pack years 30 31
  Spirometry 
 Abnormal 24% 27%
  SGRQ 29 27
  Cigarettes
 Per day 17 16
Control Intervention
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Intervention group
 Given result of test as LUNG AGE
 Shown graphic display
 Sent letter with results and advice on local 
smoking cessation resources
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Control group
  Told that their measurements will be repeated 
after 12 months to see if their lung function has 
changed 
  Sent letter with advice on local smoking cessation 
resources
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12 months later
Control  
follow up
249(88.6%)
Intervention 
follow up
249(88.9%)
Not followed up (n=32, 
11.38%)
2 died
2 cancer/asbestosis
28 moved/failed to 
respond
Not followed up 
(n=31,11.07%)  
1 died
1 cancer/asbestosis
29 moved/failed to respond
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Results
Quit rates
6.4%  v 13.6% 
control group  v intervention group
(participants who failed follow up are assumed to be 
smokers)
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What causes the increased quitting?
  Does more lung damage lead to improved 
smoking cessation?
  (Lung Age  – Age) = Lung age deficit (yrs)
 e.g. lung age 75  and real age 45  
LAD= 30 years
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Lung age deficit (LAD) and 
quitting Intervention group
 LAD= Spirometric lung age – chronological age 
  Quitters LAD= 8.0 years
  Non-quitters LAD = 8.8 years
  Quitting success is NOT related to severity of 
lung damage.
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Other findings
  20% of the smokers had significant co -morbidity 
(CHD, DM, CVD, HT, Asthma)
  A new diagnosis of COPD was made in 16% of 
participants
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What this adds.
  Screening and lung age estimation is useful for 
smokers of 35 years of age
  NICE- guidelines for COPD and Smoking
 Update evidence
  QuOF – new GMS contract could include 
incentives for screening all smokers
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The end
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Bednarek M, et al 
2006
  Observational study
  Non randomised
  4494 smokers from Poland
  Those with lung damage shown a visual display.
  Normal lungs - quit rate 12%   v 
  Lung damage – quit rate 16.3%
(2) Bednarek M, et al. Smokers with airway obstruction are more likely to qu it smoking. 
Thorax 2006; 61(10):869 -873.
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Summary 
 
Hypothesis tested in the pilot RCT  
This pilot study tests the hypothesis that it is feasible to set up a study 1.using 
lung function screening of smokers in General Practice 2.using the concept of 
lung age as a sensitive biomarker of lung damage 3.using personal lung age as 
a communication tool to inform smokers about their health, in a way that may 
change rates of smoking cessation.  
Hypothesis to be tested in the definitive RCT 
Routine  use  of  spirometry  and  lung  age  assessment  in  smokers  improves 
success of smoking cessation in the setting of primary care. 
 
Primary care clinicians are repeatedly encouraged in the medical literature to 
screen smokers for the detection of lung damage. Not all people are equally 
susceptible to lung damage from smoking and people with early damage may 
have no symptoms. The assumption is that smokers with damaged lungs can 
then be successfully targeted with smoking cessation programmes. 
 
There is a lack of evidence that detection and knowledge of lung damage leads 
to an increase in smoking cessation. Therefore The Aims of the definitive study 
are  to  ‘to  strengthen  the  evidence  base  about  the  influence  of  personal   354 
biomarkers  on  motivation  to  quit  smoking’  and  to  inform  the  debate  about 
‘whether screening of smokers in primary care is worthwhile’. 
 
Lots  of  research  has  identified  medicines  (patches,  gum  etc)  that  will  help 
smokers to quit, who are ready for change, but the benefit of lung screening of 
smokers has so far not been researched in the NHS context. 
 
The objectives of the definitive research study are to determine if : 
1. Telling smokers their lung age changes motivation to quit.  
2. Knowledge of lung age increases successful smoking cessation.  
Lung function declines naturally with age. These changes can be detected and 
measured with a device called a spirometer. With reference to standard tables 
of normality for different ages (gender and height) the lungs of smokers may 
behave  as  if  they  are  'older'  than  normal.  The  thesis  is  that  improving  the 
knowledge about an individual’s lung function and quantifying damage in an 
understandable way will improve success of smoking cessation.  
This dissertation gives details of the background, literature review and a pilot 
project.  The  results  and  reflections  on  the  processes  involved  are  used  to 
inform the development of a full scale research proposal which has led to a 
successful bid for a two year research grant for the definitive study. 
I  conclude  that  this  dissertation  demonstrates  the  feasibility  and  potential 
usefulness of a full research project as detailed.  
 
This is the abstract of the Masters dissertation. If the full dissertation is 
required I can supply a copy on request. 